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Abstract 
Polymer drug conjugates are an emerging class of therapeutic agent that offer advantages 
in the treatment of cancer through long circulation times and passive targeting. A further 
benefit of using a polymeric framework is that it readily allows attachment of targeting 
motifs to enhance the drug specificity, as well as allowing variation of the drug 
component. In this work a series of targeted polymer drug conjugates were prepared 
that incorporated different drugs via peptide linkers designed to be stable in circulation 
but degradable at the target site. 
In order to ensure stability in circulation, it was necessary to ensure the drugs were 
conjugated to the biodegradable linkers via amides, which required the introduction of 
amine functionalities to the natural-product drugs. The required hemisyntheses were 
successfully carried out, although yields were sometimes disappointing. 
An effort to allow an assessment of the pharmacokinetic effects of using a polymeric 
scaffold was made through the attempted synthesis oflow molecular weight analogues of 
the polymer drug conjugates, with success in some cases. 
A recently developed polymeric precursor was used in the preparation of the polymer 
drug conjugates but was found to undergo an unexpected side-reaction, which may 
prevent the long term development of this particular precursor. The desired conjugates 
were nonetheless successfully produced on a scale suitable for initial biological testing. 
Both the high and low molecular weight constructs synthesised showed reduced 
cytotoxicities to P388 murine leukemia cells and are currently awaiting in vitro testing to 
truly evaluate their utility. 
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Chapter 1 
Introduction 
1.1 Cancer 
Cancer, a disease caused by uncontrolled division of cells, is one of the leading causes of 
death and discomfort in the world today, particularly in developed nations. There are 
currently over 22 million cancer patients in the world; ten million people are diagnosed 
with cancer and six million die of cancer each year.l With an almost 20% increase in 
both cancer incidence and mortality from 1990 to 2000, 1 it is clear that cancer is a 
disease that is going to continue to be a great burden on society for many years to come. 
As developing nations improve their standards of living, the rates of cancer in those 
countries can be expected to rise dramatically, adding greatly to the worldwide cancer 
burden. Consequently, the number of new diagnoses is projected to rise to 20 million 
per year by the year 2020.2 
In New Zealand a study carried out in 2002 looked at the cancer burden in the country in 
1996/7 and forecast figures for 2011112. The authors found that the number of people 
living with cancer in New Zealand was expected to increase by almost 50%, from 14808 
to 21 777, over the 15 year period, with annual deaths rising from 7447 to 8963, an 
increase of 20%. 3 The increase in the incidence of cancer in New Zealand will continue 
to place a heavy burden on both the health system and the patients and their families until 
such time as cancer becomes a curable disease. 
The term cancer actually refers to a large family of disorders which can generally be 
broken into three broad classes based on the type of tissue involved.4 Carcinomas are 
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cancers of the epithelial cells and are by far the most COlmnon type of cancer, 
representing around 90% of all cancers. This is thought to be due to the fact that 
epithelial cells are among the most rapidly dividing cells in the body, and also, being 
located on the suface of organs, are easily exposed to physical and chemical abuse. 
Leukemias are cancers of the haemopoietic cells and cells of the nervous system, while 
sarcomas originate in the connective tissue or muscle cells. There are cancers that do 
not fall into these categories, but they are relatively rare. 
2 
When a cancer develops, it begins as a benign tumour, which consists of a simple mass of 
cells undergoing uncontrolled cell division. A benign tumour is relatively easily treated 
as it is well contained. If a benign tumour goes unnoticed it will eventually develop into 
a malignant tumour, which is a cancer that has taken on the characteristics of invasion 
and colonisation of other areas of the body. This type of tumour is much more difficult 
to treat due to the presence of secondary tumours that are spread throughout the body.5,6 
The progression of a healthy cell to a benign tumour and [mally a malignant tumour is a 
result of accumulation of damage to the genetic material. 7 In a human lifetime, 
approximately 1016 cell divisions will be undertaken, with each replication of the genome 
presenting a 10-6 chance of making an error in any particular gene. This means that in 
the course of a lifetime, each gene will experience about 1010 mutations, so it is almost 
surprising that cancer does not occur more frequently or earlier in life. 8 The reason why 
cancer is not more common is that for a cell to become cancerous, it must accumulate 
independent mutations in between three and seven particular genes associated with 
control of cell division, which is highly unlikely in any particular cell. 
Not all genes can cause cancer when mutated, and those that can are divided into two 
groups - oncogenes and tumour repressor genes. Oncogenes typically code for proteins 
whose action induces cell division. Typically, cancer-causing mutations in oncogenes 
will result in increased protein production or production of a constitutively active 
protein. Due to the dominant nature ofa mutant oncogene, if just one of the two 
available copies of a particular oncogene is defective, it is sufficient to put a cell on the 
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pathway to cancer. Tumour repressor genes code for proteins that restrict or prevent 
cell division. Cells with only one operational copy of a tumour repressor gene will still 
produce some fully functional protein and therefore will not be transformed to a 
cancerous phenotype. 
3 
1.1.1 Current therapies 
Traditional cancer treatment has relied on surgery, radiotherapy and chemotherapeutic 
agents. Surgery is typically the fIrst form of treatment used in cancer therapy. Where 
possible, the bulle of the tumour mass is surgicallyexcised.5,9 However, this technique is 
generally unable to remove all of the cancerous cells, so surgery is followed by 
radiotherapy or chemotherapy or in some cases, both together. Surgery cannot be 
carried out when the tumour is so large that removal would result in unacceptable 
damage to the surrounding tissue and organs. In these cases, radiotherapy and 
chemotherapy can be utilised fIrst in an effort to reduce the tumour to a resectable size. 
In some patients with a strong family history of cancer or a known genetic 
predisposition, cancer-prone organs may be removed as a preventative measure prior to 
the development of cancer. 
Radiotherapy involves the targeted delivery of high intensity radiation to the area of a 
tumour.9 Usually non-ionising radiation such as x-rays or gamma rays is used, with the 
ideal source being a linear accelerator which can provide a powerful and highly directed 
beam of radiation. The treatment regime is commonly carried out using moderate 
intensity irradiations daily to allow time for healthy tissue to heal between sessions. To 
further limit the damage to normal cells, the radiation is applied from a number of 
different directions during each session so that healthy tissue is exposed to the lowest 
possible dose while the tumour receives the maximum radiation. The effect of 
radiotherapy is to cause extensive DNA damage. Unfortunately, the damage is maximal 
in the presence of oxygen, which means that radiotherapy is less effective against hypoxic 
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areas of a tumour. The use of hyperbaric oxygen, hypoxic cell sensitizers and neutron 
radiation have all been proposed as methods of overcoming the intrinsic resistance of 
hypoxic cells to radiation, but have met with only limited success. Despite this 
limitation, radiotherapy remains an affordable and effective treatment for many cancer 
patients. 
4 
Chemotherapy is the last major weapon in the armamentarium of the oncologist, and has 
very varied utility. Some tumours are very responsive to chemotherapy; for example, 
90% of patients with advanced germ cell tumours are cured by treatment with cisplatin, 
while others remain highly refractory. The World Health Organisation has assembled a 
list of 17 essential cancer drugs; all are generic, and thus affordable, drugs useful for 
treating the most responsive tumour types (Table 1.1).10 
Table 1.1 The World Health Organisation essential cancer drug list 
Drug Class/mechanism of action 
5 -Fluorouracil Anti-metabo lite 
6-Mercaptopurine 
Cytarabine 
Methotrexate 
Chlorambucil 
Cisplatin 
Cyclophosphamide 
Procarbazine 
Daunorubicin 
Doxorubicin 
Etoposide 
Vinblastine 
Vincristine 
Bleomycin 
Dactinomycin 
Prednisolone 
Tamoxifen 
Anti-metabolite 
Anti-metabo lite 
Anti-metabo lite 
DNA alkylator 
DNA alkylator 
DNA alkylator 
DNA alkylator (presumed) 
Topo II inhibitor 
T opo II inhibitor 
Topo II inhibitor 
Tubulin binder 
Tubulin binder 
Nucleic acid oxidiser 
RNA synthesis inhibitor 
Glucocorticoid 
Anti-oestro gen 
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The chemotherapeutic agents used have typically been compounds which are toxic to 
mitotic, or dividing, cells and act by interfering with one or more of the processes 
involved in cell division. Most of the dmgs on the WHO essential dmg list can be placed 
in one offour groups based on their mechanism of action, as can most other cancer 
dmgs, although currently a number of dmgs are in development that have novel 
mechanisms of action. 
1.1.1.1 Antimetabolites 
The term antimetabolite refers to a compound that interferes with biosynthesis or 
utilisation of a normal cellular metabolite. II Due to their reliance on hindering a 
particular enzymatic reaction, or, in some cases, their requirement for enzymatic 
activation to produce the cytotoxic agent, resistance to antimetabolites is a common 
problem through simple up- or down-regulation of the relevant enzyme. In order to 
minimise the development of resistant cancer cells, antimetabolites are almost always 
used in combination with other chemotherapeutic dmgs. 
The majority of the dmgs in the antimetabolite class are analogues of nucleic acid 
components that are selectively toxic to cells that are undergoing DNA replication. 5-
fluorouracil l2 (1), 6-mercaptopurine l3 (2) and cytarabine l4 (3) are all nucleic acid 
analo gues. All three of these drugs undergo metabolism within the target cell before 
being incorporated into the DNA, leading to formation of fatal protein adducts and 
single- and double-strand breaks. 
o 
O:t'YF 
H 
S 
(~NH NJl .. ~ 
H N 
5-fluorouracil (1) 2-mercaptopurine (2) Cytarabine (3) 
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Methotrexate15 (4) is not a nucleotide analogue; it acts as a potent inhibitor of 
dihydrofolate reductase, an enzyme involved in the biosynthetic pathway ofnucleotides. 
Restricted biosynthesis of the nucleotides required for DNA replication leads to 
suspension of cell proliferation and induction of apoptosis. 
1.1.1.2 ])~~ aI~Iators 
6 
The DNA allcylators are among the oldest anti-cancer drugs known; 16 the first drug ever 
used clinically for treatment of cancer was mechlorethamine (5), or nitrogen mustard, 
which is a strong allcylator of DNA. The primary cause of toxicity of mechlorethamine 
(5) is thought to be due to formation of DNA-DNA crosslinks, in which two bases of the 
DNA helix are alkylated by the two arms of the drug. This can result in either an inter-
or intra-strand crosslink, both of which prevent any further DNA replication. 
Chlorambucil17 (6) is an analogue of mechlorethamine which is still commonly used 
today, primarily in the treatment of lymphocytic leukemia. The parent compound is 
active in vitro, but has been found to be rapidly converted to the slightly more toxic 
phenyl acetic acid mustard (7) in the body,18 which may be the form responsible for the 
Methotrexate (4) 
CI~ 
I 
CI~N~CI 
CI~NY) R 
~OH 
n 
Mechlorethamine (5) n = 3 Chlorambucil (6) 
n = 1 Phenyl acetic acid mustard (7) 
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observed in vivo anticancer activity. Chlorambucil (6) can be administered orally as it has 
significantly lower alicylating ability than mechlorethamine (5) and thus is able to survive 
transition through the gut. 
Cyclophosphamide19 (8) is a widely used anti-cancer drug that relies on metabolic 
activation to produce an active alkylating species. Initially it was thought that the active 
derivative of cyclophosphamide (8) was norNHz (9), but more recently it has been found 
that phosphoramide mustard (10) is actually the species responsible for the majority of 
the DNA alicylation observed. Interestingly, researchers found that the metabolic 
derivatisation of cyclophosphamide (8) takes place primarily in the liver rather than the 
tumour, which explains the lack of cytotoxicity of cyclophosphamide (8) to tumour cells 
grown in vivo. 
Another major class of DNA alicylating agents, the platinum complexes, contains the 
very well known drug cisplatinzo,zl (11). The discovery of the anti-cancer properties of 
cisplatin (11) was made serendipitously in 1965 when Rosenberg noted that Escherichia 
coli cells were unable to grow near a platinum electrode in an electrolysis bath containing 
ammonium chloride, Since that discovery, over 2000 analogues of cisplatin (11) have 
I'NH 'o~1,o 
CI~N~CI 
Cyclophosphamide (8) 
H3N, ,CI 
Pt 
H3N" 'CI 
Cisplatin (11) 
H2 CI (XN'I ... CI P.t N"I "CI 
H2 CI 
Iproplatin (13) 
NH2 
I 
HO-P-O 
I 
CI~NH~CI CI~N~CI 
NorNH2 (9) Phosphoramide mustard (10) 
o 
H3N, ,o~ Pt 
H3N" b 
o 
Carboplatin (12) 
OH (H3ChHCH2N .. I ... CI 
,P.1t .. (H3ChHCH2N OHC1 
Tetraplatin (14) 
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been synthesised and examined for their ability to form cytotoxic intra-strand cross-links. 
A number ofthese analogues have progressed to clinical use, including carboplatin (12), 
iproplatin (13) and tetraplatin (14). The critical feature shared by all of these drugs is the 
presence of two labile ligands in a cis relationship. The remaining ligands can be 
relatively inert, and it is variation of these moeities that gives rise to distinct 
pharmacological properties by altering the physical and chemical properties of the drugs. 
Procarbazine (15) is a synthetic antitumour compound which was developed in 1963 
following discovery of cytotoxic activity in the members of a library of N,N'-
dialkylhydrazines.22 Structure-activity studies led to the discovery that one ofthe alkyl 
substituents on the hydrazine absolutely had to be a methyl group for any activity to be 
displayed, while alterating the other alleyl substituent changed the biological profile, 
including cytotoxicity, of the drug.> Pure procarbazine (15) itselfhas no effect on 
isolated DNA, RNA or protein but in the body it is rapidly oxidised in the presence of 
oxygen and a redox active metal to the azo derivative 16 with production of hydrogen 
peroxide. 23 Further oxidation can lead to formation of a mixture of the azoxy derivatives 
17 and 18, which have been shown to cause extensive DNA damage and lead to single 
strand breaks.24 
~o 
~N-N~-HIN-< 
Procarbazine (15) 
~o 
;N=N~-H1N-< 
ONN-azoxy-procarbazine (17) 
~o 
\=N~-HIN-< 
Azo-procarbazine (16) 
~o 
\=N~-H1i'J'-< 
NNO-azoxy-procarbazine (18) 
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1.1.1.3 Topoisomerase inhibitors 
Topoisomerases are enzymes that are able to cleave one or both strands of the DNA 
helix to release the supercoiling that is caused by localised unwinding during replication. 
After cleavage, the topoisomerase controls the motion ofthe cut end(s) to release the 
excess torsion before re-annealing the strands.25 If this process does not occur, the DNA 
helix is put at risk of breaking during replication as the supercoiling becomes gradually 
tighter. Topoisomerase inhibitors are somewhat misnamed as they do not actually inhibit 
the activity of topoisomerases, but rather exert their toxicity by interacting with the 
DNA-enzyme complex and stabilising it in a 'cleavable' conformation. Action of cellular 
proteases on the complex leads to the release of cleaved DNA with residual protein 
material conjugated to the cut ends. The exact mechanism by which this DNA damage 
causes cell death is still not fully understood, but it is clear that extensive damage of this 
sort is beyond the repair capabilities of cells and leads eventually to cell death. 
Topoisomerase inhibitors can be broadly divided into two classes, depending on whether 
they interact initially with the DNA or the enzyme in the cleavable complex. 
The structure of DNA, with a regular arrangement of stacked aromatic bases, is prone to 
disruption by other flat aromatic molecules which can intercalate (insert between 
adjacent base pairs). Intercalation of a drug molecule increases the base pair spacing 
from 3.4 A to approximately 7 A, leading to a change in the torsional angle of the helix.26 
This distortion is sufficient to trap the topoisomerase-DNA complex in its cleavable 
conformation. Interestingly, not all compounds that are able to intercalate into DNA are 
topoisomerase inhibitors; for example ethidium, which is a wellimown intercalator, does 
not cause any formation of cleavable complexes and does not show significant 
antitumour activity.27 The specific features that lead to efficient stabilisation of the 
cleavable ternary complex are still not lmown. 
The most well known family of intercalating topoisomerase inhibitors are the 
anthracyclines.28 Members of this class of drug are widely used in modern cancer 
chemotherapy, in particular doxorubicin (19) and daunorubicin (20). The mechanism of 
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action of the anthracyclines is not restricted to intercalation, with both doxorubicin (19) 
and daunorubicin (20) showing the ability to undergo redox reactions resulting in the 
generation of toxic free radicals, and they are also known to be able to interfere with and 
alter plasma membranes. The primary limitation of all anthracyclines is their dose-
limiting cardiotoxicity, which limits the recommended life-time dose to 550 mg/m2, 
although reduction in cardiac efficiency has been noted with doses as low as 300 
mg/m2•29 Efforts to ameliorate this side-effect have largely been unsuccessful, with the 
analogue epirubicin (21) reported to exhibit reduced cardiotoxicity, although not enough 
to warrant the replacement of doxorubicin (19) or daunorubicin (20) in clinical use. 
The non-intercalating topoisomerase inhibitors are less well known and also rarer than 
those that interact directly with DNA. The epipodophyllotoxins are a family of 
semisynthetic compounds based on the naturally produced compound podophyllotoxin 
(22), which is a cytotoxin that exhibits no topoisomerase inhibitory activity and has not 
proven to be useful in cancer therapy.30 Investigation of analo gues of podophyllotoxin 
resulted in the discovery of etoposide31 (23). This compound is a potent topoisomerase 
inhibitor, but shows no interaction with free DNA, indicating that it interacts with 
topoisomerase directly to stabilise the cleavable DNA-enzyme complex. 
OMe 
OH 0 
R = -CH20H Doxorubicin (19) 
-CH3 Daunorubicin (20) 
HO 
o OH 0 
Epirubicin (21) 
Chapter 1,' Introduction 
QH 
<:~o 
~O 
H3CO~OCH3 
OCH3 
Podophyllotoxin (22) 
1.1.1.4 Tubulin binders 
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Microtubules, which form an endoskeleton within cells, are essential to many cellular 
functions, not least of all separating the newly duplicated chromosomes during cellular 
replication through formation of the mitotic spindle. Due to their central role in both cell 
division and regular cellular maintenance, inhibition of their assembly or disassembly 
leads to cell death. The heterodimeric protein tubulin is the basic building block of 
microtubules, and a number of compounds are known to bind to tubulin and inhibit the 
proper activity of micro tubules by inhibiting either polymerisation or depolymerisation of 
tubulin. 32 
The vinca alkaloids vinblastine (24) and vincristine (25) are efficient inhibitors oftubulin 
polymerisation.32 At low concentrations (from 10 nM to 1 ~M) they bind to the growing 
ends of the microtubules and prevent any further aggregation oftubulin heterodimers 
leading to an 'end-capping' effect. At higher concentrations (> 1 0 ~M) they can induce 
formation of crystals consisting of two intertwined microtubules. Despite their structural 
similarities, vinblastine (24) and vincristine (25) have distinct anti-cancer activity profiles 
and thus are both included in the World Health Organisation essential drugs list. 
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1.1.1.5 Others 
R = -CH3 Vinblastine (24) 
-CHO Vincristine (25) 
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The tenn 'bleomycin' actually refers to a mixture of related compounds, the predominant 
members of which are bleomycin A2 (26) and bleomycin B2 (27).33 The members of the 
bleomycin family are thought to exert their cytotoxicity through oxidation of nucleic 
acids mediated by a redox active metal such as Fe2+ or Cu+ and requiring molecular 
oxygen. It is thought that the primary target of bleomycin is DNA, although there are 
some indications that damage to cytosolic RNA could be the main mechanism of cell 
death. 
R = -S+(CH3h X' Bleomycin A2 (26) 
\ NH2 
HN-{ Bleomycin B2 (27) 
NH 
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Dactinomycin/4 (28) or actinomycin D, is an antitumour antibiotic that was isolated from 
an actinomycetes fungus in 1940. In mammalian cells it concentrates in the nucleus, 
where it is found to be bound to DNA. Despite its planar structure, which would 
suggest a mechanism of action involving intercalation and topoisomerase inhibition, it 
exerts its toxicity through inhibiting the synthesis of RNA from a DNA template. 
Prednisolone35 (29) is a glucocorticoid steroid that is used primarily in the treatment of 
lymphoma. The exact mechanism of action of prednisolone is not known; however, it is 
known that glucocorticoids bind to specific receptors on target cells and cause a 
reduction in the level of transcription of numerous genes. It also appears that some cells, 
in particular immature lymphocytes, are programmed to undergo apoptosis when 
exposed to high levels of glucocorticoids, which may well be the reason why 
prednisolone is effective against lymphoma. 
Tamoxifen36,37 (30), first synthesized in 1963, is an anti-oestrogen which has become the 
benchmark treatment for breast cancer. It works by competitively inhibiting the binding 
of oestrogen to the oestrogen receptor, leading to an attenuation of transcription of 
certain growth-related genes and a decrease in the rate of proliferation of cells. 
Interestingly, tamoxifen provided the first example of contrasting biological activity 
between isomeric forms in that the trans-isomer is an anti-oestrogen while the cis-isomer 
is a pure oestrogen. 
o I:{) I 0 ~~lrN 'X" NIf~~""\ <Vy~N~~ 0 0 0 O~ ..... N...../ o 0 0 0 0 0 ""r 
N)~ ~ JlN~ 
H :. ., Y'H I 
HN NH 
Dactinomycin (28) 
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1.1.1.6 Recent developments 
While the toxins described thus far do show some ability to target the relatively rapidly 
dividing cells of a cancer, they also cause a number of unpleasant side effects due to 
toxicity to other, non-cancerous mitotic cells in the body such as those of the stomach 
lining, hair follicles and the blood cell progenitors in the bone marrow. Recently, 
research has focused on the development of anti-cancer drugs that are more specific. 
Tactics employed for improving the efficiency of drugs include causing cancer cells to 
revert to normal cells, targeting cytotoxins specifically to cancerous cells, or affecting 
the body's own response to the tumour rather than attacking the tumour directly. 
14 
Developments in the field of gene therapy have led some researchers to believe that it is 
possible to cause tumour cells to lose their cancerous characteristics and become normal 
tissue once again. One gene that has been seen as a potential target is the tumour 
suppressor gene p53, which is found to be mutated in over 50% of all tumours. 38 p53 
codes for a protein that is able to detect genetic damage and either stop cell division to 
allow repair to take place, or induce cell death if the damage is extensive. Ifa fully 
functioning copy ofthe p53 gene could be delivered to cancer cells, it may be able to 
restore normal function, leading to a return of growth control and thus eliminating the 
cancer. Despite a number of clinical trials, no major successes have yet been 
reported. 39,40 
Cancer cells are known to express proteins on their cell surfaces that are not present on 
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normal cells. These proteins are known as tumour-associated antigens, and antibodies 
that bind to such antigens are currently being intensively researched to determine their 
ability to mediate anti-cancer activity. Some antibodies are able to directly cause the 
death of cells to which they bind through a process known as antibody-dependent 
cellular cytotoxicity.41 More commonly, however, antibodies are being developed as 
targeting systems to deliver radioisotopes or cytotoxins directly and specifically to 
tumour cells.42-45 
15 
The antigens expressed by tumour cells are also able to be utilised by the body's own 
immune system. Some researchers have suggested that cancer cells occur spontaneously 
within the body relatively frequently, but are almost always eliminated by the immune 
system before they become a threat. Whether or not this is correct, the observation by 
Coley in the 1890s that a subcutaneous injection ofa bacterial extract could lead to the 
elimination of some tumours has led researchers to investigate whether stimulation of the 
body's immune response could be used as a treatment for cancer.46 To this end, current 
research is directed toward the development of a cancer vaccine, with more vaccines 
having been developed than can be tested in patients.42 Unfortunately, it appears that 
tumours do not display unique antigens, although they do express many antigens at 
higher levels than healthy tissues. This means that vaccination may cause an autoimmune 
condition to arise in which the immune system attacks healthy tissue as well as cancer 
cells, although this may be a price worth paying. 42 
1.1.2 Angiogenesis 
Angiogenesis is the process whereby existing blood vessels branch out to form new 
vasculature and takes place primarily during foetal development and to a lesser extent 
during certain tightly controlled processes in adults, such as wound healing and 
menstruation.47,48 In 1971, Follanan first described the central role of angiogenesis in 
tumour development and outlined the concept of 'tumour dormancy' in the absence of 
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angiogenesis. 49 It is now known that angiogenesis is not only essential to the growth ofa 
solid tumour, but, perhaps more importantly, is required to enable a tumour to 
metastasize and thereby spread through the body. 50 As angiogenesis must occur before a 
tumour can progress beyond about 2 mm3,50-52 inhibition of angiogenesis is seen as 
another valid target for anti-cancer therapy. 53 
Angiogenesis is controlled by a complex interplay of activators and inhibitors in a system 
that has been described as the 'angiogenic switch' .48 There have been over forty 
regulators of angiogenesis identified to date, some of which are shown in Table 1.2.54 It 
has been shown that the angiogenic activators aFGF, bFGF and VEGF are widely 
expressed in normal, healthy tissue without inducing angiogenesis, due to the 
concomitant expression of inhibitors of angiogenesis. 48 Within the tumour environment, 
it is thought that the induction of angiogenesis only begins with the onset ofhypoxia,55,56 
which can, in tum, lead to either an increase in expression of activators of angiogenesis 
or a decrease in expression of inhibitors, with examples of both mechanisms known. 48 
Interestingly, it is also known that primary tumours often release inhibitors of 
angiogenesis into the bloodstream, which has the effect of preventing the growth of any 
Table 1.2 Selected regulators of angiogenesis 
Activators 
Acidic Fibroblast Growth Factor (aFGF) 
Angiogenin 
Basic Fibroblast Growth Factor (bFGF) 
Follistatin 
Interleukin-3 
Interleukin-8 
Leptin 
Placental Growth Factor 
Platelet Derived Growth Factor 
Pleiotrophin 
Proliferin 
Vascular Endothelial Growth Factor (VEGF) 
Inhibitors 
Angiostatin 
Canstatin 
Endostatin 
Interferons a./P 
Interleukin-10 
Interleukin -12 
Interleukin-18 
Platelet factor-4 
Restin 
Thrombospondin-1 
Tumstatin 
Vasostatin 
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met.astasised tumour cells. TJ:riS. contro~ is lost if the primary tumour is removed, leading 
to a rapid gro-wth. of. numerous secondary tumours.. 
The process of angiogenesis, as shown in FIgure 1.1, begins' witfr initiation through 
release of act ivat o.rs. of ang·iogenesis. by rhe tumour. F o-Howing activation, the endothelial 
cells secrete proteases to dissolve the basal membrane. Initially cells migrate to fonn the 
budding neovascu lature, but before long the cells just before the tip 0 f the sprouting 
vessel undergo replication to supply sufficient cells to allow the vessel to grow. 
Eventually the vessel will meet another new sprouting vessel and form a loop, allowing 
blood to flow through. Further sprouts can develop from the initially formed loop if 
required, and, in the case of cancer, the rapidly developing tumour mass can cause 
persistent angiogenesis. Finally, the new capillary lays down a basal membrane and 
undergoes a number of physiological changes to become a properly developed blood 
vessel. 57 
Targeting angiogenesis as a way of preventing tumour growth has two intrinsic 
advantages over targeting the tumour itself. 57 First, the accessibility of endothelial cells 
to drugs administered via the blood means that much lower doses are required 10 ensure 
Tumour releases angiogenesis activators 
Activators bind endothelial 
cell receptors 
Basal membrane 
is degraded and 
endothelial cells migrate 
j;;nlintl"AIi,!:II1 cells divide and 
grow towards tumour 
Loops are fanned, allowing blood flow 
Figure 1.1 The process of angiogenesis 
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a therapeutic dose at the target tissue, which in tum reduces the severity of any side-
effects of treatment. The second advantage is that the endothelial cells are genetically 
stable, unlike cancerous cells. This means that the cells targeted are phenotypically 
homogeneous, so the drug can be expected to have a uniform effect, even amongst 
different types of cancer. Perhaps more importantly, their genetic stability means that 
endothelial cells are not likely to develop resistance to drugs, which is a major problem 
with current cancer drugs that are targeted to the genetically plastic tumour cells 
themselves. 
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There are currently over 75 drugs in various stages of clinical trials aimed at developing 
an anti-angiogenic drug that is effective against cancer. In early 2004 the Federal Drug 
Administration in the United States approved Avastin (bevacizumab, a humanized 
recombinant anti-VEGF -antibody) .for clinical use in combination chemotherapy with 5-
fluorouracil (1) for treatment of patients with first line or previously untreated-metastatic 
cancer of the colon or rectum.58 This is the first example of an anti-angiogenic drug 
being approved for clinical use, which is somewhat disappointing given their huge 
potential. There are, however, a number of conventional cancer chemotherapeutics that 
are thought to be anti-angiogenic, including compounds such as doxorubicin, 
cyclophosphamide and vincristine. These drugs are all able to exhibit anti-angiogenic 
activity at concentrations insufficient to kill tumour cells; however, their current clinical 
usage is not directed toward utilising their anti-angiogenic activities. 
The fact that vascular development can be inhibited at sub-cytotoxic concentrations has 
led to suggestions that therapies aimed at preventing angiogenesis would be best 
administered using a schedule of low doses given frequently.54,59 This so-called 
'metronomic' dosing scheme is in strong contrast to that usually used in cancer 
chemotherapy i.e. administration ofthe maximum tolerated dose followed by an 
extended recovery period before re-administration. 6o,61 Furthermore, it may be necessary 
to revise the endpoint targets when examining anti-angio genic drugs as they have been 
found to lead to disease stabilisation rather than a reduction of the tumour mass. 62,63 
Considering that improving patient survival and quality of life are the crucial goals in 
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disease treatment, these factors would be more appropriate markers of success than 
tumour regression, which will not necessarily be achieved through an anti-angiogenesis-
based treatment regime. 
1.1.2.1 Targeting angiogenesis 
In 1998 a paper was published in Science that described the use of pep tides to target 
doxorubicin to tumour vasculature.64 The peptides that were used were isolated from 
phage display libraries, which are collections ofbacteriophage, each of which display a 
single random peptide on their surface. 65,66 In order to isolate the desired peptides, a 
phage display library is injected into a subject, in this case nude mice bearing human 
breast carcinoma xenografts. Following distribution of the phage through the body of 
the subject, excision of the target tissue allows recovery and amplification of any bound 
phage. This process can be repeated to further purify the bound phage. Once a 
sufficiently enriched phage pool is obtained, the peptide ligands exposed on the phage 
surfaces are sequenced and quantified to detennine relative affinity for the target tissue. 
Three libraries were investigated for tumour vasculature targeting members. 64 The 
libraries contained cyclic peptides of the forms CX5C, CX7C and CX3CX3CX3C, where C 
is cystine and X is any amino acid. Each library yielded one motif that stood out as 
targeting the implanted tumour. From the CX5C library, the motif Gly-Ser-Leu was 
isolated, but no further study was carried out on that peptide. The CX7C library yielded 
a peptide containing Arg-Gly-Asp, a sequence known to bind to CX vP3 and cxvP5 
integrins. 67,68 The full sequence of the peptide was Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-
Cys, abbreviated as RGD-4C, which clearly has the potential to form a number of 
different disulfide bonds. Only in 2001 was the disulfide bond arrangement of the most 
active fonn of this peptide found to be 1-4 and 2-3, where the numbers represent the 
cysteine residues numbered from the N-tenninus to the C-terminus.69 A final motif, Asn-
Gly-Arg, was isolated from the CX3CX3CX3C library. This sequence was already known 
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to bind the fibronectin receptor, integrin CX S p!.68,70 Due to the size of the full peptide, the 
authors synthesised the minimal peptide, cyclo-Cys-Asn-Gly-Arg-Cys (CNGRC), and 
found that it was able to inhibit binding of the parent tridecapeptide. 
More recent work on the CNGRC pentapeptide has revealed that, while it is able to bind 
to integrin CXSP!, its primary cellular target is aminopeptidase N.7! Aminopeptidase N, 
also known as cluster differentiation antigen 13 (CD13), is a zinc-dependent 
transmembrane peptidase that is expressed in a variety of tissues throughout the body, 
with particularly high levels found in the lumen of the small intestine where it is involved 
in protein digestion.72-74 The natural substrates of the enzyme are N-terminal hydrophobic 
amino acids;74 thus the peptide CNGRC is not expected to be efficiently cleaved by 
aminopeptidase N. It has been found that CD13 exists in a number ofisoforms 
throughout the body, with only the form found in the tumour vasculature being a strong 
binder of the CNGRC motif, thus providing the possibility of selective targeting despite 
the widespread distribution of the enzyme.7! 
The two targeting sequences RGD-4C and CNGRC were coupled directly to 
doxorubicin, although no precautions were taken to prevent the possibility of forming 
peptide oligomers.64 Furthermore, no data were presented to show that the peptide-
doxorubicin conjugates formed in a one-to-one ratio. The constructs were tested in vivo 
on mice bearing human breast carcinomas, and were found to greatly improve the 
survival of the mice and reduce the toxicity of doxorubicin. Examination of the tumours 
after extended treatment showed significant reduction in the tumour volume of mice 
treated with the doxorubicin conjugates and notable necroses. Finally, a substantial 
decrease in the number of metastases was reported for those mice treated with the 
targeted doxorubicin constructs. 
More recently, the CNGRC motifhas been studied further as a targeting residue to 
which doxorubicin was attached via a hydrolysable ester linker. 7s It was found that the 
intracellular distribution ofthe dox-CNGRC conjugate differed from that offree 
doxorubicin by being initially localised in the cytoplasm and moving slowly to the 
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nucleus, whereas free doxorubucin was seen only in the nucleus. Furthermore, addition 
of anti-APN antibodies did not change the intracellular distribution pattern of the 
conjugate, leading to the suggestion that the enzymatic activity of APN is not necessary 
for uptake of the conjugate. These results were reflected in the cytotoxicities determined 
for the conjugate and free doxorubicin which were not significantly different versus 
either APN positive or negative cells, suggesting that, in the studied systems, the 
CNGRC motifwas playing little, if any, role in the behaviour of the conjugate. 
While the observed results may cast doubt on the utility of the CNGRC motifas a 
targeting residue for anti-angiogenic directed cancer therapeutics, it is worth noting that 
the dox-CNGRC conjugate used in this research was notably more lipophilic than free 
doxorubicin, as detennined by a l-octanollphosphate buffered saline (PH 7.2) 
distribution measurement (5.3 vs 1 :2).75 This would not necessarily be expected, and 
may in fact be a reason for the relatively poor activity of the conjugate, as it may have 
been entering the cells by passive diffusion rather than receptor-mediated endocytosis. If 
this was the case, the reduced hydrophilicity of the conjugate may have contributed to 
the observed slow diffusion into the nucleus or even led to the conjugate being trapped in 
the many lipid membranes of the cytoplasmic organelles with free doxorubicin diffusing 
to the nucleus following release by cytoplasmic esterases. In any case, more study of this 
conjugate is clearly required to fully understand the observed results. 
Another research group has examined the use of the CNGRC motif to guide the delivery 
ofTNF-a to the vascular endothelium.76 TNF-a is an inflammatory cytokine that has 
been found to enhance the penetration into tumours, and hence the activity, of anticancer 
drugs (such as doxorubicin) when co-administered. Unfortunately, TNF-a is also highly 
toxic, with an effective dose being estimated at 10-50 times the maximum tolerated dose; 
therefore systemic administration is not viable. Conjugating the CNGRC targeting 
residue to TNF-a to was found to increase the effectivity of the drug by about five 
orders of magnitude, thus bringing the effective dose well below the maximum tolerated 
dose. 
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1.2 Natural Products 
The term 'natural product' is commonly used to refer to any of the secondary 
metabolites produced by living organisms. These are compounds which play no part in 
the primary metabolism of an organism. 77 Because natural products are not required for 
the basic functioning of a producing organism, the enzymes involved in their synthesis 
are subject to relatively little evolutionary constraint; thus natural products represent a 
huge range of structural diversity compared to primary metabolites. 
The structural diversity present in natural products has been exploited by humanity 
throughout the ages for a huge range of applications ranging from fragrances, flavours 
and dyes to medical remedies. The use of natural products in human medicine has 
received the most attention due to the necessity for ever-improved treatments for the 
array of ailments and diseases that afflict humans. The fact that over 60% of currently 
approved drugs are derived from natural products shows the value of investigating 
secondary metabolites for useful drug lead compounds.78 
A number of theories have been suggested to explain why organisms produce secondary 
metabolites; however, the most convincing was presented in a strong argument by 
Williams et al. 77 They propose that organisms that biosynthesize natural products gain a 
competitive advantage over those that do not due to the specific interaction of the 
produced secondary metabolites with biological receptors in competing organisms. This 
theory has become the accepted dogma and provides strong support for the investigation 
ofnatural products in the search for medically relevant compounds. 
1.2.1 Marine Natural Products 
Investigation of the secondary metabolites of terrestrial organisms has obviously been 
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much more extensive due to convenience of both sample collection and familiarity with 
the organisms present. Over the last three decades there has, however, been a dramatic 
increase in the interest expressed in chemicals produced by aquatic, and in particular 
marine, organisms. This has largely been caused by the availability of Self Contained 
Underwater Breathing Apparatus (SCUBA), which allows divers to access the seabed at 
depths of up to 40 meters, and submersible vehicles that allow access to depths of 1 000 
meters or more. Furthermore, the realisation that the oceans contain a biodiversity that 
surpasses that of the terrestrial environment and has been much less widely explored has 
provided motivation for researchers to begin investigating marine natural products. 
The marine environment seems to encourage the production of novel structures due to 
the high levels of halogens and nitrogen present, as well as the need for soft, sessile 
animals to develop chemical defenses against predation. Indeed, it has been shown that 
many marine animals produce natural products while under stress, and furthermore that 
natural products are common in organisms without an immune system. An interesting 
feature of marine natural products research is the variability in the compounds produced 
by an organism depending on the location and season. It is possible that this variation 
may be due to the presence of natural product-producing symbiotic micro-organisms, 
although this is far from certain.79 
Data from the National Cancer Institute (NCI) in the USA further illustrate the value of 
screening marine animals for potential pharmaceutical leads; the likelihood of discovering 
a novel anticancer lead compound has been found to be far greater when examining 
marine animals than other possible sources (Figure 1.2).80 Results from the Australian 
Institute of Marine Sciences have further shown that marine sponges (Phylum: Porifera) 
provide a particularly rich source of cytotoxic natural products, with over 11 % of 
specimens investigated displaying significant cytotoxicity. 80 
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1.2.2 The Marine Chemistry Group 
The Marine Chemistry Group at the University of Canterbury was formed in 1975 and in 
1983 began a programme aimed at investigating biologically active natural products 
produced by marine organisms, with a particular focus on sponges, from the oceans 
around New Zealand.8l Since 2000, the group has diversified somewhat with the 
development of a fungal programme to complement the well established sponge 
collection. The fungi obtained are largely marine in origin, although a significant number 
of terrestrial fungi have also been isolated. 
The Group has an extensive collection of New Zealand marine organisms, all of which 
have had a subsample extracted and examined for biological activity in the Marine 
Chemistry Group's in-house antitumour, antiviral and antimicrobial assays. Those 
organisms that display promising bioactivity in the small-scale extract are then extracted 
on a larger scale. These extracts are subjected to bioactivity-guided fractionation to 
isolate the active component(s) which are then identified using spectrometric and 
spectroscopic techniques. Over the last 20 years, a number of potent cytotoxins have 
been discovered by members of the Marine Chemistry Group, some of which are shown 
in Figure 1.3.82-87 
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Figure 1.2 Anticancer leads with significant selective cytotoxicity in the NCI 
Preclinical Antitumor Drug Discovery Screen by source 
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Unfortunately, none ofthe compounds discovered by researchers in the Marine 
Chemistry Group have yet proceeded to development as pharmaceuticals. One reason 
for this is the extreme cytotoxicity displayed by many of these compounds, some of 
which are toxic at nanomolar concentrations. It has been suggested that future cancer 
chemotherapies will rely on the targeted delivery of highly toxic compounds to cancer 
cells,88 and this is an area of research that is currently being investigated within the 
Marine Chemistry Group and indeed in the research described in this thesis which utilised 
the mycalamides (31 and 32), doxorubicin (19) and fumagillol (35). 
1.2.3 Mycalamides A (31) and B (32) 
Mycalamide A (31) was isolated and characterised from a highly active antiviral extract 
ofa New Zealand sponge of the genus Mycale. 89 The sponge was of particular interest 
as a crude extract showed antiviral activity not just in vitro, but also in vivo, which was 
unusual for sponge extracts. When 31 was re-isolated to provide material for extensive 
biological testing, a closely related and also highly antiviral compound, mycalamide B 
(32), was isolated, although it was present in less than half the level of my calami de A 
(31).90 
Pure mycalamides A (31) and B (32) both showed good in vitro bioactivity against P388 
murine leukemia and three human tumour cell lines, with nanomolar IC50s.91 In all 
cases, 32 was between two- and six-fold more active than 31. In vivo, both compounds 
possessed moderate to good activity against a range of murine and human tumours in a 
mouse model, with mycalamide B (32) again showing slightly better activity. An 
investigation into the mechanism of action of the mycalamides revealed that they 
inhibited protein synthesis, and it was suggested that this was the cause of their 
cytotoxicity.91 
The total synthesis of enantiomerically pure 31 and 32 was first reported in 1990, and 
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served to confIrm the stereochemistry which had previously been assigned on the basis of 
structural similarity to pederin (33).92 A number of subsequent syntheses have been 
reported for both mycalamide A (31) and B (32).93.94 While the syntheses remain lengthy, 
and therefore low yielding, synthesis would be a viable, albeit costly, source for material 
should either of the mycalamides or derivatives thereof show value as therapeutic agents. 
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1.2.4 Fumagillol (35) 
The natural product fumagillin (34) was isolated in 1949, although it was another eleven 
years before the structure was elucidated, and the stereochemistry was determined 
in1962.95-97 It was initially investigated due to its activity against bacteriophage, but 
more recently, fumagillin (34) was rediscovered by workers in the laboratory of Judah 
Folkman in a serendipitous uncovering of its anti-angiogenic activity.98 
Fumagillol (35), a hydrolysis product offumagillin, is a convenient starting material for 
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producing derivatives of the core structure through reaction at the hydroxy group, and 
indeed a number of derivatives at this position have been prepared and investigated for 
anti-angiogenic activity.99,loo 
One fumagillol derivative, TNP-470 (36), is currently under investigation as a potential 
anti-angiogenic cancer therapeutic agent. The ability of36 to inhibit endothelial cell 
proliferation in vitro is approximately 50 times higher than that of fumagillin (34).98 
Further in vitro examination ofTNP-470 (36) has confmned its ability to inhibit 
angiogenesis in a number of systems. IOI ,I02 TNP-470 (36) has completed phase I trials 
and was found to cause only modest and reversible side effects, and led to disease 
stabilisation in some cases, although no objective responses were observed. 62 
The cellular target offumagillin (34) and derivatives has been determined to be 
methionine aminopeptidase-2 (MetAP2).I03,I04 MetAP2 is an intracellular peptidase that 
is able to catalyse the removal ofN-terminal methionine residues from newly synthesised 
polypeptides. Fumagillin (34) binds in the active site of the enzyme where an histidine 
residue attacks the spiro-epoxide, leading to covalent modification and permanent 
inactivation of the enzyme. 105 The exact effect of MetAP2 inhibition is still not known, 
but it is known that fumagillin (34) does not cause a decrease in the bulle synthesis of 
o 
o 
o Fumagillin (34) Fumagillol (35) 
TNP-470 (36) 
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protein in affected cells, so some other downstream effect must be responsible for 
cessation of cell division. 
29 
The total synthesis of fumagillol has been reported, with an eleven step synthesis 
providing material indistinguishable from fumagillol prepared from natural fumagillin. 106 
The synthesis is relatively efficient, and can be used to provide fumagillol on a medically 
relevant scale. 
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1.3 Polymer Drug Conjugates 
The idea of using polymers as drug carriers was first put forward in 1975 by Ringsdorf 
and represents an entirely new way of transporting drugs to their target site. 107 The basic 
structure of a polymer drug conjugate (Figure 1.4) is based upon a biocompatible, 
water-soluble polymer to which a low molecular weight drug is attached. In order to 
enable the drug to be released at the target site, it is attached to the polymer by a 
biodegradable linker, or biolinker. The use of a polymeric scaffold presents the 
opportunity for attachment of other compounds, such as a second drug or a targeting 
residue. The conjugation of a second drug to a single polymeric backbone could be used 
to maximise the efficacy of a pair of drugs through synergistic effects, which are already 
well known in cancer chemotherapy. A targeting residue can be used to ensure selective 
drug delivery to the disease site. 
In the absence of a targeting residue, passive targeting determines the biodistribution of a 
polymer drug conjugate. This is essentially the mechanism utilised by all of the Jaw 
molecular weight pharmaceuticals currently used for treating cancer, in which the final 
distribution is determined by the body's circulatory system. With low molecular weight 
molecules, this results in an essentially even load through most of the body, with the liver 
rapidly processing the drug and the kidneys removing the drug and drug metabolites 
-C3 .. 1tC. BIodegradable 
linker 
Figure 1.4 Schematic representation of a polymer drug conjugate 
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from the blood. This situation is far from ideal as the drug has to be adrn.in.istered in a 
high dose to achieve an effective concentration at tbe tumour site and also leads to 
extensive drug activity at non-cancerous sites. lOS 
31 
Polymer therapeutics are known to show a different biodistribution profile to low 
molecular weight drugs under passive targeting via a mechanism called the enhanced 
permeability and retention (EPR) effect (Figure l.S).I09.111 The newly recruited 
vasculature of a tumour is incomplete, with gaps between endothelial cells which allow 
the extravasation of plasma and dissolved molecules. Hydrophilic polymers are not 
efficiently translocated across the endothelium present throughout healthy tissue, so only 
the 'Leaky' vessels within a tumour allow a significant fraction ofpolymer therapeutic to 
escape the circulatory system. Beyond having a leaky vascular system, tumours also 
have poor lymphatic drainage. In ordinary tissue, plasma that escapes into the interstitial 
space is returned to the venous system via the lymphatic system. However, in a tumour 
the network of lymph vessels is not developed to the same extent as it is in non-
cancerous tissue, leading to poor drainage of interstitial plasma. This reduction in 
interstitial drainage acts in concert with the increased rate of extravasation to cause an 
accumulation of solutes in a tumour. Polymers are known to be particularly susceptible 
to passive accumulation in tumours caused by the EPR effect, with between five and ten 
percent of a polymeric probe being accumulated per gram of tumour in a study using 
mouse models. 112 It has aJso been shown that the use ofpolymer-bound drugs leads to a 
Norma) tissue 
Lower vasculature permeability 
in normal tissue prevents the 
poe from escaping 
Figure I.S The enhanced permeation and retention (EPR) effect 
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more homogeneous drug distribution and thus more efficient antitumour activity within a 
tumour. 113 
Another advantage of polymer drug conjugates, quite unrelated to the EPR effect, is that 
the high molecular weights of the conjugates ensure a prolonged circulation time. One 
of the difficulties with using low molecular weight drugs is maintaining a therapeutic 
concentration of drug in the blood for any length of time without reaching a toxic 
concentration. The rapid elimination of low molecular weight compounds from the 
blood tends to lead to a treatment regime consisting of many dosings, which causes a 
saw-tooth like profile of drug concentration in the blood. Polymer therapeutics are only 
slowly eliminated from the blood compartment, thus acheiving a prolonged release type 
profile where a concentration within the therapeutic window can be maintained (Figure 
1.6).114,115 Increasing molecular weight has been shown to lead to longer circulation 
times and an increase in therapeutic efficiency of polymer doxorubicin conjugates. 116 
The conjugation of highly hydrophobic drugs to a hydrophilic polymer results in an 
overall increase in the solubility of the drug, which in some cases is an important 
consideration as it bypasses any requirement for drug administration via an oil or 
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Figure 1.6 Comparison of prolonged and immediate release drug delivery 
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emulsion injection. The increased polarity and size ofa polymer drug conjugate also lead 
to an alternative and more efficient mechanism of entry of the compound into cells 
(Figure 1.7).114 Low mo lecular weight lipophilic drugs enter cells by simple diffusion 
across the plasma membrane into the cytosol, but this route is unavailable to polymer 
drug conjugates, which are instead taken into the cell by pinocytosis. Depending on the 
composition of a polymer~drug conjugate, it may be taken up by either fluid~phase, 
adsorptive or receptor~mediated pinocytOSiS.11 7 Fluid~phase pinocytosis involves the 
capture of extracellular fluid and is the mechanism of uptake of soluble compounds 
which display no interactions with the cell membrane. Uptake is a slow process with a 
rate that is dependent solely on the concentration of the compound in the extracellular 
fluid. Adsorptive pinocytosis describes the uptake of compounds that interact non~ 
specifically with the plasma membrane through either hydrophobic moeities that can 
insert into the membrane or cationic components that can interact with the charged 
phospholipid head groups on the surface of the membrane. The rate of adsorptive 
pinocytosis is greater than that of fluid~phase pinocytosis, due to an increase in the 
effective concentration of the polymer in the vicinity of the cell membrane, but the 
localisation remains random. Receptor-mediated pinocytosis is the uptake mode 
Drug -... 
Figure 1.7 Comparison of cellular uptake offree and polymer bound drug 
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accessible to polymers conjugated to ligands for cell membrane receptors. These ligands 
can themselves be large or small molecules that bind to the receptors embedded in the 
cell membrane of ideally only target cells. This mode of uptake has the two advantages 
oftargeting specific cells as well as increasing the rate of drug uptake beyond that of 
adsorptive pinocytosis. 
Following pinocytosis, the newly formed intracellular vesicle fuses with transport vesicles 
from the trans Golgi network, leading to a progressive decrease in the pH ofthe vesicle 
as it becomes an endosome and [mally a lysosome. As well as being acidic, lysosomes 
are rich in proteases and these two features can be harnessed to allow intracellular 
release of the drug from a polymer drug conjugate. 118 Just as they are unable to cross the 
cell membrane, polymers are unable to diffuse across the lysosomal membrane, so a 
release mechanism is required to free the drug which can then diffuse into the cytosol to 
exert its cytotoxicity.119 The release mechanism is provided by the incorporation of a 
biodegradable linker between the polymer backbone and the drug moiety. Researchers 
have investigated the use of pH sensitive biolinkers,120-122 but there is only a difference of 
about two pH units between the blood (pH 7.4), where the biolinker should be 
completely stable, and the lysosome (pH 5.5), where the biolinker should be rapidly 
degraded, so it has proven difficult to achieve the desired properties. Another possibility 
is to take advantage of the degradative enzymes that are found in the lysosome and not 
at significant levels elsewhere. To this end, peptide biolinkers have been developed that 
are totally stable in circulation, but are rapidly degraded by the peptidases ofthe 
lysosome. 123-125 
1.3.1 HPMA Copolymer Conjugates 
Drug conjugates utilising N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer as 
the backbone are amongst the earliest developed and most extensively studied. 126 HPMA 
is a hydrophilic, non-immunogenic and biocompatable polymer that was originally 
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developed as a plasma expander. 127 
PIG (37) is a simple HPMA based drug conjugate containing doxorubicin conjugated to 
the polymer backbone by a Gly-Phe-Leu-Gly peptidyl biolinker. PKI (37) has been 
found to be more effective than free doxorubicin in in vivo studies with mice,128-130 with 
an apparent absence of any cardiotoxicity,131,132 which is usually the dose-limiting toxicity 
in treatments with free doxorubicin. Phase I clinical trials have corroborated these 
results in humans, with the maximum tolerated dose being 4.5 times that offree 
doxorubicin. 133 PIG (37) is currently undergoing Phase II clinical investigation to clarify 
the significance of its antitumour activity. 
o OH 0 
PIG (37) 
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PK2 (38) is a second generation analogue ofPK1 (37) in which a galactosamine 
targeting moiety has been incorporated to direct the conjugate to hepatocytes, which 
express the galactose-binding asialoglycoprotein receptor. Investigation of the biological 
distribution ofPK2 (38) revealed that it did in fact selectively target the liver, with 
approximately 60% of the polymer being located in the liver after one hour, compared to 
4% for the untargeted PIG (37).119 As with PIG (37), PK2 (38) was found to possess 
greatly reduced cardiotoxicity compared to free doxorubicin. 134,135 PK2 (38) has entered 
phase I clinical trials and a recommended dose of 1.7 times that of free doxorubicin has 
been determined for future trials. 136 
o 
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1.4 Aims of this work 
The primary aim of the work presented in this thesis is to prepare polymer drug 
conjugates that are targeted to tumour neovasculature. This approach seeks to utilise the 
remarkable targeting properties of the small peptides discovered by Arap et al. (see 
Section 1.1.2.1) in concert with the pharmacological advantages presented by a 
polymeric scaffold. In particular, the polymer was seen as providing a longer circulation 
time and reduced immunogenicity. The EPR effect was not a primary reason for moving 
to a po lymeric structure as the active targeting was designed to ensure appropriate drug 
distribution. 
The preparation and testing of polymers targeted to the developing tumour vasculature 
was undertaken as a proof of principle investigation to determine whether small targeting 
residues are able to direct the localisation ofa much larger polymer to specific cells in the 
body. If this is found to be the case, it opens a number of possibilities for targeting not 
only the tumour vasculature, but any cellular address within the body. Researchers have 
previously demonstrated the ability oflarge molecules such as antibodies and proteins to 
target polymer drug conjugates. 137 Galactosamine has also been used to successfully 
target hepatocytes. The use of small peptidic targeting residues has the advantages of 
low molecular weight, high specificity, and provides the opportunity to develop novel 
sequences to target any desired tissue using the phage display libraries described 
previously (Section 1.1.2.1).65,66 
The pentapeptide cyclo-Cys-Asn-Gly-Arg-Cys was chosen to be used as the targeting 
moiety for four main reasons. First, it is a shorter peptide than the alternative RGD-4C 
motif, which simplifies the synthesis. Second, the RGD-4C peptide contains two aspartic 
acid residues, which require side chain protection whereas CNGRC contains asparagine, 
which can be used without any extra protection. Third, the optimal cystine bond 
arrangement was not defmed until 2001, and there was concern prior to this that 
preparation of a homogeneous and active targeting component based on RGD-4C would 
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be difficult. Finally, the cellular target ofCNGRC is the receptor aminopeptidase N, 
which is known to be internalised and recycled by cells.73 This is important as it ensures 
that any polymer drug conjugate that binds to the receptor will be taken into the cell. 
Beyond the preparation of polymer drug conjugates, a further aim of this work was to 
prepare monomeric conjugates which incorporated the targeting peptide, a biolinker and 
a drug. The testing of these low molecular weight conjugates beside their polymer-based 
analogues would enable some determination ofthe effect of the polymeric scaffold. The 
monomeric constructs would also allow an examination of the necessity of a biolinker, 
which is of interest as drug release was not addressed with the original targeted peptide-
doxorubicin conjugates.64 
Finally, the use of a number of different drug components was considered to be an 
important goal ofthis research. L-Tyrosinamide (39) was to be used as a drug substitute 
as it is a non-toxic amino acid derivative that can be radio labelled with 1231 or 1251 for 
biodistribution studies. 138 The basic drug to be included was the well established and 
very well-researched drug doxorubicin (19). This would allow the effect of the targeting 
residue to be detenruned by comparison with PIG (37). The anti-angiogenic compound 
fumagillol (35) was also to be used to determine whether targeting could enhance its 
toxicity to angiogenic cells. Finally, the marine natural products mycalamide A (31) and 
B (32), both discovered by researchers in the Marine Chemistry Group, were to be 
utilised in an attempt to control and take advantage of their extraordinary cytotoxicities. 
OH 
o 
L-Tyrosinamide (39) 
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Chapter 2 
Peptide Synthesis 
2.1 Introduction 
The chemical synthesis of pep tides is a useful technique for the preparation of short 
oligopeptides or modified peptides which are either impractical or impossible to produce 
using recombinant expression systems. The central reaction sequence in peptide 
synthesis is the condensation of an N-protected amino acid with a carboxyl-protected 
amino acid followed by deprotection of one of the termini to allow another coupling 
reaction (Figure 2.1). This process is repeated, allowing the build-up of the full peptide 
sequence in an iterative manner. 
There is a huge variety of protecting groups available for the termini as well as for the 
reactive functionalities found in the side-chains of some amino acids. The decision as to 
which protecting group should be used at any particular position is largely guided by 
both ease of use and orthogonality. For practical reasons, it is important to have 
relatively easily removed protecting groups on the termini of the peptide as these are the 
groups which must be removed most frequently. The protecting groups used on the 
+ 
t N-terminal deprotection 
or 
C-terminal de rotection 
Figure 2.1 Representative peptide synthesis cycle 
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side-chains of amino acids are generally selected to be orthogonal, meaning they require 
different conditions for removal, to those on the termini. This allows the side-chains to 
remain protected during the peptide synthesis itself, with release of any potentially 
reactive groups only at the end of the synthesis. 
The production of synthetic peptides was revolutionised in 1963 when Merrifield 
introduced the technique of Solid Phase Peptide Synthesis (SPPS).139 This technique 
uses an insoluble resin in place of one the protecting groups. The preferred point of 
attachment of a peptide to the solid phase is at the carboxyl terminus. The primary 
advantage of using SPPS is that the growing peptide remains attached to the solid resin 
during the synthesis, allowing spent reagents to be removed from the reaction vessel by 
filtration. This greatly simplifies the synthetic process by obviating the need for 
purification after each reaction during the stepwise generation of a peptide; however, it 
does create a requirement for very high coupling efficiencies (ideally over 99%) because 
purifying the desired peptide away from a family of deletion peptides (where at least one 
amino acid residue is missing) can be a very difficult and time consuming task. The 
required reaction efficiencies can be achieved routinely using modern coupling reagents 
such as members of the phosphonium family (BOP, PyBOP, PyBroP) and the uronium 
family (HBTU, TNTU, TSTU) (Figure 2.2).140 
[ CJ~-Br t PF6-
BOP PyBOP PyBroP 
HBTU TNTU TSTU 
Figure 2.2 Some modern coupling reagents 
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There are currently two main systems commonly used for SPPS which rely on either 
acid-labile t-butyloxycarbonyl (tBoc) or base-labile fluorenylmethoxycarbonyl 
(Fmoc)'41,'42 protection chemistry for the N-terminus of the growing peptide. The 
carboxyl terminus is protected by attachment to a base-labile or acid-labile solid phase 
respectively, thus ensuring total orthogonality between the two termini of the peptide. 
41 
The work in this project utilised only Fmoc N-terminal protection as the mild 
deprotection conditions were considered unlikely to cause degradation of chemically 
sensitive natural products. This provided the possibility for final deprotection of the 
peptides in the presence of the drug components at the end of the low molecular weight 
conjugate syntheses (see Chapter 4). 
Chapter 2: Peptide Synthesis 
2.2 Tetrapeptide biolinker 
Due to the overall strategy for the synthesis of the polymer drug conjugate, the 
tetrapeptide biolinker, Gly-Phe-Leu-Gly, was required in an N-protected form so that 
amine containing drugs could be coupled to the peptide without the potential for 
formation of polymers through coupling of unprotected tetrapeptide units. The Fmoc 
protecting group was chosen for N-protection as the gentle removal conditions were 
considered to be the most compatible with the natural product toxins that were to be 
used as the drug component. 
42 
There was no necessity for protection other than at the N-terminus during the synthesis 
of the tetrapeptide Fmoc-Gly-Phe-Leu-Gly-OH as all of the amino acid side-chains are 
umeactive. 
2.2.1 Fmoc-Gly-Wang resin 
Initially, loading of fresh Wang resin (p-alkoxybenzyl alcohol resin) 143 was carried out 
using the Sieber method recommended for high loading levels in which a high-capacity 
(2.07 mmollg) resin is reacted with one equivalent ofFmoc-protected amino acid, 1.1 
equivalents of2,6-dichlorobenzoyl chloride and two equivalents of pyridine in DMF 
overnight. 144 During the course of this work it was found that superior results were 
obtained when reacting a low- to medium-capacity resin (0.83 mmollg) with Fmoc-
glycine (1.15 equiv.), 2,6-dichlorobenzoyl chloride (3.45 equiv.) and pyridine (6.9 
equiv.) again in DMF overnight. On one occasion the reaction mixture was stirred at a 
moderate rate, and the following day all that could be recovered from the suspension by 
filtration was a fine white powder (where usually a granular tan solid could be expected). 
Examination of this powder under a light microscope revealed that the resin beads had 
been mechanically destroyed by the magnetic flea during the overnight stirring. After 
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this discovery the reaction mixture was always vigorously shaken instead of being stirred, 
which was found to be a suitable method for preventing damage to the resin while 
ensuring homogeneity of the reaction. 
The determination of the level of substitution ofFmoc-protected amino acid onto the 
resin is a procedure which is prone some degree of error, so can only be considered to 
provide an approximate loading level which can be used to calculate required amounts of 
reagents later in the synthesis. In particular, the need to weigh very small amounts of 
resin « 1 mg) accurately was the frrst problem. It was also found that the age of the 
20% piperidine/DMF solution used in the analysis greatly affects the UV readings 
obtained, so it is imperative that only a freshly made solution is used, but the effect of the 
ages of the individual reagents remains unlmown. 
Once the level ofFmoc-glycine attached to the resin was determined and found to be 
sufficiently high (typically the loading level achieved was about 0.8 mmol/g), the 
remaining benzyl alcohol groups of the resin had to be end-capped. This was carried out 
using benzoyl chloride (4 equiv.) and pyridine (6 equiv.) in 1,2-dichloroethane. The 
equivalents are determined relative to the total number of potential sites of the unloaded 
resin, so in fact there was a huge excess of reagents as approximately 80% of the benzyl 
alcohol groups had already been reacted. The resin was washed and dried thoroughly 
prior to peptide synthesis. 
2.2.2 Fmoc-Gly-Phe-Leu-Gly-Wang resin synthesis 
The glassware used for all solid phase peptide syntheses allowed the resin to be agitated 
by bubbling N2 through a frit and then subsequently switched to vacuum to allow 
drainage. 
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Fmoc-Gly-Wang resin was suspended in DMF and agitated for 15 minutes to preswell 
the resin beads, thus allowing easy access for reagents during the synthesis itself. The 
DMF was drained and a 20% piperidine/DMF solution was added, with bubbling, to 
deprotect the glycine residue. After ten minutes the reaction was drained and the resin 
was washed thoroughly with DMF and isopropanol. A small sample of the resin was 
removed and sUbjected to the Kaiser test (see Section 7.1) to confirm the presence ofa 
free amine. The resin was then rinsed again with DMF before changing the collection 
flask. It was found that if the collection flask was not replaced between deprotection and 
coupling stages, the nitrogen bubbling up through the resin could transfer piperidine 
vapour from the flask to the reaction suspension during coupling, which resulted in 
deprotection during this stage. This inevitably led to failure of the whole synthesis, so 
the importance of changing the collection flask cannot be overstated. The synthesis 
continued with the addition of a DMF solution containing Fmoc-Leucine (2 equiv.), 
HBTU (2 equiv.) and DIPEA (4 equiv.). After bubbling for 60 minutes, the resin was 
again drained, rinsed with DMF and sUbjected to the Kaiser test which indicated the 
absence of any free amine groups. The process was then repeated, with deprotection 
followed by coupling ofFmoc-glycine and finally Fmoc-phenylalanine. The synthesis 
cycle is represented in a general form in Figure 2.3. Following the final coupling step, 
the resin was washed thoroughly with DMF, MeOH and DCM before drying overnight 
under vacuum and in the presence ofP 205' 
Rn 
Fmoc .... ~ _OH 
I\J~ Ir + 
H 0 
HBTU (2 equiv.) AyRn Hy....° 
DIPEA (4 equiv.) /moc .... N N R' DMF H eSIn 
o Rn+1 
20% Piperidine/OIV1F 
Figure 2.3 Synthetic cycle used throughout this research for peptide preparation 
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2.2.3 Fmoc-Gly-Phe-Leu-Gly-OH (40) 
The peptide-bearing resin was cleaved twice with a strongly acidic mixture consisting of 
95% TFAl2.5% H20/2.5% TES and rinsed with the same solution. The TES was 
included in the cleavage mixture as a cation scavenger, which was not entirely necessary 
in the case of this peptide as there are neither any sources of reactive cations from the 
cleavage process nor any residues which would be prone to attack; however, as the 
purification was easily achieved there was also no good reason to exclude TES from the 
reaction. The collected acidic solutions were diluted with water, which caused the 
formation of a soft, gel-like white precipitate and extracted with DCM. The combined 
organic fractions were taken to dryness and the solid residue was re-dissolved in THF, 
which was added to an excess of hexane to precipitate the pure peptide in a 36% yield. 
While this yield is lower than desired, the ease of synthesis and purification made the 
solid phase process a viable option. 
2.2.4 Characterisation of Fmoc-Gly-Phe-Leu-Gly-OH (40) 
The proton and carbon NMR spectra ofFmoc-Gly-Phe-Leu-Gly-OH (40) were readily 
assignable from COSY, HSQC and CIGAR 2D NMR experiments. The chemical shifts 
for the proton and carbon NMR spectra are shown in Table 2.1 with the structure and 
important CIGAR correlations shown in Figure 2.4. 
An obvious starting point for assigning the structure was the geminal methyl groups of 
leucine, Hl6 and Hl7 at 0.97 and 0.93 ppm respectively. COSY correlations enabled 
the stepwise identification ofHl5, H14, the (X-proton H13 and amide NH12 in that 
order, with the HSQC spectrum providing the chemical shifts of all the corresponding 
carbon atoms. CIGAR correlations confirmed the structure of the leucine residue and 
provided the important inter-residue linkages from NH12 to the neighbouring carbonyl at 
C 11 and also from H 13 to the carbonyls at C 11 and C 18. C 18 was also seen by the 
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Table 2.1 Proton and carbon NMR data for 40 obtained in d6-DMSO 
Position 
2a 
2b 
3 
4 
5 
6a 
6b 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20a 
20b 
21 
l' 
3' 
4' 
5' 
6' 
7' 
8' 
9' 
7.62 
3.73 
3.61 
8.10 
4.65 
3.12 
2.88 
7.31 
7.31 
7.26 
8.22 
4.44 
1.58 
1.70 
0.97 
0.93 
8.19 
3.86 
3.81 
4.35 
4.31 
7.80 
7.42 
7.51 
7.99 
43.3 
43.3 
169.6 
54.3 
37.6 
37.6 
138.3 
129.8 
128.5 
126.8 
171.7 
51.4 
41.5 
24.7 
23.5 
22.3 
172.9 
41.2 
41.2 
172.0 
157.2 
66.3 
47.1 
144.0 
125.9 
127.7 
128.3 
120.7 
COSY 
H2a, H2b 
HI, H2b 
HI, H2a 
H5 
H4, H6a, H6b 
H5, H6b 
H5, H6a 
HI3 
Hl2, H14 
H13, HI5 
HI4, HI6, HI7 
HI5 
HI5 
H20a, H20b 
HI9, H20b 
HI9, H20a 
H7' 
H6', H8' 
HT, H9' 
H8' 
CIGAR 
C3, CI' 
C3, C1' 
C3 
C3, C6, C7, Cll 
C7, C8, Cll 
C7, C8, CII 
C6, C7, C8, C9, CIO 
C6, C7, C8, C9, ClO 
C6, C7, C8, C9, CIO 
Cll 
Cl1, C14, CI5, CI8 
C13, CI6, Cl7, CI8 
CI4, C15, C17 
CI4, CI5, C16 
CI8, C20 
C21 
C21 
CI', C4" C5' 
C3' 
C4" C8' C10' 
C5', C9' 
C6', CIO' 
C5', CT, CIO' 
46 
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Figure 2.4 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
observed for 40 
47 
amide NH 19, which showed a correlation to C20. The diastereotopic protons H20a and 
b were readily identified ttu-ough HSQC correlations and in turn indicated the carbonyl 
C21, which was not correlated to any other protons, thus implying the presence of the 
expected C-terminal acid group. Referring back to the leucine residue, the carbonyl at 
Cil was observed to show a correlation from protons H5, H6a and H6b of the 
phenylalanine residue. These protons were aU correlated to each other in the COSY 
spectnun, indicating the presence of an ABX system, and the HSQC spectral data 
confumed the cotu1ectiviry ofH6a and H6b to C6 as well as providing the chemical shift 
ofC5. H5 provided a CIGAR correlation to the relatively downfield, non-protonated 
aromatic carbon C7, and H6a,b provided correlations further into the aromatic ring to 
C8. The proton shifts of the phenylalanine aromatic ring were overlapping and not 
clearly identifiable in the proton spectrum; however, COSY, HSQC and CIGAR spectra 
clearly showed all of the expected correlations. The connection to the N-terminal glycine 
residue was provided by CIGAR correlations to the carbonyl C3 from both the a-proton 
H5 and the amide NH4 (which was in tum identified by a COSY correlation from H5). 
The glycine residue itselfwas identified by the diastereotopic protons H2a and H2b 
which showed CIGAR correlations to C3 and the distinctively upfield carbamate 
carbonyl C] '. HSQC spectroscopy gave the chemical shift 0[C2, and the COSY 
spectrum provided the chemical shift ofNHl. Interestingly, NHI did not show any 
correlations in the CIGAR spectrum which was unexpected given that aU of the main 
chain amide protons had shown clear correlations to their neighbouring carbonyl carbon. 
The reason for this is not known, but carbamate protons in other peptides prepared also 
failed to show CIGAR correlations to neighbouring carbonyl groups so this would seem 
to be a general property of carbamates. H3' showed CIGAR correlations to C 1 " C4' and 
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C5', thus clearly indicating its position in the molecule. H4' shared a COSY correlation 
with H3', but did not provide any CIGAR correlations deeper into the aromatic ring(s) of 
the Fmoc group. The protons H6' to H9' were clearly identified by their relationships in 
the COSY spectrum, and their orientation was indicated by a CIGAR correlation from 
H6' to C4'. The last remaining chemical shift, that ofClO', was provided by CIGAR 
correlations from H6', H8' and H9'. 
The molecular formula for 40, C34H38N407' was obtained by HRESIMS as the 
protonated adduct with a mass of 615.28 (1.95 ppm). 
An analytical HPLC injection (C18, A: HzO(A), B: ACN, gradient I) showed a single 
peak at a retention time of 15.37 min with a characteristic UV chromophore representing 
the Fmoc group ofthe tetrapeptide. 
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2.3 Targeting peptide 
The targeting peptide, cyclo-Cys-Asn-Gly-Arg-Cys, was required in two forms - fully 
protected for coupling to the biolinker tetrapeptide to produce low molecular weight 
targeted drugs, and cyclised and fully deprotected for coupling directly to the polymer to 
produce the high molecular weight targeted drugs. 
As with the biolinker synthesis, Fmoc was used for protection of the N-terminus. This 
was due to the need for deprotection in the presence of the drug components in the case 
of the low molecular weight conjugates. 
The protecting group that was chosen for the cysteine residues was acetamidomethyl 
(Acm). There were a number of reasons for selecting this protecting group over other 
available options. Due to the need to prepare the targeting peptide in a fully protected 
form, it was not possible to use the most common cysteine derivative, S-trityl cysteine, as 
this protecting group is removed by TFA so would not survive cleavage of the peptide 
from the resin. Acm, along with a number of other groups, can be removed with 
concomitant oxidation to form a disulfide. 145 This process can be carried out while the 
peptide is still attached to the resin, providing a pseudo-dilution effect leading to the 
preferential formation of intramolecular disulfides. In the case of Acm, the deprotection-
oxidation can be carried out using either 12 or thallium (III) salts, which provides a 
degree of flexibility not offered by other groups which allow direct disulfide bond 
formation under only one set of reaction conditions each. The final advantage of the 
Acm group is its polarity which helps to prevent hydrophobic collapse of the resin-bound 
peptide by ensuring efficient solvation. 
The nucleophilic guanidine of arginine was protected using the 4-methoxy-2,3,6-
trimethylbenzenesulfonyl (Mtr) derivative. This was the most suitable protecting group 
as the nitro derivative, which is the only commercially available non-acid labile option, is 
prone to side reactions during acylation and cleavage as well as being incompatible with 
a disulfide due to its requirement for reductive cleavage. The remaining options are all 
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sulfonyl derivatives which display varying degrees of acid lability. Mtr was chosen as it 
is intermediate in lability, so could be removed without the need to resort to extreme 
conditions but could also be retained during removal of the peptide from the resin. 
2.3.1 Fmoc-Cys(Acm)-Wang resin 
Although this reaction was carried out in exactly the same manner as that described 
already for the loading ofFmoc-glycine onto Wang resin, the actual levels of substitution 
achieved were consistently lower than those achieved using the other amino acid. The 
reasons for this are unknown; however, a variation in the loading level achieved 
dependent on amino acid is well known, leading to the possibility of steric hindrance, 
electronic effects, or a combination of the two being likely cause(s). 
2.3.2 Fmoc-Cys(Acm)-Asn-Gly-Arg(Mtr)-Cys(Acm)-Wang resin 
The synthesis of this resin-bound peptide was initially carried out in exactly the same 
manner as described earlier for Fmoc-Gly-Phe-Leu-Gly-Wang. For the final two 
coupling reactions with Fmoc-asparagine and Fmoc-cysteine(Acm), HOBt (2 equiv.) was 
added to help prevent any dehydration of the asparagine amide side chain, which is a 
known side-reaction during peptide synthesis using unprotected asparagine 
(Figure 2.5).141,146 
o 
~NH2 R R' 'N H 
o 
~N R 7 R, 'N H 0 
Figure 2.5 Conversion of asparagine to ~-cyanoalanine under dehydrating 
conditions 
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Despite this precaution, the product of the synthesis when HOBt was included was still 
found to contain a sizable proportion (approximately one third of the total peptide 
present) of asparagine-dehydrated peptide. 
While methods for the conversion of nitriles to amides have been reported,147-149 it was 
felt that the most efficient technique would be to prevent the formation of the nitrile in 
the first place, so another synthesis of the peptide was carried out, with the HOBt 
additive replaced by N-hydroxysuccinimide. As N-hydroxysucciJtimjde esters are 
somewhat less 'activated' than HOBt esters, it was boped that NHS might provide 
superior protection. This was found to be the case; in fact, with the addition ofNHS, no 
dehydrated product could be detected by HPLC (CI8, A: H20(A), B: ACN, gradient 1) 
or ESIMS (Figure 2.6). 
2.3.3 Fmoc-Cys(Acm)-Asn-Gly-Arg(Mtr)-Cys(Acm)-OH (41) 
The protected targeting peptide was cleaved from the resin with a TF A soJution 
containing phenol as a calion scavenger, and the acidic solution was diluted with water 
,'" 
"" 
...-- Desired peptide 
s 
......... 
I 
Asparagi ne-dehydrated peP! ide 
Figure 2.6 HPLC chromatogram of crude peptide from synthesis incorporating HOBt 
(black trace) and NHS (blue trace) to reduce asparagine dehydration 
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and dried immediately to prevent cleavage of the acid labile Mtr protecting group. 
Initially, a small scale attempt at purification was carried out using nonnal phase 
chromatography on a bed of silica by diluting the combined acidic cleavage solutions 
with acetone, applying to the top of the dry silica bed then eluting with acetone, ACN 
and 20% H20IACN. The desired peptide material eluted in the third fraction but was 
heavily contaminated with silica as well as retaining the initial contaminants. Other 
eluant systems attempted for silica chromatography on a small, trial scale, were a stepped 
gradient consisting ofDCM, 1: 1 DCM:acetone, acetone, 1: 1 acetone:ACN, ACN, 1: 1 
ACN:MeOH and MeOH, in which the peptide eluted in the final, methanolic, fraction; 
and a gradient from 50% MeOHlACN to 100% MeOH in 10% steps in which 41 eluted 
over the first three fractions. None of the silica chromatography carried out was 
successful in providing a significant purification of the peptide. 
The combined peptide-containing fractions were dried and subjected to reverse phase 
chromatography using the :MPLC system running an isocratic SO% MeOHlH20 eluant 
with detection at 254 nm; however, the separation was poor, with both the desired 
peptide 41 and its asparagine dehydrated counterpart co-eluting. 
Purification was then attempted using preparative HPLC (Dynamax C IS) with a gradient 
running from 40% ACN/H20(A) to 60% ACNIH20(A) over 20 minutes with UV 
detection at 254 nm. Peaks eluting at 14 minutes and 18 minutes were collected and 
found by LRESIMS to be the desired peptide 41 and the dehydrated derivative 
respectively. While this did provide the pure peptides as desired, it was far too laborious 
and time-consuming to be carried out on as large a scale as required, thus work 
continued toward detennining an appropriate preparative purification technique. 
Purification was carried out using reverse phase MPLC run using an isocratic 50% 
ACN/H20(A) eluant, collecting three cuts - early, middle and late. The middle cut was 
pure except for the presence of a single contaminating p-substituted aromatic compound 
which co-eluted even under analytical HPLC conditions (CIS, A: H20(A), B: ACN, 
gradient: 50% B (0 min), 50% B (4 min), 56% B (7 min), 100% B (S min)) . 
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In order to remove this lower molecular weight contaminant, size exclusion 
chromatography was attempted using LH20 with MeOH as the eluting solvent but no 
separation was achieved - both high and low molecular weight compounds eluted 
together in one very broad peak. The chromatography was then repeated using 50% 
ACNIH20 as the eluant, which was found to be a far superior solvent system. The first 
peak, eluting at a volume of approximately 270 mL consisted of primarily the desired 
peptide 41. 
It was found that by an iterative cycle ofMPLC and size exclusion chromatography the 
fully protected peptide 41 could be isolated in a very pure state with a yield of 6.6%. 
2.3.4 Characterisation of fully protected CNGRC (41) 
Due to the poor solubility of 41 in nearly all solvent systems, a solvent mixture of 50% 
CD3CNID20 had to be used for the NMR analysis. The presence of deuterated water 
resulted in the immediate exchange of all of the amide protons and hence they were not 
observed in any of the spectra. A full assignment of the proton and carbon chemical 
shifts was achieved using COSY, HSQC, CIGAR and IMPRESS 2D NMR experiments. 
The IMPRESS experiment is a variation of the CIGAR experiment which provides very 
high resolution over a short chemical shift range in the carbon dimension. It was 
necessary to use the IMPRESS experiment to resolve the different carbonyl chemical 
shifts because 41 contains eight amide carbonyls, which are spread over a range of only 
3.2 ppm, and with a resolution of approximately 1 ppm, a regular CIGAR experiment is 
unable to differentiate most of these carbon atoms. The chemical shifts for the proton 
and carbon NMR spectra are shown in Table 2.2 with the structure and important 
COSY, CIGAR and IMPRESS correlations shown in Figure 2.7. 
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23' 
OMe 
24' 
Fmoc-Cys( Acm)-Asn-Gly-Arg(Mtr )-Cys( Acm)-OH (41) 
Table 2.2 Proton and carbon NMR data for 41 obtained in 50% CD3CNID2O 
Position lH 13C COSY CIGAR IMPRESS 
2 4.38 54.2 H3a, H3b Cl ' C4 
3a 3.03 31.8 H2 C2, Cll' C4 
3b 2.82 31.8 H2 C2, Cll' C4 
4 171.5 
6 4.65 50.7 H7 C7 C4, C8, ClO 
7 2.78 36.4 H6 C6 C8, ClO 
8 173.3 
10 171.8 
12a 3.91 42.9 ClO, C13 
12b 3.82 42.9 ClO, CI3 
13 170.1 
15 4.32 52.6 HI6a, HI6b CI6 C13, C23 
I6a 1.79 27.9 HI5, HI7 CI5 
I6b 1.68 27.9 HI5, HI7 CI5 
17 1.52 25.7 HI6a, HI6b, 
HI8 
18 3.12 40 HI7 
23 172.3 
25 4.57 52.2 H26a, H26b C26 C23, C27 
26a 3.08 31.3 H25 C25, C26' C27 
26b 2.93 31.3 H25 C25, C26' C27 
27 172 
l' 156.7 
3'a 4.39 66.5 Cl', C4', C5' 
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3'b 4.34 66.5 
4' 4.27 46.4 
5' 143.4 
6' 7.71 124.9 
l' 7.38 126.9 
8' 7.46 127.4 
9' 7.85 119 .6 
10' 140.6 
11 'a 4.2 40 
11 'b 4.34 40 
13' 172.3 
14' 1.95 21.64 
16' 132.9 
IT 138.1 
18' 124.3 
19' 158.2 
20' 6.71 111.7 
21 ' 131.4 
22' 2.55 17.3 
23' 2.1 10.8 
24' 3.82 55 
25' 2.63 22.8 
26' 4.27 40 .6 
28' 172 .1 
29' 1.94 21.6 
H1' 
H6', H8' 
H7', H9' 
H8' 
C 1', C4', C5' 
C3', C5', C6', CI0' 
C8', CIO' 
C5', C6', C8', C9', 
ctO' 
C5', C6', C9', C 1 0' 
C5', C6', C7', C J 0' 
C18', C25' 
CIT, C16', C18' 
CIT, C18'. C19' 
C19' 
C16', C20', e21' 
CI3' 
CI3' 
C26 C28' 
C28' 
55 
Figure 2.7 Important COSY (blue bonds), CIGAR (black arrows) and IMPRESS (red 
arrows) correlations observed for 41 
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Individual residues were identified primarily using the COSY spectrum to elucidate the 
side chain proton resonances using the <x-protons as starting points. With the proton 
chemical shifts in hand it was easy to determine the chemical shifts of the corresponding 
carbon atoms using the HSQC spectrum. The final step involved confirming that the 
peptide sequence was the desired one using CIGAR and IMPRESS correlations to 
observe inter-residue correlations from <x-protons to amide carbonyls. In the case of this 
structure, the elucidation was started using the Fmoc group with its characteristic upfield 
carbonyl resonance as an entry point and proceeded along the peptide toward the C-
terminus. 
In general the assignment was straightforward; however, the p-protons and carbons of 
the two cysteine residues have very similar chemical shifts and it was necessary to 
examine the CIGAR correlations fr.om both the <x-protons and the methylenes of the 
acetamidomethyl protecting groups very carefully to clearly assign them. A final point of 
difficulty concerned the arginine protecting group. Due to the number of intervening 
bonds, it is not possible to directly confirm attachment of the protecting group; however, 
the full structure of the methoxytrimethylphenyl skeleton itself was elucidated. As there 
was no way to confirm the point of attachment, it was assumed that the protecting group 
had remained attached in the indicated position. 
The molecular formula for 41, C49H6SNl1014S3' was confirmed using HRESIMS in which 
the protonated adduct at 1128.39 (0.53 ppm) was observed. 
An analytical HPLC injection (C18, A: H20(A), B: ACN, gradient: 50% B (0 min), 50% 
B (4 min), 56% B (7 min), 100% B (8 min)) showed a single peak at a retention time of 
4.96 min which had a UV spectrum characteristic of the Fmoc protecting group. 
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2.3.5 cyclo-Cys-Asn-Gly-Arg-Cys-OH (42) 
Following cysteine deprotection and oxidation, the N-terminus of the peptide was 
deprotected and cyclo-Cys-Asn-Gly-Arg-Cys-OH (42) was removed from the resin using 
a 95% TFAl5% H20 solution which had been determined to be the optimal cleavage 
brew as described in Section 2.4.2.1. The peptide was allowed to sit for 24 hours in the 
cleavage solution to allow the Mtr protecting group to be removed from the arginine 
residue then the TF A was removed to provide the crude peptide mixture. 
The crude peptide mixture was dissolved in a minimal volume of water and applied to a 
C18 column that had been equilibrated to water. The column was then eluted with H20, 
5% ACN/H20, 10% ACNIH20, 50% ACN/H20 and finally 100% ACN with the peptide 
eluting in the first two fractions. 
Due to the presence of the extremely basic arginine residue in this peptide, it was thought 
that ion-exchange chromato graphy may have been a suitable technique for purification. 
Initially, this was attempted on a small scale using strong cation exchange resin (Bond 
Elut SCX). The column was washed with ACN to prime it, then equilibrated to H20 
before addition of the peptide in distilled water. The column was eluted with a series of 
acidic washes consisting of 0.1 % TF AlH20, 1% TF AlH20, 10% TF AlH20 and 100% 
TFA; however, none of these fractions contained 42 so the column was fmally washed 
with concentrated NH40H which did elute the peptide. Unfortunately the strongly basic 
eluant appeared to have damaged the column packing as a new contaminant co-eluted 
with the peptide, so the use of strong cation exchange was abandoned. 
Weak cation exchange was attempted on a small scale (Bakerbond CBX) column which 
was primed with ACN then equilibrated to 0.1 % concentrated NH40HlH20 before 
application of the sample and initial elution in 0.1 % concentrated NH40H/H20. The 
column was then run with water increasing in TF A concentration from 10-5% to 0.1 % by 
an order of magnitude each time. 42 eluted, along with all of the initial contaminants, in 
the fIrst, ammoniacal, fraction and the last acidic fraction, which were combined and 
rerun with similar results. 
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An attempt was made to purify the material using normal phase chromatography on a 
'flash' silica column with 0.1 % TFAlH20 as the eluant. As expected, 42 was late 
eluting; however, it came off as a very broad peak over three fractions and was still not 
pure so the use of normal phase chromatography was abandoned. 
The combined silica fractions were evaporated to dryness and the material therein 
dissolved in water, filtered to remove silica that had leached from the column, and 
subjected to semi-preparative HPLC, which was successful in purifying 42. 
A second batch of peptide was taken directly from the first crude C 18 purification to 
semi-preparative HPLC as described until enough mass was obtained for polymer 
synthesis at which point semi-preparative HPLC was halted and the remaining crude 
material stored. 
2.3.6 Characterisation of cyclo-Cys-Asn-Gly-Arg-Cys-OH (42) 
Due to the extreme polarity of 42, no exchangable protons were observed in the NMR 
spectra as all experiments had to be run using D20. The proton and carbon spectra were 
fully assigned using COSY, HSQC and CIGAR 2D NMR experiments to confirm the 
assignments shown in Table 2.3. The important CIGAR correlations are shown in 
Figure 2.8. 
The COSY spectrum allowed the rapid identification of the isolated spin systems 
corresponding to the five amino acids, with the HSQC spectrum providing the chemical 
shifts for all of the protonated carbon atoms. The connectivity of the amino acids was 
confirmed using the CIGAR correlations from the a-protons to neighbouring amide 
carbonyls. As in the case of 41, the cystine residues have similar proton and carbon 
o 0 rt6 ~ 6 II ~12 13 ~ 15 II 27 OH ~N ~N 
.: H .: H 
7'1tNH2 0 16,,17 0 
o HN)1El 
cyclo-Cys-Asn-Gly-Arg·Cys-OH (42) 
Table 2.3 Proton and carbon NMR data for 42 obtained in 
Position 
2 
4 
6 
8 
10 
1 
12b 
13 
IS 
16a 
16b 
17 
18 
20 
26a 
Figure 
4.07 
3 
3.14 
4.8 
2. 
4.04 
3.55 
18 
1.74 
1.66 
I. 
3.11 
4. 
3 
3.01 
41.2 
174.1 
171.7 
42.4 
42.4 
170.8 
.6 
3 
24.2 
40.6 
156.8 
I .9 
40.2 
40.2 
COSY 
H3a, H3b 
H2, H3b 
H2, H3a 
H7a, H7b 
H6, H7a 
H6, H7b 
12b 
HI2b 
HI6a, H16b 
HIS, H16b, HI7 
HIS, H16a, H17 
H16a, H16b, H18 
H17 
H26a, H26b 
H26a 
H26b 
(blue 
C4, C8, ClO 
C6, C8, CIO 
C6, C8, CIO 
CIO, CI3 
C10,C13 
cn, C16, C23 
CIS 
C16, C17, C20 
C23, C26, C27 
C27 
C2S, C27 
OH 
(black correlations 
59 
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chemical shifts; however, these were easily distinguished through correlations from their 
quite distinct £x-protons. 
The molecular fonnula of 42, ClsH31N907S2' was confirmed using HRESIMS in which 
the protonated adduct at 550.19 (0.73 ppm) was observed. 
An analytical HPLC injection (C18, A: H20(A), B: ACN, gradient: 0% B (0 min), 0% B 
(4 min), 5% B (9 min), 100% B (10 min)) showed a single peak at a retention time of 
7.95 min. 
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2.4 Targeted biolinker nonapeptide 
The initial strategy for the synthesis ofthis peptide was to couple the already prepared 
fragment 41 to the resin bound biolinker. The use offragment condensation strategies in 
the synthesis of oligopeptides is a well known and often successful approach that can 
help to improve the proportion of desired product in the crude material, thus simplifying 
purification. 141 
2.4.1 Fmoc-cyclo-Cys-Asn-Gly-Arg-Cys-Gly-Phe-Leu-Gly-OH (43) 
Fmoc-Gly-Phe-Leu-Gly-Wang resin was deprotected and then coupling to the fully 
protected peptide 41 (0.9 equiv.) was attempted. The resin-bound peptide fragment was 
used in a slight excess as the protected peptide 41 was more valuable due to the 
laborious purification procedure carried out on it. After the standard one hour reaction 
time for coupling, the resin was drained and washed. The washings were collected and 
analysed by HPLC (C18, A: H20(A), B: ACN, gradient: 50% B (0 min), 50% B (4 min), 
56% B (7 min), 100% B (8 min)) which revealed the presence of 41. Due to the value of 
this peptide, these washings were dried down and stored to allow the later recovery of 
the peptide. 
The peptide could have been cyclized and cleaved from the resin at this point; however, 
the free amine groups of the unreacted tetrapeptide had the potential to cause problems 
later on. The primary concern was that the amines could have catalysed the removal of 
the base-labile Fmoc protecting group which was required on the N-tenninus of the 
nonapeptide. It is known that primary amines are generally able to cause only the very 
slow removal ofFmoc; however, the consequence of any slow deprotection would have 
been dire so all remaining free amine groups were acetylated with acetic anhydride. 
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Following cysteine deprotection and oxidation to form the cyclic peptide, the peptide 
was cleaved from the resin using an acidic mixture consisting of 87% TF Al8% 
pheno1l5% H20. The peptide was left in this acidic mixture and the cleavage of the Mtr 
protecting group from the side chain of the arginine residue was monitored by HPLC 
(CI8, A: H20(A), B: ACN, Gradient II). After 60 hours, the peptide was found to be 
fully deprotected so the cleavage mixture was removed to furnish the crude mixture 
containing Fmoc-cyclo-CNGRCGFLG-OH (43). 
2.4.1.1 Purification of Fmoc-cyclo-CNGRCGFLG-OH (43) 
The crude peptide material was dissolved in 50% ACN/H20 and filtered to remove the 
insoluble material. A preliminary purification, aimed at removing all or most of the 
phenol which was included in the cleavage solution, was carried out using size exclusion 
chromatography. The soluble material was chromatographed on LH20, eluting with 
50% ACNIH20. The material eluted from the column as one broad peak by UV 
detection at 254 nm, but fractions were taken across the peak despite the lack of clear 
separation. The peptide was found by mass spectrometry to be located in two of the 
early fractions along with a significant amount of contamination. The main contaminant, 
as determined by mass spectrometry, had a molecular mass of 464 Da, which does not 
correspond to any of the expected products of the synthesis. NMR spectroscopy clearly 
showed that the most abundant compound in the fraction contained an easily identified 
leucine residue, so it must have been a derivative of the tetrapeptide biolinker. 
Unfortunately, the NMR spectrum did not contain obvious peaks corresponding to an 
arginine residue, leading to the suspicion that the nonapeptide was only a minor 
component ofthe mixture. The insoluble material that was removed prior to size 
exclusion chromatography was analysed by HPLC (CI8, A: H20(A), B: ACN, Gradient 
II) and found to have a similar make-up to the peptide-containing fractions from the 
LH20. 
Chapter 2: Peptide Synthesis 63 
Because the major component of the contammated peptide did not appear to contain an 
arginine residue, it was thought that cation-exchange chromatography could selectively 
retain 43. A small sample of the contammated peptide was subjected to weak cation-
exchange chromatography on a Trisacryl M CM column which was equilibrated to 30% 
ACN/H20 before application of the sample and elution with 30% ACN/H20 followed by 
30% ACN/H20 + 0.1 % TFA. The desired product eluted in the fIrst two, non-acidifIed 
fractions, which was unexpected. Possible reasons for this failure could have been the 
high proportion of acetonitrile included in the eluant, which was necessary to prevent 
precipitation, or not using buffered solutions. Buffers were not used because this would 
have resulted in salt contammation of the product, which would have caused difficulties 
with removal as well as determmation of the extent of contammation, as most salts used 
for buffer formation are spectroscopically silent. 
The material was then chromatographed on a silica column running 50% ACN/H20 + 
0.1 % TF A with UV detection at 254 run; however, no peaks were detected so all 
fractions were combined and taken to dryness. 
Semi-preparative HPLC (Phenomenex Luna C18 column) was then carried out on the 
combined silica fractions as well as the insoluble material isolated prior to size exclusion 
chromatography, running an isocratic solvent system of 35% AC]\l/H20 + 0.1 % TF A for 
12 mmutes followed by a one mmute wash with 100% ACN before re-equilibration. 
Peaks eluting at 7:30, 8:00 and 12:00 mmutes were collected and examined by NMR but 
were found to contain too little material to allow any structural determmation to be 
carried out. 
2.4.2 Resynthesis of Fmoc-cyclo-CNGRCGFLG-OH (43) 
Following the failure of the attempted peptide-fragment coupling strategy, it was decided 
that the most efficient way of producing 43 was lilcely to be through stepwise SPPS. 
Some Fmoc-Gly-Phe-Leu-Gly-Wang resin which had been prepared earlier was extended 
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by standard SPPS techniques to produce the side-chain protected, resin-bound 
nonapeptide. N-hydroxysuccinimide was included in the final two coupling steps to 
protect the asparagine residue from side-chain dehydration. The acetamidomethyl-
cysteine residues were deprotected and cyclised using thallium trifluoroacetate. 
2.4.2.1 Cleavage of Fmoc-cyclo-CNGRCGFLG-OH (43) 
64 
Due to the difficulties experienced with the removal of the bisphenol derivative from 41 
(Section 2.3.3), an experiment was carried out to determine whether or not phenol was 
required in the cleavage mixture. Two small samples of resin-bound 43 were 
simultaneously cleaved using the standard mixture (87% TF N8% phenol/5% H,o) and a 
phenol-free mixture (95% TFNH,o). Monitoring of this reaction by HPLC (C18, A: 
HP(A), B: ACN, Gradient II) indicated that the arginine deprotection reaction 
proceeded more rapidly in the absence of phenol, with complete removal of the 
protecting group being achieved in 24 hours, whereas the same reaction took 60 hours in 
the presence of phenol (Figure 2.9). Importantly, it was also found that no extra side-
products were formed when the cation-scavenging phenol was omitted. 
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Figure 2.9 HPLC chromatogram showing state of arginine deprotection after cleavage 
for 24 hours with (blue trace) and without phenol (black trace) 
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The remaining resin was then cleaved and the arginine protecting group was removed 
over a 24 hour period after which the cleavage solvents were removed. 
2.4.2.2 Purification of Fmoc-cyclo-CNGRCGFLG-OH (43) 
The crude peptide preparation was dissolved with sonication and heating in 50% 
ACN/H20 and then the peptide was precipitated by the addition of ACN. The 
precipitate was collected by filtration to provide an off-white solid which was washed 
with ACN and MeOH. The combined washings were analysed by HPLC (CI8, A: 
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H20(A), B: ACN, Gradient III) and found to contain some nonapeptide, but the peptide 
was heavily contaminated and present at only low levels, thus making it not worthwhile 
to try to extract the peptide. The solid, however, was predominantly peptide so was 
purified immediately by preparative HPLC (C18, A: H20(A), B: ACN, gradient: 50% B 
(0 min), 50% B (4 min), 56% B (7 min), 100% B (8 min), 100% B (9 min, 50% B (10 
min), 50% B (13 min)). This was a very slow process due to the low solubility of the 
nonapeptide in just about all solvent systems suitable for HPLC. This low solubility 
presented problems both in loading the peptide onto the HPLC, which was done from a 
50% ACNIH20 solution that often contained a small amount of gelatinous precipitate, 
and in the peak shape, with the peptide eluting as a very broad peak which was prone to 
tailing at higher loadings. 
2.4.3 Characterisation of Fmoc-cyclo-CNGRCGFLG-OH (43) 
The proton and carbon ]\lMR spectra of 43 were fully assigned through the use of 
COSY, HSQC-DEPT, CIGAR and IMPRESS 2D NMR experiments. The chemical 
shifts determined are shown in Table 2.4, while Figure 2.10 shows the important 
CIGAR and IMPRESS correlations. 
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Table 2.4 Proton and carbon NMR data for 43 obtained in d6-DMSO 
Position IH l3C COSY CIGAR IMPRESS 
1 7.86 H2 
2 4.27 55.0 HI, H3a, H3b 
3a 3.27 41.3 H2, H3b 
3b 3.01 41.3 H2, H3a 
4 171.0 
5 8.77 H6 CI0 C4 
6 4.62 49.8 H5, H7a, H7b C7, C8, CI0 C8, ClO 
7a 2.81 36.3 H6, H7b C6,C8 C8, CI0 
7b 2.40 36.3 H6, H7a C6,C8 C8, ClO 
8 172.0 
10 170.9 
11 7.94 HI2a, H12b ClO 
12a 4.28 42.9 H11, H12b C13 ClO, C13 
12b 3.51 42.9 H11, HI2a C13 ClO, C13 
13 169.9 
14 7.79 ' H15 C13 C13 
15 4.43 52.0 H14, H16a, H16b C13, C23 
16a 2.00 28.5 H15, H16b, H17 
16b 1.63 28.5 H15, H16a, H17 
17 1.55 25.3 H16, HI8 
18 3.17 40.6 H17, H19 C16, C17, C20 
19 7.62 H18 
20 156.9 
23 171.9 
24 8.11 H25 C23 
25 4.57 52.0 H24, H26a, H26b C23, C27 
26a 3.31 41.1 H25, H26a 
26b 3.05 41.1 H25, H26b 
27 170.2 
28 8.34 H29 C27 C27 
29 3.75 42.1 H28 C27, C30 C27, C30 
30 168.5 
31 8.09 H32 C30 
32 4.63 54.0 H31, H33a, H33b C30, C33, C34, C30, C38 
C38 
33a 3.13 37.8 H32, H33b C32, C34, C35 C38 
33b 2.84 37.8 H32, H33a C32, C34, C35, C38 
C38 
34 137.8 
35 7.31 129.5 C35 
36 7.33 128.3 C34, C36, C37 
37 7.26 126.5 
38 171.0 
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39 8.25 H40 C38 C38 
40 4.41 51.2 H39, H41 C41, C42 C38, C45 
41 1.58 41.4 H40, H42 C40, C43, C44 C45 
42 1.69 24.3 H41, H43, H44 C40 
43 0.97 23.3 H42 C40, C42, C44 
44 0.93 21.9 H42 C40, C42, C43 
45 172.6 
46 8.20 H47 C45, C47 C45 
47 3.83 40.9 H46 C45, C48 
48 171.3 
I' 156.4 
3' 4.46 66.0 H4' C1', C4', C5' 
4' 4.32 46.9 H3' C3', C5', C6', 
C10' 
5' 144.0 
6' 7.80 125.5 H7' C4', C8', C10' 
7' 7.42 127.4 H6',H8' C5', C9', C10' 
8' 7.51 128.0 H7',H9' C5', C6', C10' 
9' 7.97 120.4 H8' C7', C10' 
10' 141 
Again, the COSY and HSQC-DEPT spectra were used to identify the proton shifts and 
then the carbon shifts of each amino acid residue, with the CIGAR spectrum being used 
to confirm the assignments by providing intra-residue correlations. The connectivity 
between individual residues was confirmed using the correlations provided by the 
IMPRESS spectrum, which had to be used to allow the ten amide carbonyls, which are 
spread over just 4.1 ppm, to be individually identified. 
The molecular formula for 43, C52H67N13013S2' was confirmed by HRESIMS which 
allowed the identification of the protonated parent ion at 1146.45 Da (0.87 ppm). 
An analytical HPLC injection (C18, A: H20(A), B: ACN, Gradient III) showed a single 
peak at a retention time of9.0 min which had strong UV absorbance in a spectrum 
characteristic ofthe Fmoc group. 
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2.5 Conclusions from peptide synthesis 
The synthesis of the required peptides was successfully carried out, albeit with low yields 
in some cases and also often requiring tedious semi-preparative HPLC purification. All 
the peptides prepared were characterised fully by NMR spectroscopy and HRESIMS. 
A modified method for loading the initial amino acid onto the resin was found to improve 
the loading level over that achieved when following the literature method exactly. Resins 
thus prepared had similar or higher levels of amino acid loading than those available 
commercially, with the cost of preparation being significantly lower than the commercial 
purchase price. 
The successful preparation of the fully protected targeting peptide was followed by an 
unsuccessful attempt at coupling said peptide to resin-bound tetrapeptide biolinker. 
Synthesis of the nonapeptide by stepwise addition of single amino acids was found to be 
a much more suitable approach than fragment coupling. 
The complete prevention of dehydration of the asparagine side-chain in the presence of 
N-hydroxysuccinimide is an interesting phenomenon that has not been reported in the 
literature thus far. Further work to determine whether this is a general property ofNHS 
or simply a fortunate occurrence in this case would be worthwhile. 
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Chapter 3 
Natural Product Modification 
3.1 Introduction 
In order to ensure that the drug conjugate would be stable in circulation, it was deemed 
necessary to use amide bonds rather than esters for attachment of the drug to the 
biolinker. A number of other functionalities could be utilised that would provide bonds 
that are stable in circulation, but the advantage of an amide linkage is that it can be 
selectively hydrolysed by enzymatic action following endocytosis, thus releasing the free 
drug intracellularly. The intracellular release of drug is central to the mechanism of 
action of polymer drug conjugates, as discussed in Section 1.3. 
In the case of doxorubicin, there is an amine group present so no derivatisation was 
required; however, in the case of the other natural products, mycalamides A and Band 
fumagillol, modification was necessary to provide the primary amine functionality. In all 
cases it was important to ensure that no alterations were made to any part of the 
molecule other than the desired site of reaction in order to guarantee that the modified 
drug would have maximal bioactivity. 
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3.2 Mycalamide A (31) 
The modification of my calami de A (31) has been extensively investigated through the 
formation of acyl, alkyl and silyl derivatives, reaction with a variety of basic nucleophiles 
and examination of acid-catalysed reactions and redox behaviour. 150-152 Despite this, the 
synthesis of an amine derivative has not yet been reported. It is, however, known that 
the mycalamide A (31) skeleton is very sensitive to acid, with catastrophic degradation 
caused by even trace quantities of strong acids such as the HCI present in commercial 
CDCI3• 
Work previously carried out by Marie Squire on derivatisation of my calami de A (31) had 
investigated the possibility of following a modification scheme established by Rachel Lill 
for the conversion ofhomohalichondrin B to an amine derivative (Figure 3.1).153 The 
synthesis proceeded successfully through to the azide, albeit in a low overall yield due to 
compounding losses at each step, at which point the reduction over Lindlar's catalyst 
gave a product with a mass two Daltons higher than expected. 154 It was thought that this 
was most lilcely due to reduction of the exocyclic methylene at C4, but this was never 
confirmed. Due to the formation of this undesired product, an alternative route was 
investigated in this work. This alternative route required the direct conversion ofthe 
easily formed aldehyde to an amine through reductive amination. 
3.2.1 Mycalamide A oxidative cleavage 
Initial attempts at the oxidative cleavage of my calami de A (31) were carried out in 
methanol using an aqueous solution of sodium periodate and reacting overnight. These 
reaction conditions did produce the desired aldehyde; however, mass spectrometry 
clearly showed that the product was actually a mixture ofthe aldehyde, the methyl hemi-
acetal and the hydrate. Whether or not these aldehyde derivatives would have interfered 
with the following reaction is not known, but it is likely that they could have provided a 
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competing equilibrium which would have resulted in a lower yield or at the very least a 
slower reaction during reductive amination. 
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The method ofDaumas et al. of carrying out the oxidative cleavage using sodium 
periodate adsorbed to silica suspended in DCM (Figure 3.2) was a vast improvement 
over the methanolic method. I55 The reaction required only one hour instead of 18 hours, 
~OH 
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Nal04 
MeOH 
OTs 
NaN3 ) 
DMF 
H2 
Lindlar's catalyst 
EtOH 
o ) 
NaBH4 
Isopropanol 
TsCI OH 
DIPEA ) 
DMAP . 
CH2CI2 • ~~ 
lyY"'oMe 
6 ............... 0 
Figure 3.1 Unsuccessful route attempted for conversion of my calami de A (31) to 
an amine derivative. 
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the product of the reaction was easily worked up by filtration to provide pure aldehyde 
free of hydrate and hemi-acetal contaminants, and the yield was quantitative as opposed 
to around 90%. The reaction was carried out many times and was always found to be 
very reliable. 
The proton and carbon chemical shifts of 44 were fully assigned using the 2D NMR 
experiments COSY, HSQC-DEPT and CIGAR and are shown in Table 3.1 with 
important CIGAR correlations being shown in Figure 3.3. 
Elucidation ofthe structure of 44 began at the distinctive downfield triplet ofHlO which 
showed a COSY correlation to the amide NH9 and also provided a convenient entry 
point to the spin system that extends through to H 13. This spin system was readily 
identified from the COSY spectrum. The CIGAR correlation from HIO to the carbonyl 
C8 was important to lin1c the two hemispheres ofthe mycalamide structure as the amide 
NH9 did not provide any correlations in the CIGAR spectrum. The carbonyl C8 also 
displayed a CIGAR correlation from the downfield singlet proton H7, which showed 
further correlations to the quaternary C6 and the methylene CS. A CIGAR correlation 
from a the singlet at 3.29 ppm in the proton spectrum identified the C6-methoxy. The 
diastereotopic protons ofCS were easily identified in the HSQC-DEPT spectrum, and in 
turn provided CIGAR correlations to both carbons of the olefin. One ofthe protons of 
the exocyclic methylene displayed a CIGAR correlation to C3. Starting from H3 the 
complete spin system indicated in Figure 3.3 was readily identified using the COSY 
spectrum, with carbon chemical shifts being provided by an HSQC-DEPT experiment. 
Referring back to the right-hand hemisphere of the molecule, the cyclic acetal carbon 
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M aq.l\laI04 MeO 9H H 0 Si02 ~~. N ", -=:;.D.::::;C.:.:.M:...-_ . OMe o 6 .............. 0 31 
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Figure 3.2 Oxidative cleavage of my calami de A (31) 
Chapter 3: Natural Product Modification 74 
14-CH3b 
6-0Me OH 9 25 0 1'5 14 2_CH3~~e?6 ~ 8 ~ \0 11 1213 "/~~~~:~OMe 
3 -
4 5 0 0 .............. 0 
3-CH3 10-0CH2 
4=CH2 
17 -oxy-18-nor-mycalamide A (44) 
Table 3.1 Proton and carbon NMR data for 44 obtained in CDCl3 
Position 1H 13C COSY CIGAR 
2 4.02 69.5 H2-CH3, H3 (w) C3-CH3 
2-CH3 1.17 17.9 H2 C2,C3 
3 2.23 40.9 H2, H3-CH3 C5 
3-CH3 0.92 12;1 H3 C2,C3,C4 
4 145 
4=CH2a 4.84 111 H4=CH2b C3 
4=CH2b 4.75 111 H4=CH2a C5 
5a 2.36 33.2 H5b C4, C4=CH2, C6 
5b 2.08 33.2 H5a C4, C4=CH2, C6 
6 100 
6-0CH3 3.29 48.5 C6 
7 4.27 71.2 C5,C6,C8 
8 171.9 
9 7.48 H10 
10 5.88 74 NH9, H11 C8 
10-0CH2a 5.13 86.5 H10-0CH2b C12 
10-0CH2b 4.87 86.5 H10-0CH2a C12 
11 3.76 70.6 HlO, H12 C12, C13 
12 4.2 74.1 H11, H13 C10-0CH2, C10 
13 3.51 79.1 H12 C12, C13-0CH3, C14, C14-CH3a 
13-0CH3 3.56 61.8 C13 
14 41.2 
14-CH3a 1.02 23.3 C13, C14, C14-CH3b, C15 
14-CH3b 0.86 13.6 C13, C14, C14-CH3a, C15 
15 4.09 74.2 H16 C17, C16 
16 2.37 43.3 H15, H17 C17, C14 
17 9.54 200.7 H16 
1O-OCH2 was identified by a CIGAR correlation from H12. H13 provided useful 
correlations in the CIGAR spectrum to both the methoxy attached to C13 and the 
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quaternary carbon C14. The two methyl groups attached to CI4 were easily identified as 
they both showed clear CIGAR correlations to C 14 itself as well as to C 13 and C 15. 
The final spin system of the molecule, that consisting ofHI5, HI6 and HI7 was 
identified in the COSY spectrum with the carbon chemical shifts being derived from an 
HSQC-DEPT experiment. The expected modification ofthe mycalamide A side chain 
was confirmed by the lack of any NMR correlations beyond position 17, indicating the 
loss ofC18 as well as the characteristically downfield chemical shifts of both H17 and 
C17 at 9.54 and 200.7 ppm respectively. 
Figure 3.3 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
observed for 44 
The molecular formula of 44, C23H37N09, was confirmed by HRESIMS which identified 
the sodiated parent ion at 494.24 Da (1.42 ppm). 
Analytical HPLC (CI8, A: H20, B: ACN, Gradient I) of 44 showed a single peak eluting 
at 14.4 minutes which had no UV chromophore. 
3.2.2 Reductive amination of aldehyde 
The reductive amination of 17-formyl-normycalamide A was carried out using a variety 
of conditions in an attempt to improve the yield ofthe reaction but a reliable, high-
yielding method was not found. 
Chapter 3: Natural Product Modification 76 
Initially, the reaction was carried out using the standard reductive amination method of 
Borch et al., using ammonium acetate (10 equiv.) and sodium cyanoborohydride (0.7 
equiv.) in dry MeOH. 156 Analysis of the product by low resolution ESIMS indicated that 
a dimer had fonned at a level of about one fifth that of the monomer (Figure 3.4). While 
ESIMS is not quantitative without prior calibration due to the different levels of 
ionisation of different molecules, both of the molecules of interest were structurally 
related and could be expected to have similar ability to ionise. In any case, it was clear 
that an unacceptably high proportion of dimer was being fonned. 
The reaction was then carried out using extra ammonium acetate (l00 equiv.) in order to 
try to reduce the amount of dimer forming. This was successful to some extent, with the 
level of dimer formed dropping to around one eighth of the total product (as detennined 
by mass spectrometry). Other attempts were made with the inclusion of dehydrating 
agents (silica and powdered, activated 4A molecular seives) but in both cases the 
reaction product consisted only of completely degraded material. 
By NMR spectroscopy it was observed that the crude reaction products seemed to be 
getting less pure as time went on. Simultaneously, the ammonium acetate that was used 
was beginning to smell more like acetic acid and less like ammonia. It was thought that 
as the hygroscopic ammonium acetate absorbed water, ammonia was being released due 
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Figure 3.4 ESIMS of crude product of reductive amination of 44 
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to its low boiling point (-33°C) while the higher boiling acetic acid (118°C) was 
remaining behind. Over time this was leading to an overall acidification of the 
ammonium acetate, which was apparently sufficient to cause the catastrophic 
degradation of the mycalamide A skeleton. 
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To remedy the problem of acidic ammonium acetate, two measures were taken. Firstly, 
the methanol that was used for the reaction was saturated with ammonium carbonate 
prior to use. This is a relatively basic salt (pH 9-10 at 100 gL-1 H20) with the added 
advantage that it can remove acid by losing carbon dioxide. Secondly, the ammonium 
acetate was treated prior to use by grinding to a fine powder and drying under vacuum to 
remove both excess acetic acid and any water that may have been absorbed by the salt. 
The purification of the amine derivative of mycalamide A (45) was attempted a number 
of times using a variety of different techniques. Column chromatography was carried out 
using C18, silica and diol; and HPLC was performed on C18. None of these solid phases 
were successful in allowing the purification of the product. Ion-exchange 
chromatography was also attempted using weak-cation exchange resin but the 
mycalamide skeleton would dissolve in water only if methanol was present at high 
concentrations (about 50%), which was enough to strip the column immediately. The 
best that could be achieved was a de-salting step using C 18 to remove the bulle of the 
mass from the crude reaction product. 
The method that was finally used for the reductive amination of 17 -formyl-
normycalamide A (44) used the best combination of the techniques attempted, and the 
o ) 
Figure 3.5 Reductive amination of 44 to form amine 45 
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crude reaction product was carried through to the next step before being purified: 44 and 
aImnonium acetate (100 equiv.) were stirred together in ammonium carbonate saturated 
dry MeOH for 30 minutes to allow imine formation to proceed. Sodium 
cyanoborohydride (5 equiv.) was added, again as a solution in ammonium carbonate 
saturated dry MeOH (Figure 3.5). The reaction was monitored by TLC and when the 
aldehyde had been consumed the reaction was worked up by passage through a C18 
cartridge. The crude amine was examined by LRESIMS and the level of dimer was 
found to be below 5%; however, l\TMR spectroscopy showed that the product was not 
pure 45. The non-polar material eluted from the cartridge was acylated (Section 4.4.1 
and Section 5.5.1) without further purification. 
45 was never characterised due to the lack of a pure sample; however, HRESIMS was 
carried out on an impure sample and confirmed the molecular formula as C23H40N208 by 
detection of the protonated parent ion at 473.29 Da (1.7 ppm). 
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3.3 Mycalamide B (32) 
While the derivatisation of my calami de B (32) has not been studied to the same extent as 
mycalamide A (31), it is known that mycalamide B (32) is prone to the same degradative 
behaviour in the presence of acid as is mycalamide A (31). 
The modification of my calami de B (32) could not be carried out using the same 
oxidation-reductive amination technique that had been used for mycalamide A (31) due 
to the lack of the vicinal diol functionality, thus preventing oxidative cleavage to provide 
an aldehyde. While it is possible to selectively oxidise a primary alcohol to an aldehyde, 
the reaction can easily over-oxidise to form a carboxylic acid, which would potentially be 
sufficient to catalyse the destruction of the mycalamide B (32) skeleton. Furthermore, 
the disappointing yields of the reductive amination procedure along with the difficulties 
experienced with dimer formation also discouraged any consideration of that strategy. 
Instead, it was decided to attempt to 'activate' the primary alcohol directly. 
3.3.1 Mycalamide B tosylate (46) 
It was hoped that the primary alcohol of my calami de B (32) could be tosylated 
preferentially in the presence of the unprotected, but hindered, secondary alcohol. The 
first attempt was carried out using tosic anhydride in pyridine, and while the primary 
alcohol did show a higher reactivity, sulphonylation of the secondary alcohol was 
observed before position 18 had reacted fully. The identity of the derivatives was 
determined by LRESIMS of individually collected peaks from the analytical HPLC 
chromatograph (CI8, A: H20, B: ACN, Gradient II) which showed the sodiated ions for 
mono- and di-tosylated mycalamide B (46 and 47) at 694.1 and 848.1 Daltons 
respectively (Figure 3.6). The points of attachment of the tosylate moeities were not 
determined, but were assumed to be as indicated (Figure 3.7). This showed that the 
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chemospecificity of the reaction was insufficient, so an attempt was made using tosic 
acid with DCC as a dehydrating agent in the hope that the bulle of the activated isourea 
adduct would prevent reaction at the secondary alcohol. However, this was found not to 
be the case. Analysis of this reaction byHPLC (CI8, A: H2O, B: ACN, Gradient II) did 
show transformation of the starting mycalamide B (32), but the product was not the 
desired tosylate 46 and was therefore not further examined. Finally, a number of 
experiments were carried out using 2,4,6-collidine as a base instead of pyridine, as 
evidence has suggested that the use of a highly hindered base can enhance the selectivity 
of tosylation reactions. 157 To this end, reactions were carried out using both tosyl 
chloride and tosic anhydride at low temperature with 2,4,6-collidine used as the base, but 
in all cases ditosylate 47 product formation was also observed. 
3.3.2 Mycalamide B phthalimide (48) 
A number of attempts were made to synthesise the mono-phthalimide derivative of 
mycalamide B (48) as an intermediate to the desired amine form (Figure 3.8). 
Mitsunobu chemistryl58 was used to activate the alcohol to nucleophilic displacement, 
and it was hoped that the large size of the triphenylphosphine, which forms an adduct 
with the reacting alcohol in the proposed mechanism, would direct reaction exclusively 
to the primary alcohol. Unfortunately, despite the use of a number of solvents as well as 
varied reaction temperatures, the phthalamide 48 was not successfully produced. 
OH ~(M' 
Me09
H H~ 
:c;rr:. N " . . 'OMe ° 0""",0 
32 
Figure 3.8 Attempted formation ofphthalimide derivative 48 of my calami de B (32) 
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3.3.3 Mycalamide B azide (49) 
Work that was being carried out simultaneously toward the derivatisation of fumagillol 
(35) into an amine had indicated that the use of zinc azide as the nucleophile under 
Mitsunobu conditions159 could be useful for conversion of my calami de B (32) to an 
amine derivative. It was hoped that in the case of my calami de B (32), the use of the 
Mitsunobu reaction would prevent the derivatisation of the secondary alcohol seen in the 
tosylation reactions. The reasoning was that the bulky triphenylphosphine reagent fonns 
an adduct with the reacting alcohol in the first step of the Mitsunobu reaction; this 
adduct could be expected to be very sensitive to the steric environment and thus direct 
reaction to the primary alcohol. This was found to be the case, but on one occasion a 
small amount of the di-azide product was isolated when a total of four equivalents of 
triphenylphosphine and diethyl azodicarboxylate were used. 
The final reaction, shown in Figure 3.9, used for the production of the mono-azide 
derivative of my calami de B (49), relied on the monitoring of reaction progress with the 
reaction being refreshed until the starting material had been completely consumed. Thus, 
mycalamide B (32) and PPh3 (2.5 equiv.) were added to a suspension of zinc azide (1 
equiv.) in dry toluene. DEAD (2.5 equiv.) was added. After four hours, HPLC (CI8, A: 
H20, B: ACN, Gradient II) showed the reaction was still not complete so a solution 
containing a further 0.75 equivalents ofPPh3 and DEAD in toluene was added. Further 
HPLC analysis (CI8, A: H20, B: ACN, Gradient II) after another four hours showed 
some starting material remaining, so the reaction was again refreshed with additional 
PPh3 (0.5 equiv.) and DEAD (0.5 equiv.) in toluene. After another two hours of 
Zn(N 3b.2Pyr OH M 
PPh3 MeO: H 
DEAD. ° ~. N ", 
Toluene 0: OMe 
° 0"-./0 
49 
Figure 3.9 Formation of azide derivative 49 of my calami de B (32) 
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reaction, HPLC (C18, A: H20, B: ACN, Gradient II) indicated that the starting material 
had been completely consumed, so the reaction solvent was removed under vacuum and 
the gummy residue purified by chromatography on a C 18 cartridge to furnish the desired 
azide 49 in an 84% yield. 
The proton and carbon NMR chemical shifts of 49 were fully assigned through the use of 
COSY, HSQC-DEPT and CIGAR experiments. The important CIGAR correlations are 
shown in Figure 3.10, while Table 3.2 provides the carbon and proton NMR data. 
The main core of the mycalamide structure through to the side chain attached to C15 
was identified in much the same fashion as already described for the mycalamide A 
derivative 45 (Section 3.2.1). From H15, a COSY correlation could be seen to H16; 
however, no further correlations were observed in the COSY spectrum, most likely due 
to the splitting ofH16 and H17 causing too Iowa signal-to-noise ratio. A CIGAR 
correlation was observed from H15 to both C16 and C17 as well as back in to the ring at 
C 13. H16 in turn provided CIGAR correlations back to C 15 as well as the important 
correlation to the terminal carbon, C18, at 52.2 ppm. The diastereotopic protons H18a,b 
were identified from the HSQC-DEPT spectrum and showed CIGAR correlations to 
C16 and C17. The methoxy attached to C17 was identified using a CIGAR correlation 
from a singlet at 3.25 ppm to C17 itself The HSQC-DEPT spectrum allowed 
identification of the proton H17 from which no correlations could be observed in any of 
the other 2D N1VIR spectroscopy experiments run. 
The transformation of the terminal alcohol to an azide was confmned by changes in 
NMR characteristics at position 18 with no significant changes being observed elsewhere 
in the molecule. The chemical shifts of the terminal protons H18a,b (3.41, 3.22 ppm) 
were similar to those reported for mycalamide B (32) (3.47 ppm), although 
diastereotopic splitting has not been observed in the parent compound. More 
importantly, C18 had shifted significantly upfield from 63.5 ppm to 52.2 ppm, which 
would be expected upon replacement of an hydroxyl with an azide. 
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_ OMe 17-0Me 
6-0Me 9 25 '14 14-CH3b 
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2-CH3 MeQ ~ H 13 14-CH3a 
~= aN10 12-. 2 ' 6 7 ,11 'OMe 3 : 13-0Me 4 5 ° 0 ............... 0 3-CH3 10-0CH2 
4=CH2 
18-azido-18-deoxy-mycalamide B (49) 
Table 3.2 Proton and carbon NMR data for 49 obtained in CDCI3 
Position lH l3C COSY CIGAR 
2 4.07 69,6 H2-CH3 C2-CH3, C3-CH3, C4, C6 
2-CH3 1.22 18 H2 C2,C3 
3 2,28 41.2 H3-CH3 C3-CH3, C4, C5 
3-CH3 1.03 12,2 'H3 C2, C3, C4 
4 144.8 
4=CH2a 4.88 111.4 H4=CH2b C3, C5 
4=CH2b 4.76 111.4 H4=CH2a, H5b (w) C3, C5 
5a 2.41 33.6 H5b C3, C4, C4=CH2, C6 
5b 2.23 33.6 H5a, H4=CH2b (w) C3, C4, C4=CH2, C6 
6 100 
6-0CH3 3.32 48.6 C6 
7 4.3 71.2 C5, C6, C8 
8 171.7 
9 7.53 HIO 
10 5.78 74 H9, H11 C8, C10-0CH2 
IO-OCH2a 5.12 86.5 H10-0CH2b CIO 
IO-OCH2b 4.87 86.5 H10-0CH2a C10 
11 3.78 70.9 H10, HI2 CI2, C13, CI5 
12 4.21 74.3 H11, H13 CIO, CIO-OCH2 
13 3.44 79.1 HI2 C12, C13-0CH3, C14, 
CI4-CH3a, CI4-CH3b 
13-0CH3 3.56 61.8 C13 
14 41.6 
14-CH3a 1 23.3 C13, C14, CI4-CH3b, CI5 
14-CH3b 0.87 13.6 C13, CI4, CI4-CH3a, CI5 
15 3.31 75.5 HI6 C13, CI6, CI7 
16 1.6 30.8 H15 CI7, CI8 
17 3.3 77.6 
17-0CH3 3.25 56.7 CI7 
18a 3.41 52.2 H18b CI6 
18b 3.22 52.2 HI8a CI7 
84 
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Figure 3.10 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
o bserved for 49. 
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The molecular formula of 49, C25H42N409' was confirmed by HRESIMS in which a peak 
at 565.28 Daltons (0.35 ppm), corresponding to the sodiated ion, was observed. 
Analytical HPLC (C18, A: H20, B: ACN, Gradient II) of 49 showed a single peak 
eluting at 16.3 minutes which had only end absorption. 
3.3.4 Mycalamide B amine (50) 
The reduction of my calami de B azide (49) was carried out using modified Staudinger 
conditions (Figure 3.11).160,161 49 and PPh3 (1.5 equiv.) were reacted together in dry 
THF at 40°C. After three hours, TLC showed the replacement of 49 with a more polar, 
UV-absorbing compound which was presumed to be the phosphine-imine. Water was 
~NH' 
_ OMe 
~ PPh3 ~ MeO <;>H H 0 H20 ~Moe<;>. 9H HN 0 " ~='N " THF . . 'OMe .....;..~-- . . 'OMe o 0 ............... 0 0 6 ............... 0 49 50 
Figure 3.11 Formation of l8-deoxyamino-mycalamide B (50) 
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added and the reaction was continued for a further three hours at 40°C, at which point 
TLC indicated that the reaction was complete by the loss ofUV activity of the baseline 
spot and appearance of the non-polar UV-active spot of triphenylphosphine oxide. Due 
to the difficulties already experienced with attempted chromatography of other natural 
product amine derivatives, the product 50 was acy1ated without further purification. 
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3.4 Fumagillol (35) 
The derivatisation of fumagillol (35) has been studied to some extent, with the 
development of 6-0-acyl, 6-0-sulfonyl, 6-0-alkyl and 6-0-(N-substituted carbamoyl) 
derivatives having been reported. 99 6-Amino-6-deoxyfumagillol and derivatives thereof 
(6-N-alkyl, 6-N-acyl, 6-N-sulfonyl, 6-N-ureido and 6-N-thioureido forms) are also 
already present in the literature. 100 All of the work reported thus far has been focussed on 
development of a more potent small molecule anti-angiogenic drug than the natural 
product parent fumagillin (34), and has resulted in the discovery ofTNP-470 (36). 
During the course of this work, which was focussed on the development of the two 
enantiomeric 6-amino fumagillol derivatives, a number of novel intermediates were 
prepared. Unfortunately, due to a lack of readily available biological testing resources 
these were not examined for anti-angiogenic activity. While it may have been possible to 
arrange testing, the aim of the work was to prepare polymer drug conjugates containing 
the two 6-amino fumagillol derivatives, so testing of the intermediates was not pursued. 
3.4.1 Fumagillol oxidation 
The secondary alcohol group offumagillol was oxidised to a ketone by chromate 
oxidation (Figure 3.12). Initially, the method used was the same as that presented by 
Marui and Kishimoto,IOO but it was found that superior results were achieved when the 
amounts of chromate and pyridine used were doubled. Thus, fumagillol (35) was added 
to a solution of chromate (15 equiv.) and pyridine (30 equiv.) in dichloromethane and 
allowed to react for 90 minutes, after which TLC indicated that the reaction was 
complete. The purification method used was also simpler than that of Marui and 
Kishimoto,IOO consisting simply of passage through a dry silica bed to provide the pure 
ketone 51 in a 97% yield. The reported yield is 82%. 
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The proton NMR data for 51 have been reported. 100 However, carbon chemical shifts 
and assignments have not been given, thus a full assignment of the chemical shifts of 51 
was undertaken. The proton and carbon chemical shifts are presented in Table 3.3, with 
Figure 3.13 showing the important CIGAR correlations observed. 
The assignment of the chemical shifts of 51 began at the most downfield proton, H4', 
which was clearly olefinic as it was attached to a carbon with a chemical shift of 118.2 
ppm. H4' showed CIGAR correlations to both of the vinyl methyl groups C6' and C7' 
and also exhibited long range COSY correlations to H6' and H7' as well as a regular 
COSY correlation to H3'a and b. Both H3'a and b were correlated to H2 in the COSY 
spectrum, which in turn showed CIGAR correlations to both the quaternary centre Cl' as 
well as C4 of the cyclohexyl core. The methyl group HS' was easily assigned due to both 
its low chemical shift and the fact that it was the only position other than H4 and H3'a, b 
which showed CIGAR correlations to both ofthe side chain epoxide carbons Cl' and 
C2'. The assignments ofthe core ring structure began with a COSY correlation from H4 
which allowed the identification ofH5, which in turn provided access to the methoxy 
group CS through a CIGAR correlation. The spiro-epoxide protons H7a and b both 
showed CIGAR correlations to C4, confirming the presence of this group at the 
expected ring position. The remaining spin system ofHla,b and H2a,b was easily 
identified in the COSY spectrum and the orientation was confirmed by CIGAR 
correlations from Hlb to C5 and H2b to C4. All of the protons of the cyclohexyl ring 
displayed CIGAR correlations to C6, which was distinctive for its downfleld shift of 
207.1 which, along with an absence of attached protons, confirmed the successful 
oxidation of fumagillol to the ketone derivative 51. 
OH 35 
Cr03 
Pyridine 
DCM 
o 51 
Figure 3.12 Oxidation offumagillol (35) 
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Table 3.3 Proton and carbon N1v1R data fOT 51 obtained in CDCI) 
Position IH IlC COSY CIGAR 
la 2.66 36.8 Hlb, H2~ H2b C2, C3, C5, C6 
Ib 2.48 36.8 Hla, H2a, H2b C2, C3, C5, C6 
2a 2.04 33.2 H1a, Hlb, H2b Cl, C3, C4, C6, C7 
2b 1.69 33.2 Hla, Bib, H2a CI, C3, C4, C6, C7 
3 58.4 
4 1.86 53.6 H5 C2, C5, C6, CI', C8' 
5 4.07 83.2 H4 C3, C4, C6 
6 207.1 
7a 3.04 51.8 H7b C2, C3, C4 
7b 2.71 51.8 H7a C2, C3, C4 
8 3.48 58.5 C5 
I' 58.6 
2' 2.58 60.4 H3'a, H3'b C4, CI', C3', C4' 
3'a 2.37 27.3 H2', H3'b, H4' CI', C2', C4', C5' 
3'b 2.13 27.3 H2', H3'a, H4' Cl ', C2', C4', C5' 
4' 5.16 118.2 H3'a, H3'b, H6', HT C6', C7' 
5' 135 
6' 1.72 25.7 H4' C4', C5', C7' 
7' 1.63 18 H4' C4', C5', C6' 
8' 1.27 13.8 C4, CI' 
Figure 3.13 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
observed for 51. 
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Interestingly, the proton H5 can be seen as a doublet of doublets in the proton spectrum. 
The larger coupling constant, 10.6 Hz, is due to the coupling with H4, but there is a 
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much smaller coupling constant of 0.7 Hz that can be identified for a long range coupling 
across the ketone to proton Hla. 
The molecular formula for 51, C16H2404' was confirmed using HREIMS in which the 
positive ion at 280.17 (0.49 ppm) was observed. 
3.4.2 Fumagillone reductive amination 
The reductive amination of dehydrofumagillol 51 has been previously reported. 100 When 
the reaction was performed according to the reported technique, the desired amine was 
formed but all attempts to purify the amine 52 were either completely unsuccessful or 
gave a very low return of slightly impure 52. Among the phases used for 
chromatography were reverse phase (C18), normal phase (silica, florisil) and ion 
exchange (CBX). The best results for the reaction were achieved using the modified 
technique that had been developed during the investigation of the reductive amination of 
the mycalamide A derivative 45 (Section 3.2.2) (Figure 3.14). Briefly, 51 was dissolved 
along with ammonium acetate (l00 equiv.) in ammonium carbonate saturated MeOH. 
After 15 minutes, sodium cyanoborohydride was added and the reaction was allowed to 
stir for two hours before being dried down and passed through a C 18 cartridge to 
remove the extremely polar salt contaminants to provide the crude amine 52. 
The amine 52 was reacted further without delay, as an investigation into the stability of 
52 revealed that it was prone to degradation. The proton NMR spectrum of a sample of 
crude 52 was collected, then the sample was dried and stored in the refrigerator for 
o 51 
NH4CH3COO 
(NH4)2C03 
NaCNBH3 
MeOH • 
Figure 3.14 Reductive amination of6-dehydro-fumagillol (51) 
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eleven days before having its spectrum taken again. The spectra obtained are shown in 
Figure 3.15, and clearly show the complete degradation of the molecule. Previous work 
has shown that the N-methyl derivative of 52 rapidly degrades through attack of the 
amine nitrogen on the spiro-epoxide and it was proposed that this reaction occurred due 
a) 
i I 
ppm 
b) 
, Iii I I I I iii iii I Iii i ( iii I I ii' iii iii I Iii iii iii I i 
5.0 5Q0 3.0 2.0 52 1.0 ppm 
Figure 3.15 Proton NMR spectra of crude 52 after a) six hours; b) eleven days 
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to the higher nucleophilicity of a secondary amine over a primary. 100 It was found, 
however, that it is possible to trap the amine by acylating the crude reaction product, 
thus preventing the amine acting as an intramolecular nucleophile. In order to prevent 
any similar intramolecular reaction occurring with 52, it was decided that 52 would be 
acylated immediately and without purification beyond desalting. 
3.4.3 Fumagillol S-tosylate (53) 
92 
It was thought that an alternative route to the 6R amine derivative offumagillol that 
could provide the desired product in a higher yield than the somewhat disappointing 
reductive amination pathway would be to produce the tosylate by Mitsunobu chemistry 
and then displace the tosylate in an SN2 manner with ammonia. To this end, fumagillol 
was reacted with zinc tosylate (1 equiv.), 162 triphenylphosphine (10 equiv.) and diethyl 
azodicarboxylate (10 equiv.) (Figure 3.16). After ten hours, the reaction mixture was 
filtered and chromatographed on silica; however, none of the desired tosylate 53 could 
be isolated and instead the only reaction product that was observed was the elimination 
product 54. 
6H 35 
Zn(OTosh 
PPh3 
DEAD 
Toluene 
Zn(OTos)2 
PPh3 
DEAD 
Toluene x-
o 
I 
o=s=o ¢ 
53 
Figure 3.16 Attempted tosylation offumagillol (35) using Mitsunobu conditions 
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The exact mechanism of the elimination is not known; however, evidence indicates that it 
is probably a direct elimination of the triphenylphosphine adduct. This could be caused 
by the reactive triphenylphosphine adduct being present for an extended period due to 
the poor nucleophilicity, and perhaps to some degree the steric bulk, of the tosylate 
anion. The fact that the tosylate was successfully produced by sulfonylation ofthe 
alcohol at C6 (Section 3.4.6) and did not spontaneously eliminate to form 54 indicates 
that it was probably not the tosylate itselfthat was leaving. However, this is not 
definitive proof, as the differing stereochemistry at C6 may prevent access to the E2 
elimination mode by preferring a confIrmation in which there is no proton in an anti-
position to the tosylate. Further evidence that it was the triphenylphosphine adduct that 
was eliminating, and not the tosylate, was the formation of 54, albeit at low levels, when 
sodium azide was used as a nucleophile (Section 3.4.8). The azide anion is a strong 
. nucleophile and as such is a poor leaving group, indicating that 54 was most likely to 
have been formed directly from the triphenylphosphine adduct. 
The proton and carbon NMR chemical shifts of 54 were fully assigned through the use of 
COSY, HSQC-DEPT and CIGAR experiments. The important CIGAR correlations are 
shown in Figure 3.17 while Table 3.4 provides the carbon and proton NMR data. 
The side chain ofthe structure was essentially identical to that already described for the 
ketone derivative 51, but the shifts of atoms in the ring differed significantly. C5 was 
identified by a CIGAR correlation from the clearly identifiable singlet methoxy protons at 
3.39 ppm. From H5, COSY correlations could be observed successively around the ring 
to H2 via the extremely downfIeld protons H6 and HI. The chemical shifts ofC6 and 
Cl, at 127.8 and 127.3 respectively, were also consistent with formation ofan olefin 
group. CIGAR correlations from the olefinic protons further confIrmed the position of 
the double bond to be as indicated. The spiro-epoxide was clearly intact as indicated by 
the characteristic diastereotopic pair of doublets at 2.84 and 2.60 ppm as well as the 
chemical shift ofC7 at 52.6 ppm. 
The molecular formula for 54, C16H2403' was confIrmed using HREIMS in which a peak 
at 264.17 (1.75 ppm) was observed. 
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S' 
7' 
6-deoxy-fumagillol (54) 
Table 3.4 Proton and carbon NMR data for 54 obtained in CDel] 
Position 'H DC COSY CIGAR 
5.84 127.3 H2a, H2b, H6 C2, C3, C5, C6 
2a 2.38 34.1 HI, H2b, H6 (w) CI, C3, C4, C6, C7 
2b 2.05 34.1 HI, H2a, H6 (w) CI, C3, C4, C6, C7 
3 57.2 
4 1.6 50.5 H5 C2, C3, C5, C6, C7, 
C I " C2', C8' 
5 4.22 76 H4, H5 C6, C8, 
6 5.97 127.8 HI. H2a (w), H2b (w), H5 Cl, C2, C4, C5 
7a 2.84 52.6 H7b C2, C3, C4 
7b 2.6 52.6 H7a C2, C3, C4 
8 3.39 55.4 C5 
1 ' 59.2 
2' 2.72 62 H3'a, H3'b C4, C 1 " C3', C4' 
3'a 2.37 27.4 H2', H3'b, H5', H6' (w), H7' (w) C1', C2', C4', C5' 
3'b 2.2 27.4 H2', H3'a, H5', H6' (w), HT (w) C I', C2', C4', C5' 
4' 5.21 118.6 H3'a, H3'b, H6', HT C3', C6', C7' 
5' 134.7 
6' 1.74 25.8 H3'a (w), H3'b (w), H4' C2', C4', C5', C7' 
7' 1.66 18 H3'a (w), H3'b (w), H4' C2', C4', C5', C6' 
8' 1.28 14.4 C4 1 Cl 'I C2' 
Figure 3.17 fmportant COSY (blue bonds) and CIGAR (black arrows) correlat.ions 
observed for 54. 
3.4.4 FumagiUol phthalimide (55) 
The synthesis of the furnagillol phthalimide derivative 55 was carried out with inversion 
of stereochemistry at C6 using Mitsunobu chemistry. Triphenylphosprune (2 equiv.) and 
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diethyl azodicarboxylate (2 equiv.) were added to a solution offumagillol (35) and 
phthalimide (1.5 equiv.) in THF and the reaction stirred overnight (Figure 3.18). The 
following day TLC indicated that the starting material had been consumed, so the 
reaction solvent was removed under a stream of nitrogen, and the residue 
chromatographed on silica. Some of the desired phthalamide 55 was obtained pure from 
this column, but most was contaminated with 1,2-carbethoxyhydrazine, which was 
removed by passage through a second silica column. The pure fractions from both 
columns were combined to provide 55 in a 68% yield. 
The proton and carbon chemical shifts of 55 were fully assigned through the use of the 
2D NMR experiments COSY, HSQC-DEPT and CIGAR. The only significant 
differences in chemical shifts from other derivatives were observed in the ring positions. 
In particular, H6, which was found to have a very similar chemical shift to that ofthe 
alcohol parent compound (4.34 ppm vs 4.36 ppm), was found to be attached to a carbon 
at 52.9 ppm, which is notably upfield from the corresponding shift of the alcohol at 64.1 
ppm. Furthermore, H6 showed a CIGAR correlation to a carbon at 168.3 ppm which 
was assigned as the two identical carbonyl carbons of the phthalimide group, and thus 
confirmed the attachment ofthe phthalimide directly to C6. 
The stereochemistry of 55 at C6 was identified as S using the coupling constant between 
H6 and H5, which is dependent on the dihedral angle between the two protons. The 
Karplus equation describes this relationship and is represented graphically in Figure 
3.19. 163 The shape of the graph is constant, but the exact magnitude ofthe coupling 
constant varies depending on nearby substituents, as indicated by the three curves 
OH 
35 
Phthalimide 
PPh3 
DEAD 
THF 
2 
N 00.,,0 55 
3" ~ Ii 
4" 
Figure 3.18 Formation of6R-phthalimidoyl-6-deoxy-fumagillol (55) 
6' 
7' 
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shown. For six-membered rings in the chair conformation, the coupling between two 
neighbouring axial protons is typically 8-13 Hz, while the coupling between an axial and 
an equatorial proton is usually 2-6 Hz, which is also the expected range for a di-
equatorial coupling. 
Unfortunately, the splitting pattern ofH6 itself could not be fully characterised due to the 
complexity caused by coupling to the diastereotopic pair of protons ofHl. However, 
H5 was observed as a triplet with a coupling constant of 10.6 Hz, with the splitting 
pattern being formed by coupling to both H6 and H4. H4 could be clearly seen and was 
a doublet with a 11.2 Hz coupling indicating that the coupling between H5 and H6 must 
have been of the order of 11 Hz to cause the doublet of doublets splitting pattern ofH5 
to appear as a triplet. A coupling of around 11 Hz is consistent with the anti 
stereochemistry as shown in Figure 3.20. 
The molecular formula for 55, C24H29NOs, was confirmed using HRESIMS in which the 
potassiated adduct at 450.17 (0.22 ppm) was observed. 
Analytical HPLC (CI8, A: H20(A), B: ACN, gradient: 70% B (0 min), 80% B (10 
.-
N 
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--C 10 
CO 
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0 
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0> 
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Figure 3.19 Graph of the Karplus equation 
11 Hz 11.2 Hz 
~~ ~ A H N \ o 
o H~e H 
Figure 3.20 Stereochemical 
relationships ofH4, 
H5 and H6 in 55 
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min), 100% B (11 min)) of 55 showed a single peak eluting at 6.5 minutes which had a 
distinctive UV chromophore that extended as far as 340 nm and had a strong maximum 
at 220 nm. 
3.4.5 Phthalimide cleavage 
The most commonly used technique for cleavage of a phthalimide group to afford a 
primary amine is refluxing the phthalimide-containing compound with hydrazine in 
EtOH. 164,165 Fumagillol (35) was refluxed in EtOH with hydrazine hydrate (10 equiv.) 
for three hours then dried down. A proton NMR spectrum obtained on the crude 
reaction product confirmed that fumagillol was stable to the reaction conditions. In 
particular neither of the epoxides had been attacked by the strongly nucleophilic 
hydrazine. 55 was then refluxed for five hours in EtOH with hydrazine hydrate (5 
equiv.) and dried down. The solid residue was extracted with DCM and the organic-
soluble material examined by proton NMR spectroscopy and found to consist of almost 
pure starting material (55). Due to the failure ofhydrazine hydrate to remove the 
phthalimide moiety under the conditions used, further attempts were made using 
methylamine, which has also been reported as a useful reagent for phthalimide 
removal,166 but this was found to rapidly attack the spiro-epoxide. Following 
unsuccessful attempts to aminolyse the phthalimide group using a large excess of 
aqueous ammonia, the reaction was abandoned as it appeared that any nucleophile that 
would attack the phthalimide carbonyl groups would also ring-open the epoxide. An 
alternative strategy to produce the desired amine was required. 
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3.4.6 Fumagillol R-tosylate (56) 
Initially, tosylation of the alcohol offumagillol (35) was carried out following the 
published method.99 Fumagillol (35) was reacted with tosyl chloride (1.25 equiv.) with 
dimethylaminopyridine (1.5 equiv.) present as both a nucleophilic catalyst and the general 
base for the reaction. The product of the reaction was found to contain a mixture of two 
compounds - the desired tosylate 56 and a compound lacking any epoxide resonances in 
the proton NMR spectrum. Further analysis of this side product was not carried out as 
the production of chlorinated adducts from nUcleophilic attack of chlorine on the 
epoxides was already known.99 The desired product 56 was obtained in a relatively low 
yield of37% (reported yield of61 %), so further work was carried out in an attempt to 
improve this. 
It was found that tosic anhydride is a superior sulphonylating reagent to tosyl chloride 
(Figure 3.21). It appears to be more reactive, requiring shorter reaction times than the 
chloride, and also does not produce any epoxide-opened products. Fumagillol (35) and 
to sic anhydride (1.5 equiv.) were dissolved in dry pyridine, with reaction progress 
monitored by HPLC (CI8, A: H20, B: ACN, Gradient II) and TLC after ten minutes 
showing the complete consumption of the fumagillol starting material. The product 56 
was isolated by a single passage through a Cl8 cartridge to provide pure tosylate 56 in a 
95% yield. 
The proton and carbon NMR spectra of 56 were fully assigned through the use of 
OH 35 
Tos20 
Pyridine 
2 
. 
o 
I 
o=s=o 
6::: ~ 
6' 
7' 
56 
Figure 3.21 Tosylation of fumagillol (35) with retention of stereochemistry 
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COSY, HSQC-DEPT and CIGAR 2D experiments. Both C6 and H6 were significantly 
further downfield than seen for any other derivative offumagillol, including the parent 
alcohol, at 7S.S ppm and S.04 ppm respectively. These chemical shifts are consistent 
with the attachment of a strong nucleofuge which has a strong electron withdrawing 
effect leading to activation of nucleophilic attack at the point of attachment. The 
stereochemistry ofC6 was determined as earlier explained (Section 3.4.4) using the 
coupling constant between H6 and HS. This was found to be 2.S Hz, which clearly 
indicates that the protons have a gauche relationship thus confirming the stereochemistry 
as 6R. 
The molecular formula for 56, C23H3206S, was confirmed using HREIMS in which the 
positive ion at 436.19 (1.17 ppm) was observed. 
Analytical HPLC (CI8, A: H20, B: ACN, Gradient II) of 56 showed a single peak 
eluting at 18.S minutes which had a UV absorbance that extended as far as 280 nm and 
had maxima at 196 nm and 226 nm. 
3.4.7 Tosylate displacement 
Following the successful production of the tosylate 56, a number of reactions were set 
up to displace the tosylate group with a variety ofnucleophiles, namely ammonia gas, 
ammonium carbonate, sodium azide and potassium phthalimide. All of the reactions 
were performed in DJVIF and were carried out at 40°C. Despite allowing the reactions to 
proceed for a week, no displacement of the theoretically labile tosylate group was seen. 
Examination of the accessibility of rear-side attack on the tosylate 56 suggests that the 
reaction should proceed. Analysis of the coupling constants in the proton NMR 
spectrum showed that in solution, the tosylate group is axially disposed. This can be 
seen by the coupling between H4 and HS being 10.S Hz, which has to be due to a di-
axial relationship. With a 2.S Hz coupling between HS and H6, H6 must be equatorial, 
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leaving the tosylate group to be axial. This initially seems unlikely as a tosylate is a bullcy 
group and as such would be expected to favour an equatorial position, but the side-chain 
and methoxy groups are both able to take equatorial positions when the tosylate is axial, 
leading to an overall minimum in steric energy. In a boat conformation it is possible to 
have both the tosylate and the fumagillol side-chain in equatorial positions. This causes 
the dihedral angle between H4 and H5 to be approximately 60°, which would lead to a 
coupling constant of2-6 Hz, not the observed 10.5 Hz and thus this conformation is not 
dominant in solution. 
3.4.8 Fumagillol azide (57) 
Following the failure of the phthalimide and tosylate routes to provide the 6R amine 
derivative of fumagillol, a route using an azide intermediate was attempted (Figure 
3.22). Fumagillol (35) was reacted with zinc azide (1 equiv.), triphenylphosphine (2.5 
equiv.) and diethyl azodicarboxylate (2.5 equiv.) for 12 hours. Analytical HPLC (CI8, 
A: H20, B: ACN, Gradient II) at this point indicated that about half of the starting 
material had been consumed, so the reaction was refreshed with a solution of2.5 
equivalents each of triphenylphosphine and diethyl azodicarboxylate in toluene. 
Following a further 12 hours of reaction, the mixture was chromatographed on silica to 
provide the desired azide 57 in a somewhat disappointing yield of 43%. Evidence of 
formation of the elimination product 54 was seen in proton NMR spectra which may help 
to account for the reduced yield as it would appear that SN2 displacement of the 
triphenylphosphine oxide moiety fonned during the Mitsunobu reaction may be impeded 
by steric hindrance as already discussed (Section 3.4.3). 
6' 
7' 
Toluene 
OH 35 
Figure 3.22 Formation of an azide derivative of fumagillol (35) 
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The proton and carbon NMR chemical shifts of 57 were fully assigned by reference to 
COSY, HSQC-DEPT and CIGAR spectra. The most significant change in chemical shift 
relative to the parent alcohol was H6, which had moved by 0.9 ppm upfield; however, 
the chemical shift ofC6 was almost identical to that ofthe alchohol at just 0.8 ppm 
downfield. The stereochemistry of the azide at C6 was again confirmed to be S by 
analysis ofthe coupling constant between H5 and H6. H5 was a heavily split multiplet, 
but H6 was clearly seen as a doublet of doublets with coupling constants of9.2 and 10.7 
Hz. The latter coupling was derived from H4, which was observed as a doublet, which 
implied a 9.2 Hz coupling between H5 and H6 which is consistent with an anti 
relationship as shown. 
The molecular formula for 57, C16H25N303' was confirmed by HRESIMS, which allowed 
observation ofthe potassiated adduct having a mass of346.15 (1.73 ppm). 
Analytical HPLC (C18, A: H20, B: ACN, Gradient II) of 57 showed a single peak 
eluting at 17.3 minutes which had a UV chromophore that gradually decreased from a 
maximum at 192 nm to show no absorbance by 240 nm 
3.4.9 Fumagillol azide reduction 
Reduction of the azide 57 to an amine was carried out using triphenylphosphine (1.1 
equiv.) and excess water (Figure 3.22). The reaction was seen to be complete by TLC 
after 18 hours, so the product was isolated by chromatography on a small silica column. 
Unlike other attempts to purify the natural product amine derivatives produced, in the 
case of 58, the amine could be purified without difficulty in a 53% yield. 
In order to ensure the success ofthe reaction, it was found that it was necessary to 
include water from the beginning ofthe reaction, which differs from the usual method for 
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Staudinger reduction of azides where water is only added after the phosphine-imine has 
had time to form. 160 
The proton and carbon NMR chemical shifts of 58 were fully assigned through the use of 
COSY, HSQC-DEPT and CIGAR 2D experiments. The NMR characteristics of 58 
were found to be very similar to those observed for the azide 57 with only position 6 
exhibiting significantly different chemical shifts. H6 had moved upfield by approximately 
0.5 ppm relative to the azide 57, while C6 was observed at 53.8 ppm where the 
corresponding atom in 57 had a chemical shift of 64.9 ppm. These upfield shifts are 
consistent with the transformation from an azide to an amine. The stereochemistry of C6 
was again confirmed using the coupling constant between H5 and H6, which was found 
to be about 9.5 Hz, indicating an anti relationship and hence the S stereochemistry 
shown. 
The molecular formula for 58, C16H27N03, was confirmed using HRESIMS in which the 
protonated adduct at 282.21 (3.90 ppm) was observed. 
6' 
2 
7' 
Figure 3.22 Reduction of azide 57 to afford amine 58 
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3.5 Biological Activity 
The purified natural product derivatives were submitted for bioactivity testing against the 
P388 murine leukemia cell line. The toxicities determined are shown below in Table 3.5. 
The bioactivity of the crude amine derivative of my calami de A (45) was an order of 
magnitude lower than that of the parent compound and the intermediate aldehyde 
derivative 45; however, this is not unexpected and is most likely due to a combination of 
being both impure and significantly more polar. While the crude material did contain a 
high proportion of the desired amine, any contaminants would have reduced the apparent 
bioactivity by contributing inactive or less active mass. Increasing the polarity of a drug 
can often lead to a decrease in activity due to a reduction in the drug's ability to diffuse 
across the cytoplasmic membrane, so the introduction of an amine functionality would be 
expected to lead to a decrease in activity. In light of these two factors, the observed ten-
fold decrease in activity is of no concern. 
Mycalamide B (32) was not submitted for bioactivity testing in an amine form as this 
material was acylated immediately after synthesis. However, based on the results 
obtained for the crude mycalamide A amine (45) and the mycalamide B azide 49, the IC50 
of the mycalamide B amine could be expected to be approximately 20 nmollL. 
Table 3.5 Cytotoxicities of natural product derivatives 
Compound IC~() (g/mL) 
Mycalamide A (31) 1.5 x 10-9 
Crude 17-amino-18-nor-mycalamide A (45) 14.0 x 10-9 
Mycalamide B (32) 1.0 x 10-9 
18-azido-18-deoxy-mycalamide B (49) 1.0 x 10-9 
Fumagillol (35) 248.3 x 10-6 
6-dehydro-fumagillol (51) 38.0 x 10-6 
6-deoxy-fumagillol (54) 23.6 x 10-6 
6R-pha1imidyl-6-deoxy-fumagillol (55) 7.2 x 10-6 
6R-tosyl-6-deoxy-fumagillol (56) 17.5 x 10-6 
6S-azido-6-deoxy-fumagillol (57) 41.6 x 10-6 
IC~n (moIlL) 
3.0 X 10-9 
29.6 X 10-9 
1.9 X 10-9 
1.8 X 10-9 
876.5 X 10-6 
135.6 X 10-6 
89.3 X 10-6 
17.5 X 10-6 
40.2 X 10-6 
135.3 X 10-6 
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The fumagillol derivatives, like their parent compound, all showed low activity in the 
P388 bioassay used. This is because the fumagillol family of compounds is known to 
possess selective activity against endothelial cells, with nanomolar concentrations 
preventing proliferation and micromolar concentrations being cytotoxic. It would be 
useful to assay the fumagillo 1 derivatives prepared here against an endothelial cell line. 
However, this is not currently available at the University of Canterbury. Samples of all 
compounds have been stored for assay at a future date should the opportunity arise. 
Given the variety of derivatives at position 6 already reported that have shown no 
significant decreases in bioactivity,99,JOo,167 it is not anticipated that the derivatives 
prepared in this work will have notably decreased bioactivity against endothelial cells 
compared to the parent fumagillol (35). 
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3.6 Conclusions from natural product modification 
The required derivatisation of natural products to amine forms was successfully carried 
out, although the yields attained were often less than would be desired. This problem 
was compounded by the fact that most reactions were carried out on a small scale (less 
than 10 mg, often as little as 1 mg) due to the value of the starting materials. Working 
on this scale lends greater significance to losses accrued during transfer or purification. 
The chemical sensitivity of the natural products investigated was a hindrance to their 
derivatisation as it limited the possible reagents and conditions that could be used as well 
as reducing the yields obtained. The scale-up of reactions that would be required should 
these compounds prove pharmaceutically useful could well present insurmountable 
problems, and in all likelihood the drug components would have to be replaced with 
other, more chemically stable, drugs. Nevertheless, the use of the highly toxic 
compounds described in this work remains a useful proof-of-principle for the utilisation 
of highly cytotoxic compounds in targeted constructs. 
The instability of the compounds is also a cause for concern in terms of their 
pharmaceutical application as it is possible that they may be degraded in the lysosome 
following cleavage from the rest of the drug conjugate. However, until biological testing 
is carried out this concern cannot be addressed. 
The reductive amination reaction to form primary amines used in this work was 
somewhat disappointing. The tendency for dimerisation was reduced by using a large 
excess of ammonium salt, but the yields were never as high as was believed might be 
achieved from an examination of the literature. 
The poor behaviour of amines in reverse phase chromato graphy, and in particular HPLC, 
meant that purification of nearly all the amines was not achievable. Many attempts were 
made using silica but degradation was often observed despite the inclusion of bases in the 
eluting solvent. Ion chromatography would be an obvious choice for purification of 
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arnines; however, the use of acidic solvents was precluded by the chemical sensitivity of 
the compounds. 
The derivatisation of the mycalarnides had a negligible effect on the bioactivity of the 
compounds, while the fumagillol derivatives were all more cytotoxic to P388 murine 
leukemia cells than the parent compound was. 
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Chapter 4 
Low Molecular Weight Conjugates 
4.1 Introduction 
The synthesis of low molecular weight conjugates was carried out in order to allow 
determination ofthe effects of both the biodegradable linker and the polymer. The 
original work describing the targeting of doxorubicin using the cyclo-CNGRC motif did 
not provide any release mechanism for the doxorubicin, so the activity observed was 
presumably caused by the intact conjugate. Incorporating a biodegradable linker could 
be expected to improve the activity of the conjugate by allowing doxorubicin to be 
released upon entry to the cell and thus freeing the drug from potential hindrance in 
reaching and binding to the DNA. It was hoped that the low molecular weight conjugate 
utilising doxorubicin described in this chapter could be used to determine whether the 
above supposition is correct or not by comparing its activity with that reported for the 
original, non-biodegradable conjugate. 
The preparation of low molecular weight conjugates of the other drugs was desirable to 
allow a comparison oftheir bioactivities to those oftheir polymer based analogues. This 
would allow some initial conclusions to be drawn concerning the effect of a polymeric 
structure on the efficacy of a targeted anti-angiogenic drug conjugate. 
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4.2 L-Tyrosinamide (39) 
4.2.1 Fmoc-cyclo-CNGRCGFLG-L-Tyrosinamide (59) 
L-Tyrosinamide (39, 2 equiv.) was condensed with 43 (1 equiv.) by reaction with DCC 
(1.9 equiv.) and NHS (2 equiv.) in DMF. NHS was included in the reaction to help 
prevent any dehydration of the asparagine side chain, as discussed in Section 2.3.2. 
HPLC analysis (C18, A: H20(A), B: ACN, Gradient III) after overnight reaction 
indicated that no product had been formed so the reaction was recharged with another 
5.4 equivalents ofDCC. Analysis of the reaction after another 24 hours indicated that 
some product had been formed but that most of the material was still unreacted so the 
reaction was again recharged, but this time with HBTU (2 equiv.) instead ofDCC in the 
hope that it would be a more efficient coupling reagent in DMF (Figure 4.1). One hour 
after the addition ofHBTU, HPLC (C18, A: H20(A), B: ACN, Gradient III) indicated 
that the reaction was complete so water was added to destroy any unreacted HBTU. 
The product, 59, was isolated in a 57% yield by direct semi-preparative HPLC (CI8, 
isocratic 40% ACN/H20(A)) purification of the reaction mixture. 
Due to the small quantity and complexity of the product, it was not fully characterised. 
A proton NMR spectrum which was collected showed a number of characteristic signals 
such as the leucine geminal methyl groups and the L-tyrosinamide aromatic signals. 2D 
NMR experiments were carried out on the compound, with COSY and ROESY spectra 
providing useful information, but the HSQC-DEPT, CIGAR and IMPRESS experiments 
provided little in the way of usable data. The fragments identified using the COSY 
spectrum are shown in Figure 4.2, as are some of the important ROESY correlations 
which were observed. The proton chemical shift data for 59 are provided in Table 4.1. 
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Figure 4.1 Reaction to fonn the protected nonapeptide-L-tyrosinamide conjugate (59) 
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Table 4.1 Proton NMR data for 59 obtained in d6-DMSO 
Position IH COSY ROESY 
1 7.88 H2 H2, H3a, H7" 
2 4.28 HI, H3a, H3b HI, H3a, H3b, H5 
3a 3.02 H2, H3b HI, H2, H3b 
3b 3.28 H2, H3a H2, H3a 
5 8.77 H6 H2,H6 
6 4.64 H5, H7a, H7b H5, H7a, H7b, Hll 
7a 2.38 H6, H7b H6, H7b, H9 
7b 2.79 H6, H7a H6, H7a, H9 
9 7.43 H7a, H7b 
11 7.92 H12a, H12b H6, H12a 
12a 3.51 Hll, H12b Hll, H12b 
12b 4.29 Hll, H12a H12a, H14 
14 7.78 H15 H12b, H15, H16a 
15 4.44 HI4, HI6a, HI6b HI4, HI6a, HI6b, HI7, H24 
I6a 1.62 HI5, HI6b, HI7 HI4, HI5, HI7 
I6b 2.02 HI5, HI6a, HI7 HI5, HI7 
17 1.54 HI6a, HI6b, HI8 HI6a, HI6b, HI8 
18 3.17 HI7, HI9 HI7, HI9 
19 7.61 HI8 HI8 
24 8.09 H25 HI5, H26a 
25 4.57 H24, H26a, H26b H26b 
26a 3.07 H25, H26b H24 
26b 3.31 H25, H26a H25 
28 8.34 H29 H25, H29 
29 3.75 H28 H28, H3I 
31 8.13 H32 H29, H32, H33a, H35 
32 4.63 H3I, H33a, H33b H3I, H33a, H33b, H35, H39 
33a 2.84 H32, H33b H3I, H32, H33b, H35 
33b 3.11 H32, H33a H32, H33a, H35 
35 7.31 H3I, H32, H33a, H33b 
36 7.3 
37 7.24 
39 8.29 H40 H32, H40, H4I, H46 
40 4.35 H39, H4I H39, H4I, H42, H43, H44, H46 
41 1.56 H40, H42 H39, H40, H43, H44, H46 
42 1.67 H4I, H43, H44 H40, H43, H44 
43 0.97 H42 H40, H4I, H42 
44 0.92 H42 H40, H42 
46 8.06 H47a, H47b H39, H40, H4I, H47a, H47b 
47a 3.67 H46, H47b H46, H47b, HI' 
47b 3.82 H46, H47a H46, H47a, HI' 
I' 7.99 H2' H47a, H47b, H2', H3'a, H5', HIO' 
2' 4.41 HI', H3'a, H3'b HI', H3'a, H3'b, HH5', HIO' 
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3'a 2.77 H2', H3'b H2', H3'b, H5' 
3'b 2.98 H2', H3'a H2', H3'a, H5' 
5' 7.09 H6' HI', H2', H3'a, H3'b, H6' 
6' 6.73 H5' H5',H8' 
8' 9.26 H6' 
10' 7.48 H1',H2' 
3" 4.42 H4" H6" 
4" 4.33 H3" H6" 
6" 7.82 H7" H3", H4", H7" 
7" 7.41 H6",H8" HI, H6", H8" 
8" 7.5 H7",H9" H7",H9" 
9" 7.99 H8" H9" 
Every ammo acid could be discerned in the COSY spectrum by begining with the 
characteristic correlations between the amide protons and the (X-protons. From these 
starting points it was possible to step through the side chains, where applicable, and 
identifY the proton chemical shifts for all ten ammo acids. The proton chemical shifts of 
59 were very similar for those determmed for the nonapeptide 43 with even the amide 
chemical shifts showing near coincidence. The only positions which deviated by more 
than 0.04 ppm were the (X-proton of the leucine residue, H39, which had moved 0.06 
ppm upfield compared to 43, and the amide, H45, and (X-protons, H46, ofthe C-termmal 
glycine residue. H45 had moved upfield by 0.14 ppm relative to 43, while H46 had 
developed diastereotopic splitting, with one proton appearing at an almost unchanged 
(0.01 ppm upfield) position at 3.82 ppm while the other had moved significantly to 3.67 
ppm. These changes in chemical shift are consistent with conversion ofthe C-terminal 
glycine acid functionality to an amide. 
The ROESY spectrum provided a useful series of correlations along the 'backbone' of 
the peptide between neighbouring amides and (X-protons. It must be remembered that 
since the ROESY experiment relies on through space nOe correlations, caution must be 
taken when interpreting the data and particular when looking to determme connectivity. 
With that restriction in mmd, the correlation between the L-tyrosinamide amide HI' and 
the (X-protons ofthe C-termmal glycine H46a,b did indicate that these protons were 
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spatially near each other. This evidence, combined with the observation of changes in 
chemical shifts elucidated from the COSY spectrum indicates that the desired compound 
59 was successfully formed. 
The molecular formula for 59 OfC61HnN15014S2 was confIrmed by HRESIMS which 
observed the protonated ion at 1308.53 (0.69 ppm). 
Analytical HPLC (CI8, A: H20(A), B: ACN, Gradient III) of 59 showed a single peak 
eluting at 9.3 minutes with a strong UV chromophore characteristic of the Fmoc group. 
4.2.2 H2N-cyclo-CNGRCGFLG-L-Tyrosinarnide (60) 
The Fmoc protecting group of 59 was removed by dissolving 59 in 20% 
piperidine/MeOH (Figure 4.3). Following cleavage of the protecting group, the reaction 
residue was purifIed by passage through a C 18 cartridge which was eluted with a stepped 
gradient from H20 to MeOH. 60 was not found to have eluted in any of the fractions 
from the aqueous-methanol gradient so the column was stripped with 100% DMSO, 
which also failed to elute 60. Finally, an acidilled solution consisting of90% 
MeOH/H20 with 0.1 % TFA was passed through the column and was successful in 
removing 60 which was isolated in a near quantitative yield of98%. 
Due to the paucity of material, no attempts were made to characterise 60 using 2D NMR 
spectroscopy; however, a proton spectrum was obtained and showed peaks characteristic 
of the phenyl group of phenylalanine, the geminal methyls ofleucine and the para 
substituted phenyl ring ofL-tyrosinamide. The characteristic Fmoc peaks were absent 
from the spectrum, indicating the deprotection of 59 had been successful. 
HRESIMS confIrmed the molecular formula of 60 to be C46H67N 15012S2 through 
detection of the protonated parent ion at 1086.46 Daltons (0.28 ppm). 
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Figure 4.3 Fmoc removal to form low molecular weight drug conjugate 60 
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4.3 Doxorubicin (19) 
4.3.1 Fmoc-cyclo-CNGRCGFLG-Doxorubicin 
Doxorubicin (19, 1.1 equiv.) was acylated with 43 using HBTU (1.9 equiv.) and NHS (2 
equiv.) in DMF. An analytical HPLC chromatograph (C18, A: H20(A), B: ACN, 
Gradient III) of the reaction taken after 16 hours of reaction indicated that the reaction 
was complete due to the absence of the starting peptide 43. Water was added to the 
reaction to quench any unreacted HBTU and the reaction solution was purified directly 
by semi-preparative HPLC(C18, isocratic 45% ACN/H20(A» to afford the desired 
doxorubicin conjugate in a 29% yield. 
An examination of the conjugate was carried out using NMR, but due to the structural 
complexity of the compound and the small amount isolated, it was not possible to fully 
characterise the compound. A proton spectrum was 0 btained and showed characteristic 
signals of the peptide and doxorubicin components such as the leucine geminal methyl 
groups, the aromatic signals of the Fmoc moiety and the downfield benzyl methoxy 
group of doxorubicin. A COSY spectrum was used to identify the proton chemical shifts 
of the amino acid residues and, more importantly, the glycone moiety of doxorubicin. 
From the characteristic downfield anomeric proton of doxorubicin at 5.32 ppm, the 
proton chemical shifts of the sugar could be traced to an amide proton at 7.60 ppm, thus 
confirming that doxorubicin had been successfully conjugated to the protected 
nonapeptide. An HSQC-DEPT and a ROESY experiment were run but unfortunately 
provided almost no data due to a poor signal to noise ratio. 
The molecular formula of the conjugate, C79H94N14023S2' was confirmed using 
HRESIMS which showed a peak corresponding to the protonated parent ion at 1671.61 
Daltons (0.00 ppm). 
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Analytical HPLC (C18, A: H20(A), B: ACN, Gradient III) of the conjugate showed a 
single peak eluting at 17.8 minutes which had a strong UV chromophore that included 
many local maxima and extended to the limit of the detector (600 nm). The 
chromophore was characteristic of doxorubicin. 
4.3.2 H2N -cyclo-CN GRCGFLG-Doxorubicin 
The deprotection of the protected nonapeptide-doxorubicin conjugate was not carried 
out due to the degradation observed in the same reaction of the corresponding 
tetrapeptide derivative during the synthesis of the analogous polymer drug conjugates. 
In that reaction, described in detail in Section 5.4.2, it was found that doxorubicin was 
completely degraded during the brief exposure to piperidine required to remove the 
Fmoc protecting group. The sensitivity of doxorubicin to basic conditions is known, but 
it was hoped that the short reaction time would prevent complete decomposition but this 
was not found to be the case. 
Due to the likelihood of damaging the conjugate during any attempts to deprotect the N-
terminus, the decision was made to assay the biological activity of the conjugate with the 
Fmoc group in place. 
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4.4 Mycalamide A (31) 
4.4.1 Fmoc-cyclo-CNGRCGFLG-Mycalamide A 
Crude 4S was acylated with the peptide 43 (1.3 equiv.) using HBTU (1.9 equiv.) and 
NBS (2.0 equiv.) in DMF. After overnight reaction at room temperature, a sample was 
examined using analytical HPLC (C 18, A: H20(A), B: ACN, Gradient III) which showed 
two major peaks and a number of minor peaks with spectra corresponding to the Fmoc 
chromophore (Figure 4.4). None of these peaks eluted at the established retention time 
of the peptide 43 (9.0 min). HPLC was then repeated, but without acidified water, as the 
acid in the water would have catalysed degradation ofconjugated mycalamide A. Under 
these conditions, only one major peak with the Fmoc cbromophore was observed 
(Figure 4.4). Semi-preparative HPLC (C 18, isocratic 40% ACNIH20) was used to 
collect this peak. Re-injection of the collected material on the analytical HPLC (C18, A; 
H20(A), B: ACN, Gradient III) showed a single peak eluting at 6.7 min, 0.8 min earlier 
than the previously detennined retention time. LRESIMS analysis of the material 
provided a molecular mass of 1 145, which is the mass of the starting peptide 43. There 
was no observable peak in the LRESIMS spectrum that corresponded to the molecular 
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Figure 4.4 HPLC chromatogram of product of acylation of 4S run with (black) and 
without (blue) TFA 
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mass ofthe desired conjugate. LRESIMS investigation ofthe waste from the attempted 
semi-preparative purification similarly showed no sign of the desired product. 
Due to the limited supply of both mycalamide A (31) and the nonapeptide 43, it was not 
possible to attempt this reaction a second time. The reason for the failure of the coupling 
reaction remains unknown. 
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4.5 Mycalamide B (32) 
4.5.1 Fmoc-cyclo-CNGRCGFLG-Mycalamide B 
Crude 50 was acylated with the peptide 43 (1.3 equiv.) using HBTU (1.9 equiv.) and 
NHS (2.0 equiv.) in DMF. After overnight reaction at room temperature, a sample was 
examined using analytical HPLC (C18, A: H20(A), B: ACN, Gradient III) which showed 
two major peaks, eluting at 9.2 min and 12.7 min, and one minor peak at 21.6 min, all 
possessing the Fmoc chromophore. The sample was also run in the absence ofTFA 
(C18, A: H20, B: ACN, Gradient III) and gave a similar chromatogram in which the two 
major peaks eluted slightly earlier (Figure 4.5). Semi-preparative HPLC (C 18, isocratic 
40% ACN/H20} was used to collect the major compound, which had an unreliable 
retention time but eluted at around 5.5 minutes. This collected material was examined by 
LRESIMS. The mass spectrum obtained showed a very small amount of the desired 
product (molecular mass 1 643), but a much larger proportion (approximately 35 times 
as much) of the starting peptide 43. Re-examination of the collected material by 
analytical HPLC (C18, A: H20, B: ACN, Gradient III) showed a single peak eluting at 
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Figure 4.5 HPLC chromatogram of the crude reaction product of32 acylation run 
without TFA 
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6.5 min. This elution time was significantly earlier than the 10.8 minutes established 
prior to semi-preparative HPLC purification, and may indicate that the reaction product 
was unstable and had hydrolysed. This would not occur if an amide had been formed 
with the mycalamide B derivative 50 thus it is likely that the acylation reaction failed. It 
is possible that the compound that was collected was an HOBt or NHS ester (Figure 
4.6), which are active esters and as such are liable to hydrolyse and can be formed during 
acylations with HBTU and NHS. 
Due to the limited supply of both mycalamide B (50) and the nonapeptide 43, it was not 
possible to attempt this reaction a second time. 
OH 
I 
W,I'J 
"- h R-~~~-U 
o 
HOBt ester 
o 
R_~'1r0p 
o 
I\JHS ester 
Figure 4.6 Possible reaction products of attempted acylations with HBTU and NHS 
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4.6 R-Fumagillol 
4.6.1 Fmoc-cyclo-CNGRCGFLG-R-Fumagillol 
Crude 52 was acylated with the peptide 43 (1.3 equiv.) using HBTU (1.9 equiv.) and 
NHS (2.0 equiv.) in DMF. After overnight reaction at room temperature, a sample was 
examined using analytical HPLC (C18, A: H20(A), B: ACN, Gradient III) which showed 
two major peaks eluting at 9.3 and 12.8 min, with the earlier eluting peak being slightly 
larger. As this peak was presumed to be the starting peptide 43, the reaction was 
recharged with extra 52 (1.3 equiv.) and HBTU (1.0 equiv.) and allowed to react for a 
further 24 hours. Analytical HPLC of the further reacted material showed a single major 
peak at 11.0 min, which was collected by semi-preparative HPLC (C18, isocratic 40% 
ACN/H20(A» in which it eluted at about 4.7 minutes. A LRESIMS spectrum obtained 
for the collected material showed a parent ion with a molecular mass of 1173.7, which 
neither corresponds to the desired product, nor any likely side-product, being just 28 
daltons heavier than the starting peptide 43. This mass difference could be caused by 
formation of an ethyl ester at the carboxyl terminus of the peptide, although there was no 
ethanol present in the reaction and this mass increase was not observed in any of the 
other coupling reactions, which were all carried out under the same conditions. 
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4.7 S-FumagiUol 
4.7.1 Fmoc-cyclo-CN GRCGFLG-S-Fu magillol 
Crude 58 (contaminated with triphenylphosphine oxide) was acylated with the peptide 43 
(J.3 equiv.) using HBTU (1.9 equiv.) and NHS (2.0 equiv.) in DMF. After overnight 
reaction at room temperature, a sample was examined using analytical HPLC (C 18, A: 
H20(A), B: ACN, Gradient Ill) which showed a single major peak with a chromophore 
corresponding to that ofFmoc eluting at 21.7 min and a series of four minor peaks at 
21.1,21.4, 24.5 and 24.8 minutes, aU of which possessed the Fmoc chromophore. While 
waiting for semi-preparative HPLC, the sample was stored at 4°C for 36 hours. Re-
ex.amination by analytical HPLC (CI8, A: H20(A), B: ACN, Gradient III) at this point 
showed that the sample had degraded to a set of six peaks displaying the Fmoc 
chromophore, eluting at 18.6, 18.9, 19.5, 19.7, 22.6 and 23.1 minutes (Figure 4.7). As 
this decomposition was not observed in the preparation of the tetrapeptide biolinker 
adduct (Section 5.8,)), in which pure 58 was used, the reaction was repeated, but using 
58 that had been purified 10 remove the contaminating triphenylphosphine oxide. HPLC 
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Figure 4.7 Chromatogram of crude reaction product after overnight reaction (blue 
trace) and 36 hours storage (black trace) 
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analysis (C18, A: H20(A), B: ACN, Gradient III) after overnight reaction showed a 
single peak eluting at 19.6 minutes, but following storage overnight at 4°C prior to 
purification again led to complete degradation. An analytical HPLC chromatogram 
(C18, A: H20(A), B: ACN, Gradient III) showed a series of peaks similar to those seen 
in the first instance. LRESIMS was carried out on the sample, but no ions 
corresponding the the desired product could be seen in the spectrum. At this point, the 
apparent instability of this compound led to a decision to abandon any further work 
toward formation of the nonapeptide adduct. 
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4.8 Biological activity 
The purified natural low molecular weight conjugates were submitted for bioassay 
against the P388 murine leukemia cell line. The toxicities determined, with 
concentrations referring to the drug component, are shown below in Table 4.2. 
As was hoped, the peptide conjugates prepared were not significantly cytotoxic. 
Unfortunately it was not possible to determine their exact toxicity as it was desirable to 
retain as much mass as possible for in vivo testing so the conjugates were tested at only 
one concentration. The primary purpose ofthis assay was to show that the peptide 
components themselves were not cytotoxic. 
The doxorubicin conjugate showed a toxicity at least five-fold lower than that offree 
doxorubicin as would be expected following conjugation to the large and relatively polar 
peptide construct. In the absence of receptor-mediated uptake, the conjugate should not 
release free doxorubicin and so will remain inactive, as doxorubicin must translocate to 
the cell nucleus to exert its toxicityThe. APN receptor targeted by this construct is not 
displayed at a significant level on non-endothelial cells so P388 murine leukemia cells will 
not endocytose these constructs efficiently. 
Table 4.2 In vivo toxicities oflow molecular weight conjugates 
Compound Iem (g/mL) 
Doxorubicin (19) 700 x 10-9 
H2N-cyclo-CNGRCGFLG-L-tyrosinamide (60) > 2.1 x 10-6 
Fmoc-cvclo-CNGRCGLFG-doxorubicin > 4.0 x 10-6 
IC.;() (moIlL) 
1.3 X 10-6 
> 11.5 X 10-6 
> 7.5 X 10-6 
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4.9 Conclusions About Low Molecular Weight Conjugates 
Two low molecular weight conjugates were successfully prepared. The fIrst 
incorporated L-tyrosinamide for use in biodistribution studies, while the second utilised 
the proven anti-cancer drug doxorubicin. The doxorubicin conjugate was prepared to 
allow an assessment of the effect of inclusion of an established biodegradable linker by 
comparison of the biological activity of the construct with that of Arap et a1. 64 Initial 
testing against P388 murine leukemia cells indicated that the conjugates could be suitable 
for in vivo studies as they did not display signifIcant cytotoxicity against this generic cell 
line. 
The preparation of the twomycalamide conjugates was unsuccessful, with the most 
likely cause being failure of the acylation reaction. The reason for this failure is not 
known, and is particularly puzzling given the success of the analagous reactions during 
polymer drug conjugate synthesis (Chapter 5). 
The preparation of two enantiomeric fumagillol conjugates was also unsuccessful, 
although in these cases it would appear that degradation was the cause of the failure. 
These problems were not noted during the preparation ofbiolinker toxins (Chapter 5), 
which indicates that the pentapeptide targeting motif may be somehow responsible for 
the observed decomposition. This is somewhat surprising, given that the pentapeptide 
does not contain any highly reactive functionalities. The only functional groups which it 
does not share with the tetrapeptide biolinker are the arginine guanidine, the asparagine 
terminal amide and the cystine disulfIde. Of these, only the disulfIde or the strongly basic 
guanidine (pKa 12.5) could be reasonably expected to present any possibility of 
undesired reaction. An unprotonated guanidine group is strongly nucleophilic so could 
lead to degradation via nucleophilic attack, although it should have remained protonated 
throughout the work as no strong bases were used at any point. The cystine disulfIde 
should not have presented any pro blems as disulfIde bonds are relatively stable. If this 
work is pursued further, it would be necessary to examine the stability of the natural 
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products in the presence of isolated guanidine and disulfide functionalities to determine 
the cause ofthe observed degradation. 
The analysis of reaction progress was complicated by the tendency of the nonapeptide to 
show non-reproducible retention times on all HPLC systems used. This is likely due to 
the presence ofthe free guanidinium group in the arginine side-chain. Non-reproducible 
behaviour of compounds containing free amine groups has been observed in other 
samples investigated during the course ofthis research, and is thought to be due to slight 
variations in the level of ionisation ofthe amine group. It appears that the guanidine 
functionality is also prone to this behaviour despite being significantly more basic than all 
ammes. 
Finally, due to the small quantities of starting materials available, in particular the 
nonapeptide, it was not possible to re-attempt the unsuccessful syntheses to try to 
circumvent the acylation and degradation difficulties. While it would have been possible 
to resynthesise the peptide, this would have required a very significant investment of 
time, which was not justifiable given the indeterminate nature ofthe difficulties 
experienced. 
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Chapter 5 
Polymer Drug Conjugates 
5.1 Introduction 
The synthesis of polymer drug conjugates has typically been carried out through the 
aminolysis ofa co-polymer of HPMA with ap-nitrophenol activated ester of the 
biolinker, the so called polymeranalagous reaction (Figure 5.1).123 The reaction progress 
is monitored by quantitation of the amount of released p-nitrophenol using UV to detect 
the highly coloured p-nitrophenoxide ion in basic conditions. The co-polymer itself is 
produced by free radical polymerisation of the component monomers in appropriate 
proportions, but this results in a polymer with high polydispersity. This distribution leads 
to a decrease in the efficacy of the polymer drug conjugate as some of the polymer will 
have a very low molecular weight, and so be rapidly eliminated, while some will be very 
f
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Figure 5.1 Synthesis of a polymer drug conjugate from HPMA copolymer 
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high molecular weight and thus may be permanently retained if it exceeds the renal 
threshold (~ 50 kDa). Furthermore, achieving regulatory approval may be difficult in the 
case of a highly polydisperse and thus poorly characterised drug. 
To circumvent these problems, the use of polymer precursors synthesised using atom 
transfer radical polymerisation (ATRP) to ensure a low polydispersity has been 
proposed.168,169 ATRP is a form of controlled radical polymerisation in which the radical 
of a growing polymer can exchange with a more stable metal atom, thus ensuring that the 
polymer radical is maintained at a low concentration, which in turn leads to a greatly 
reduced rate of premature termination of polymerisation. 170 The polymer precursor 
proposed is poly(methacryloxy succinimide) (pMAOS, 61). This is a homopolymer of an 
activated ester of methacrylic acid which can be amino lysed to produce the fmal polymer 
drug conjugate (Figure 5.2). 
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Figure 5.2 Synthesis of a polymer drug conjugate from pMAOS 
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The use of this type of activated polymer precursor has a further advantage that the 
components to be incorporated, such as the biolinker, can be changed easily without 
requiring new polymerisation reactions to be carried out. Furthermore, it has the 
advantage that targeting residues no longer have to be attached via the biodegradable 
linker as in PK2 (38), but rather can be attached directly to the polymer backbone, via a 
spacer if desired. 
A sample ofpMAOS was supplied for this work by Miss Hsin-I Chang and had a weight 
average molecular weight of 16 100 and a polydispersity of 1.18.171 
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5.2 Optimisation of Polymer Aminolysis 
The mildest conditions reported to date for the aminolysis ofpMAOS (61) are an initial 
treatment with a peptide-drug substitute (0.1 equiv.) for 2.5 hours at 50°C followed by 
complete aminolysis with 1-amino-2-propanol (2 equiv.) for 1.25 hours at 50°C. The 
characterisation of the polymer was carried out using FT -IR in attenuated total 
reflectance mode to observe the loss of the characteristic IR absorbance of the 
oxysuccinimide ester at 1735 cm-I •169 
Due to the tendency for degradation, we try to avoid subjecting natural products to 
elevated temperatures, in particular conditions significantly higher than body temperature 
(37°C) are considered to present an undesirable risk to the integrity of the natural 
products. For this reason, it was necessary to investigate the aminolysis ofpMAOS (61) 
at a reduced temperature. 
Initially, a reaction was carried out amino lysing pMAOS (61) with L-tyrosinamide (39, 
0.25 equiv.) at 40°C in the presence ofEt3N (0.5 equiv.) with DMSO as the solvent. 
The reaction progress was monitored by ATR-IR at 1735 cm- I but the peak height 
fluctuated, with some measurements providing a reading greater than the initial reading. 
Examination of the region surrounding the peak of interest in the IR spectrum revealed 
that there were broad peaks nearby which were influencing the baseline selection, and 
thus the measured height of the peak at 1735 cm- I . Due to these difficulties, it was 
decided that a different analytical technique should be investigated. 
A time course investigation was carried out using proton NMR spectroscopy. pMAOS 
(61) was reacted with phenylglycine methyl ester (0.25 equiv.) at 50°C in d6-DMSO in 
the presence ofEt3N (0.75 equiv.). It was hoped that the downfield movement of the cx-
proton from its initial position of 5.37 ppm could be observed upon conjugation to the 
polymer backbone. Unfortunately the phenylglycine appeared to have a very low 
reaction rate with the polymer, presumably due to steric hindrance, as the reaction 
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remained largely incomplete after 13 hours. This low reactivity precluded the use of 
phenylglycine as a valid model. 
131 
An alternative method of examining the progression of the aminolysis reaction was 
attempted in which reaction samples were purified prior to analysis by NMR 
spectroscopy. This series of experiments also provided an opportunity to investigate the 
purification of the polymer product. Initially, pMAOS (61) was reacted with 1-amino-2-
propanol (2 equiv.) at 40°C in dry DMSO for four hours. The first attempt at polymer 
purification was made using a CentriPrep ultrafiltration system with a molecular weight 
cut-off of 5 000 Da; however, the purification was unsuccessful as the polymer passed 
through the membrane. The failure of the ultrafiltration membrane to retain the polymer 
drug conjugate could well have been because the membrane is designed to retain 
globular molecules such as proteins; The polymer is linear and would not be expected to 
form a globular structure as it contains no extended hydrophobic domains to drive 
hydrophobic collapse, which is believed to be crucial to the formation of protein tertiary 
structure. 172 
The contaminated polymer was then passed through an LH20 column, eluting with 
MeOH, which did remove most of the contaminants as determined by proton NMR 
spectroscopy; however, some contamination remained. The polymer was then passed 
through LH20 a second time, again eluting with MeOH, to remove the remaining low 
molecular weight contaminants. 
The proton NMR spectrum of the purified polymer (Figure 5.3) showed an unexpected 
broad peak at 2.56 ppm so 2D NNlR experiments were carried out. The HSQC-DEPT 
spectrum showed that the protons at 2.56 ppm were correlated to two carbons at 28.2 
and 30.8 ppm and that these were both methylenes. A CIGAR experiment revealed that 
the same protons were also correlated to two carbonyl carbons at 170.3 and 173.5 ppm 
as well as carbons at 28.2 and 30.8. The evidence thus collected strongly suggested that 
the succinimide moiety had undergone a ring opening reaction by attack of the nitrogen 
nucleophile on an imide carbonyls rather than the desired ester carbonyl (Figure 5.4). 
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Figure 5.3 Proton NMR spectrum of polymer showing ullexpected peak at 2.56 ppm 
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Figure 5.4 Proposed side reaction of pMAOS polymer precursor 
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This is a known reaction that has been previously reported for reactions of succinimidyl 
esters with amino acids in which one of the reagents is sterically hindered. 173-175 
The polymer was reacted a second time with 1-amino-2-propanol (2 equiv.) in dry 
DMSO for 16 hours at 40°C in an effort to displace the putative oxysuccinamide groups. 
After purification by passage twice through LH20 eluted with MeOH, proton NMR 
spectroscopy revealed that the peak at 2.56 ppm was greatly reduced in size. The later 
eluting, low molecular weight fractions from the LH20 column were examined, with one 
containing a mixture of compounds which seemed to include the unexpected side 
product from the polymer aminolysis. This fraction was passed through a silica column 
(0.6 g, 60 x 5 nnn) and then finally purified by semi-preparative HPLC (C18, isocratic 
2% ACNIH20(A)) to provide two pure isomers (63 and 64). 
The proton and carbon NMR spectra of 63 and 64 were fully assigned using COSY, 
HSQC and CIGAR 2D NMR experiments. The chemical shift assignments are shown in 
Tables 5.1 and 5.2 with the important COSY and CIGAR correlations shown in Figures 
5.5 and 5.6. 
N-Z-Hydroxy-N'-(2-hydroxypropyl)-succinamide (63) 
Table 5.1 Proton and carbon NMR data for 63 obtained in d6-DMSO 
Position 1H 13C COSY CIGAR 
1 8.7 H2 
2 10.39 HI C3 
3 168.6 
4 2.18 28 H5 C3, C5, C6 
5 2.33 30.7 H4 C3, C4, C6 
6 171.3 
7 7.82 H8 C6, C8 
8 2.98 46.5 H7,H9 C6, C9, C10 
9 3.62 65.3 H8, H10, H11 C8 
10 1.01 21.2 H9 C8, C9 
11 4.65 H9 C8 l C9 l C10 
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Figure 5.5 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
observed for 63 
1 
OH 0 
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2HNt '(6'~~ 
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N-E-Hydroxy-N'-(2-hydroxypropyl)-succinamide (64) 
Table 5.2 Proton and carbon NMR data for 64 obtained in d6-DMSO 
Position IH 13C COSY CIGAR 
1 7.37 6.82 
2 6.82 7.37 
3 173.7 
4 2.38 30.74* C3, CS, C6 
S 2.38 30.66* C3, C4, C6 
6 171.7 
7 7.86 H8 C6, C8 
8 3.06 46.S H7,H9 C6, C9, ClO 
9 3.7 6S.3 H8, HIO, HII C8, ClO 
10 1.09 21.2 H9 C8, C9 
11 4.73 H9 
* These values may be interchanged 
OH 0 
H~~~~ 
o OH 
Figure 5.6 Important COSY (blue bonds) and CIGAR (black arrows) correlations 
observed for 64 
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Initially NMR spectra were obtained in D20, but in order to visualise the exchangable 
protons spectra were re-collected in d6-DMSO. The spectra of the Z-isomer in D20 
were pure, but when obtained in d6-DMSO, the material had partially (about 25%) 
isomerised to the E-isomer. This is likely to have occurred during removal of the D20 
solvent which was carried out at approximately 45°C. 
The assignments of the proton and carbon chemical shifts of the two isomers was 
straightforward but required the use of 1D NOESY experiments to complete the 
characterisation of the two isomers. In 63, correlations were observed between the 
amide proton H7 and the methylene protons H5 as well as between the hydroxyamide H2 
and the methylene H4. This unambiguously established the orientation of the 
succinamide moiety. With 64, the protons of the succinamide moiety were coincident, 
although the chemical shifts of C4 and C5 did differ, albeit by only 0.1 ppm, which is less 
than the default resolution of the CIGAR experiment. In the CIGAR experiment that 
was run, the amide H7 did not show a correlation beyond the carbonyl group, so even if 
this experiment had been reacquired at a higher resolution it would not have been 
possible to establish the orientation of the carbon chemical shifts of the succinamide 
moiety. NOESY experiments run on 64 did, however, show correlations between 
H4/H5 and both HI and H2, thus allowing the assignment of the stereochemistry as E, 
whereas in 63, only H2 showed a correlation in to the succinamide protons. Neither HI 
nor H2 showed CIGAR correlations to the carbonyl C3, so the orientation of these two 
chemical shifts was determined by the relative strengths of their correlations to H41H5 as 
observed in the NOESY experiments run. The proton at 7.37 showed a stronger 
correlation and was thus assigned as HI, as this proton is closer to H4/H5, at a distance 
of approximately 2.3 A, than H2, at approximately 3.6 A. 
The molecular formula of 63, was confirmed by HRESIMS in which the expected parent 
ion was not observed, but rather the protonoted, deoxygenated ion, C7H,sN20 3 at 175.11 
Daltons (1.18 ppm) was identified. The loss of oxygen from hydroxamic acids under 
mass spectrometric conditions has been previously reported for electron ionisation mass 
spectrometry.'76 Strangely, the isomeric 64 did not exhibit deoxygenation to any notable 
extent, thus the formula C7H,sN20 4 was obtained by observation ofa peak at 191.10 
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Daltons (1.50 ppm). The loss of oxygen from 63 is confirmed to be occurring only in 
the mass spectrometer by the observation of conversion of 63 to 64 during removal of 
d6-DMSO as previously discussed. 
A further aminolysis reaction was carried out, this time at 60°C with l-amino-2-propanol 
(3 equiv.) in dry DMSO. Samples were removed periodically and purified by LH20 
chromatography eluting with MeOH, then analysed by proton NMR. The sample taken 
after the reaction had been underway for two hours showed complete aminolysis ofthe 
polymer precursor and no peak at 2.56 ppm, thus indicating that poly(N-2-
hydroxypropyl-methacrylamide) (HPMA, 62) had been successfully formed. An identical 
reaction was then carried out but at the reduced temperature of 40°C. A sample 
removed from the reaction after eight hours did contain a peak at 2.56 ppm in the proton 
NMR spectrum,· but the next sample, after 14 hours, had a proton NMR spectrum 
consistent with HPMA. 
With the determination of suitable reaction conditions for aminolysis ofthe polymer 
precursor in the presence of natural product derivatives, it was possible to continue with 
formation of the desired polymer drug conjugates. 
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5.3 L-Tyrosinamide (39) 
5.3.1 Fmoc-Gly-Phe-Leu-Gly-L-Tyrosinamide (65) 
The coupling reaction between L-tyrosinamide (39, 1 equiv.) and 40 was carried out 
using DCC (1.9 equiv.) and NHS (2 equiv.) (Figure 5.7). Following overnight reaction, 
the reaction was found to be complete by analytical HPLC (CI8, A: H20(A), B: ACN, 
Gradient II) so the THF solvent was removed and the crude reaction mixture was 
purified by preparative HPLC (CI8, isocratic 90% MeOH/H20(A)) to furnish the desired 
conjugate 65 in a 45% yield. 
The proton and carbon NMR chemical shifts for 65 were fully assigned through 
reference to 2D COSY, HSQC-DEPT and CIGAR spectra. Because the spectra were 
obtained in CD30D, none of the exchangable amide protons were observed, and more 
importantly, the chemical shifts could not be be compared directly to those already 
established for the tetrapeptide 40, for which NMR spectra were obtained in d6-DMSO. 
The crucial correlation which confirmed the successful formation of 65 was a CIGAR 
correlation from the a-proton of the L-tyrosinamide residue to the carbonyl of the C-
terminal glycine. 
Interestingly, in CD30D, all of the carbon chemical shifts of the Fmoc-Gly-Phe-Leu-Gly 
portion of65 were slightly downfield (by between 0.1 and 3.4 ppm) from the 
corresponding shifts of 40 in d6-DMSO with the exception of the p-methylene of the 
leucine residue and the carbonyl of the C-terminal glycine. Both of these positions were 
slightly upfield compared to the parent compound. The main chain carbons (a-carbons 
and carbonyls) exhibited the greatest changes in chemical shift, with the carbonyls in 
particular showing relatively large increases in chemical shift (between 2.5 and 3.4 ppm) 
with the exception of the carbonyl of the C-terminal glycine which was up field by 0.1 
ppm. These changes are likely to be due to the fact that methanol is a hydrogen bond 
donating solvent, and so can cause a slight increase in the polarity of a carbonyl bond, 
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Figure 5.7 Reaction scheme leading to formation of a polymer drug conjugate 
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with a reduction in electron density around the carbon atom and hence a higher chemical 
shift. The fact that the C-terminal carbonyl was shifted in the opposite direction to the 
others strongly suggests a change in chemical environment expected for the successful 
formation ofthe conjugate 65. 
The formula for 65, C43H4gN60g, was confirmed by HRESIMS in which the protonated 
ion at 777.36 Da (0.38 ppm) was identified. 
5.3.2 H 2N-Gly-Phe-Leu-Gly-Tyrosinamide (66) 
The Pmoc protecting group of 65 was removed by dissolving the compound in a 
solution of 20% piperidinelMeOH for 20 minutes, after which 66 was isolated in a 55% 
yield by passage through a C 18 cartridge. 
A proton NMR spectrum was obtained of 66 (Figure 5.8), and showed the expected 
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Figure 5.8 Proton NMR spectrum of 66 
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peaks and an absence of peaks corresponding to an Fmoc group; however, a full 
characterisation was not carried out as the material was carried through to form the 
polymer conjugate as soon as possible to avoid any potential for degradation at this late 
stage. 
Analysis of66 by HRESIMS allowed identification of the protonated parent ion at 
555.29 Da (1.26 ppm), which confirmed the formula OfC28H38N606' 
5.3.3 Synthesis and purification of targeted polymer drug conjugate (67) 
The polymer drug conjugate 67 was formed by reaction of the polymer precursor 61 (50 
equiv.) with 66 and the targeting peptide 42 (1 equiv.) in the presence of triethylamine (3 
equiv.) followed by quenching of the active ester groups of the polymer with 1-amino-2-
propanol (150 equiv.). The crude polymer was passed twice through an LH20 column, 
eluting with MeOH, to provide the product 67 in a 57% yield. 
Due to the fact that 67 is a heterogeneous polymer, characterisation of the material could 
not be carried out to the usual standard. The formation of the co-polymer was 
confirmed by NMR and LRESIMS analysis of all of the fractions obtained from the 
LH20 fractionation. 
The proton NMR spectrum of the purified polymer 67 was free oflow molecular weight 
contaminants. There was a single peak that could be identified as being due to one of the 
aromatic protons of the L-tyrosinarnide moiety (Figure 5.9). Integration of this peak 
gave a relative integral of 4.3 relative to the methine of the 1-amino-2-propanol at 96. 
While there is certain to be some inaccuracy in this ratio due to the peak broadness and 
differing relaxation times, it does indicate that the biolinker tetrapeptide construct was 
incorporated into the polymer at an approximately quantitative level. There were no 
peaks corresponding to the targeting moiety that could be identified as these all fall in the 
region of the spectrum that is dominated by the polymer itself. There was a small peak at 
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2.5 ppm due to ring-opened succinamide that integrated for approximately 20 protons, 
corresponding to about 5% incorporation. It was decided that it would not be 
worthwhile to react the polymer again in an attempt to aminolyse this material as it may 
have needed a prolonged reaction time, would have led to a reduced yield and was 
present at a relatively low level. LRESIMS of the polymeric fraction had a very low ion 
current and showed no recognisable ions as the polymer itself is not ionisable under 
ESIMS conditions. 
None of the late eluting, and thus low-molecular weight compound containing, fractions 
showed any signs of either the biolinker-tetrapeptide, 66, or the targeting peptide 42, 
which indicated that they must have been entirely consumed by reaction with the 
polymer precursor. 
The combined evidence from the examination of all the fractions led to the belief that 
the desired polymer conjugate 67 had been successfully fonned and purified to a 
sufficient level for bioactivity srudies. 
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Figure 5.9 Overlaid proton NMR spectra of polymer conjugate 67 (black) and 
precursor 66 (blue) 
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5.4 Doxorubicin (19) 
5.4.1 Fmoc-Gly-Phe-Leu-Gly-Doxorubicin (68) 
Prior to using doxorubicin (19), it was necessary to desalt the commercially obtained 
doxorubicin hydrochloride to ensure solubility in organic solvents. Doxorubicin (19) is 
known to be sensitive to allcali conditions so the neutralisation was carried out by adding 
dilute aqueous ammonia, to an aqueous solution of doxorubicin hydrochloride. Upon 
addition of the base, the solution immediately changed colour from a deep red-orange to 
violet. The basic solution of doxorubicin (19) was then passed through a C18 cartridge 
without delay, trapping the doxorubicin (19) as a red layer on the solid phase. The 
cartridge was rinsed with more of the dilute aqueous ammonia followed by water and the 
doxorubicin (19) was eluted with acetone. It was never possible to remove all of the red 
colour from the cartridge, regardless of the solvents used; however the doxorubicin (19) 
was recovered in a 92% yield, so the residual colour on the cartridge accounted for only 
a small proportion of the mass. 
Doxorubicin was (19) conjugated to the biolinlcer 40 (1.1 equiv.) with DCC (1.9 equiv.) 
in the presence ofNHS (2 equiv.) and then purified by preparative HPLC (C18, isocratic 
90% MeOHIH20(A)) to afford the desired conjugate 68 in a 52% yield. 
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The proton and carbon NMR chemical shifts of 68 were fully assigned using COSY, 
HSQC-DEPT and CIGAR experiments with the exception of the amide proton HI, 
which was not apparent in the COSY spectrum, and four quaternary carbon shifts in the 
anthraquinone moiety of doxorubucin (C5a', C6', C11' and C11a') which could not be 
seen in the CIGAR spectrum. Too little material was collected to allow the collection of 
a carbon spectrum to detect those four resonances so a full characterisation could not be 
carried out. 
Unfortunately no CIGAR correlations were observed from doxorubicin to the carbonyl 
of the N-terminal glycine of the tetrapeptide biolinker; however, H3" showed a 
correlation in the COSY spectrum to a proton at 7.04 ppm, which was clearly an amide 
proton due to its downfield chemical shift and absence from the HSQC-DEPT spectrum. 
Further evidence for the structure indicated was that the proton chemical shift of position 
3" had moved approximately 1 ppm downfield from those reported for the free base in 
CDCl3 and CD30D. 177 The chemical shifts of all of the positions, except the amide 
proton, of the sugar moiety agreed closely with those determined for PIG (37), although 
these data were obtained in a different solvent. l78 Finally, the chemical shift of the 
terminal carbonyl of the peptide, C21, had moved upfield by 2.8 ppm, which could be 
expected upon conversion from a free acid to an amide. 
The formula of 68, C61H65N5017' was confirmed by HRESIMS which showed a peak for 
the sodiated parent ion at 1162.43 Da (0.69 ppm). 
5.4.2 H2N -Gly-Phe-Leu-Gly-Doxorubicin 
In order to remove the Fmoc protecting group of 68, it was dissolved in a solution of 
20% piperidine/MeOH for 20 minutes and then passed through a C 18 cartridge. A 
number of red coloured fractions, indicative of the presence of doxorubicin, were 
collected from the cartridge; however, none of them showed any sign of the desired 
product by NMR or LRESIMS. In fact, none of the red fractions showed any peaks in 
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the NMR spectra corresponding to doxorubicin thus suggesting that the red compound 
was only present at a very low level. HPLC (C18, A: H20(A), B: ACN, Gradient I) 
analysis of all the fractions from the cartridge showed the presence of a large number of 
compounds with just one major peak, eluting at 16.8 minutes, with a doxorubicin-like 
chromophore (Figure 5.10). This major peak was collected and analysed by LRESIMS 
but the peaks in the mass spectrum corresponded to neither the desired product nor any 
other likely products ofthe reaction. 
It is known that doxorubicin is unstable to basic conditions, so it may be that the 
conditions for removal of the Fmoc protecting group were too harsh and caused the 
degradation of the doxorubicin component of 68. The main pathway for alkaline 
degradation of doxorubicin involves loss of the glycoside followed by aromatisation of 
the A-ring. 179, 180 It was hoped that the doxorubicin conjugate would be able to survive 
the relatively mild deprotection conditions; however, it appears that complete 
degradation occurred. 
The deprotection of a protected peptide N-terminus in the presence of doxorubicin may 
not be achievable. Doxorubicin is known to be sensitive to acidic conditions with 
cleavage ofthe sugar moiety occuring at low pH «2) thus precluding the use ofthe 
other most commonly used N-terminal protecting group, tBoc (t-butoxycarbonyl).181 
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Figure 5.10 HPLC chromatogram of product of attempted deprotection of68 
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The reductive conditions required for removal of the Cbz (benzyloxycarbonyl) group are 
not compatible with doxorubicin and can lead to deoxygenation of the quinone moiety 
and also cleavage of the glycoside residue. 182 The only protecting group which seems to 
present a strong possibility of success is the trityl group or derivatives thereof. This is 
rapidly cleaved under acidic conditions, which may be mild enough to allow the reaction 
to be carried out in the presence of doxorubicin, although this is not certain. The 
preparation of an N-trityl protected biolinker would require the use of a different solid 
phase, most likely using tBoc chemistry to build up the peptide before incorporation of 
the final N-trityl glycine because the trityl group is not compatible with the acid-cleaved 
resins used for Fmoc SPPS. 
Due to the complications experienced with the deprotection of 68, the preparation of a 
. polymer drug conjugate incorporating doxorubicin as the drug component was 
abandoned. 
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5.5 Mycalantide A (31) 
5.5.1 Frnoc-Gly-Phe-Leu-Gly-Mycalarnide A (69) 
The crude reductive amination product 45 was acylated with the biolinker 40 (1.1 equiv.) 
using DCC (1.9 equiv.) and NHS (2 equiv.) until analytical HPLC (C18, A: H20, B: 
ACN, Gradient II) indicated consumption of the majority of the starting material. The 
crude reaction product was purified directly by preparative HPLC (C18, A: H20, B: 
ACN, Gradient II) to provide 69 in a 23% yield, calculated over two steps from formyl-
normycalamide A (45). 
The proton and carbon NMR chemical shifts of 69 were fully assigned through the use of 
2D COSY, HSQC-DEPT and CIGAR experiments. The chemical shifts of the peptide 
component of69, determined using CDCl3 + 0.05% d5-pyridine, were similar to those 
determined for the tetrapeptide 40 in d6- DMSO with the exception of the amide protons 
which were all shifted significantly upfield. This could be due to the fact that d6-DMSO 
is a hydrogen bond acceptor, so can form hydrogen bonds with the protons ofthe amides 
leading to an electron withdrawing effect and thus a downfield shift whereas CDCl3 is 
unable to accept hydrogen bonds so the amide protons appear upfield by comparison. 
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Evidence of the success of the reductive amination reaction to produce 45 was provided 
indirectly by the identification ofthe amide linkage between mycalamide A and the 
biolinker. The chemical shift ofCI7', 36.2 ppm, is consistent with direct attachment of 
an amide. Furthermore, HI7', a diastereotopic pair of protons at 3.38 and 2.78 ppm, 
showed a COSY correlation to a proton at 7.04 ppm which was an amide proton as 
evidenced by the lack ofa correlation for this proton in the HSQC-DEPT spectrum. The 
connectivity of the tetrapeptide and drug components were easily established and a 
crucial CIGAR correlation from 17'-NH to the carbonyl C21 was evidence that the 
conjugate had been formed as desired. 
The molecular formula ofCs7H76N6014 for 69 was confirmed by HRESIMS which 
provided a peak corresponding to the sodiated parent ion at 1091.53 (1.65 ppm). 
5.5.2 H2N-Gly-Phe-Leu-Gly-Mycalamide A (70) 
Compound 69 was deprotected by dissolving the compound in 20% piperidine/MeOH 
and standing at room temperature for 20 minutes before drying. The crude reaction 
product was purified by chromatography on a C18 cartridge, using a stepped 
MeOHIH20 gradient to provide 70 in a quantitative yield. 
H2N-Gly-Phe-Leu-Gly-Mycalamide A (70) 
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The proton NMR spectrum of 70 showed all of the expected resonances were present, 
while at the same time confirming the absence of any peaks corresponding to the Fmoc 
protecting group (Figure 5.11). The material was carried directly through to form a 
polymer conjugate without any further characterisation to eliminate any possibility of 
degradation. 
The formula of70, C42H65N6012' was confirmed by HRESIMS which showed a peak at 
847.48 Daltons (0.94 ppm) that corresponded to the protonated parent ion. 
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Figure 5.11 Proton NMR spectrum of 70 
5.5.3 Synthesis and purification of targeted polymer drug conjugate 
The biolinker-drug moiety 70 and the targeting peptide 42 (1 equiv.) were coupled with 
the polymer (61, 50 equiv.) in the presence of triethylamine (3 equiv.). After overnight 
reaction, the remaining activated esters of the polymer were aminolysed with l-amino-2-
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propanol (150 equiv.). The purified polymer drug conjugate was obtained in a 53% yield 
by subjecting the total reaction solution to size separation chromatography twice on an 
LH20 column run with MeOH. 
Proton NMR spectroscopy and LRESIMS of all of the fractions collected from the size 
exclusion chromatography showed that the polymer had been satisfactorily purified away 
from low molecular weight contaminants. Furthermore, it showed a lack of any signs of 
either free biolinker-drug or free targeting components, thus indicating that the 
conjugation ofthese to the polymer backbone had proceeded successfully. 
Close examination of the proton NMR spectrum ofthe polymer revealed a small peak at 
5.70 ppm which is the same position as the HI0 of my calami de A (31) appears. Relative 
to the methine of the hydroxypropylamide set to 96 protons, the peak at 5.70 ppm 
integrated for 2.6 protons which is slightly higher than expected. This is not surprising 
given that there are a number ofpeptidic protons obscured by the methine and the low 
level of the peak as well as the peak broadness will lead to inaccuracies. The presence of 
this peak provides positive confirmation that the biolinker drug construct has been 
successfully conjugated to the polymer backbone. It is not possible to identify any 
resonances from the targeting peptide in the spectrum, but on the basis ofthe successful 
conjugation ofthe biolinker drug moiety and the lack of any apparent free peptide, it is 
assumed that the targeting peptide has also successfully reacted. 
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5.6 Mycalanlide B (32) 
5.6.1 Fmoc-Gly-Phe-Leu-Gly-Mycalamide B (71) 
Crude 50 was acylated with 40 (1.1 equiv.) using DCC (1.9 equiv.) in the presence of 
NHS (2 equiv.) in an overnight reaction. The solvent was removed and the crude 
product purified directly by preparative HPLC to provide the product 71 in a 79% yield, 
calculated over two steps from the azide 49. 
The proton and carbon NMR chemical shifts for 71 were fully assigned through 
reference to 2D COSY, HSQC-DEPT and CIGAR spectra with the exception of the 
carbonyl carbons C 1 7 and C21 which were not observed in the CIGAR spectrum due to 
a paucity of material. 
The NMR chemical shifts determined for the mycalamide B portion of 71 confmned that 
the azide 49 had been successfully reduced and the amine so formed had been acylated 
with the peptide 40. The chemical shift of C 18' was the only carbon chemical shift that 
differed by more than 1 ppm from those of 49, being shifted upfield by 10.5 ppm to 41.7 
ppm. This lower chemical shift is consistent with a directly attached amide. The only 
proton chemical shifts that differed significantly from those of corresponding positions in 
9 
1 0 
4" H II 01"N~ 
'j( 2 ~ 
8 ':?" 1 0 
~I 
o 
H_ II 19 
N~~O 
. N ; H 8" 
o o 14y17 HN118' 
16 16'~OMe 
7" 4 
MeO 9H H 0 14' 
~'O:' N10' 12'· . 7' ( :. 11' 'IOMe 4' 5' 0 0 .... .;0 3' ........... 
Fmoc-Gly-Phe-Leu-Gly-Mycalamide B (71) 
Chapter 5: Polymer Drug Conjugates 151 
49 were in the side chain. Interestingly, H16'a and b were seen as a separate pair of 
diastereotopic protons in 71 where they were coincident in 49, while the opposite was 
observed for the protons ofHI8'. A correlation could be clearly seen in the COSY 
spectrum from H18' to an amide proton at 6.73 ppm. This single correlation confirmed 
both the success of the reduction of the azide 49 to an amine, and the following acylation 
of that amine. Unfortunately no correlations from the amide proton 18'-NH were seen in 
the CIGAR spectrum so the connectivity of71 could not be unequivocally proven but 
the fact that there was only one carboxylic acid group capable of acylating the amine 
mitigates the need for direct proof somewhat. In the peptide component of71, the 
chemical shifts of the C-terminal glycine residue were very similar to those determined 
for the other tetrapeptide-drug conjugates, which strongly indicated that the amide had 
been formed as desired. 
The formula of C59HsoN6015 for 71 was confirmed using HRESIMS which allowed 
identification of the sodiated parent ion at 1135.56 Daltons (0.26 ppm). 
5.6.2 H2N-Gly-Phe-Leu-Gly-Mycalamide B (72) 
The Fmoc protecting group of 71 was removed by dissolving it in a 20% 
piperidine/MeOH solution and standing for 20 minutes before removing the solvents. 
The reaction product was purified by chromatography on a C18 cartridge to provide 72 
in a 96% yield. 
A proton NMR spectrum was taken of 72 and showed the absence of all the Fmoc 
resonances of the parent compound but all of the expected pealcs were present. No 
further NMR spectroscopy experiments were carried out on 72 as it was reacted to form 
a polymer drug conjugate as soon as possible. 
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The molecular formula for 72 ofC44H69N6013 was confirmed by HRESIMS which 
showed a peak: for the protonated parent ion at 891.51 Daltons (4.49 ppm). 
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5.6.3 Synthesis and purification of polymer drug conjugate 
The polymer precursor 61 (50 equiv.) was stirred with 72,42 (1 equiv.) and 
triethylamine (3 equiv.) in dry DMSO overnight before quenching the remaining active 
sites of the polymer precursor with 1-amino-2-propanol (150 equiv.). The product 
polymer was isolated in a 66% yield by passage twice through LH20, eluting both times 
with MeOH. 
All fractions from the purification of the polymer conjugate were analysed using both 
proton NMR spectroscopy and LRESIMS. Neither the free biolinker-drug 72 nor the 
targeting peptide 42 were detected in the low molecular weight compound containing 
fractions, while the late eluting, high molecular material was found to be free of 
contamination to a level suitable for biological testing. 
Upon close examination of the proton NMR spectrum of the polymer, a small hump at 
5.70 ppm could be observed. This peak was too small to allow integration, which could 
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suggest that the coupling of the biolinker drug moiety to the polymer backbone had 
occurred at less than quantitative yield; however, it did show that some coupling had 
occurred. It is possible to identify a low shoulder on the amide proton peak at around 
7.2 ppm that was not present in a sample of pure HPMA. This peak is thought to be 
primarily due to the aromatic protons of phenylalanine as it has been observed in proton 
NMR spectra of other polymer drug conjugates, an example of which is provided in 
Figure 5.9. Unfortunately, the peak cannot be accurately integrated as it lies over the 
edge of the amide proton peak; however, it does indicate that the tetrapeptide residue 
has been incorporated, and thus, by inference, that the drug itselfhas been conjugated to 
the polymer backbone. 
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5.7 R -Fumagillol 
5.7.1 Fmoc-Gly-Phe-Leu-Gly-R-Fumagillol (73) 
The crude product of the reductive amination to Conn 52 was acylated with the 
tetrapeptide biolinker 40 (1.1 equiv.) using DCC (1.9 equiv.) in the presence ofNHS (2 
equiv.). After overnight reaction, the product was examined by analytical HPLC and 
was found to contain six peaks which had UV spectra corresponding to the Fmoc 
chromophore (Figure 5.12). These six peaks were individually collected (C18, A: H20, 
B: ACN, gradient: 68% B (0 min), 68% B (2 min), 71% B (14 min)) and were all found 
to contain compounds similar to the desired product 72 as their proton NMR spectra 
showed resonances corresponding to both the peptide and fumagillol components. The 
largest peak in the HPLC chromatogram, eluting at 11.8 min, corresponded to the 
product 72, which was isolated in a disappointing 13% yield, calculated over two steps 
from the ketone 51. 
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Figure 5.12 HPLC trace of reaction product from acylation of crude 52 with the 
tetrapeptide biolinker. Collected peaks are boxed in blue. 
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The proton and carbon NMR chemical shifts of 72 were full assigned using the 2D NNlR 
experiments COSY, HSQC-DEPT and CIGAR. Assignment of the majority of the 
structure was straightforward and was carried out as already described for the smaller 
components (Sections 2.2.4 and 3.4). 
The carbon chemical shift of the modified position of fumag illo 1, C6', was 44.5 ppm 
which is consistent with the attachment of an amide to that carbon atom. Further, the 
proton H6' showed a correlation in the COSY spectrum to a proton at 6.65 ppm, which 
was clearly an amide proton as the HSQC-DEPT spectrum showed that it was not 
attached to a carbon atom. These factors indicated, albeit indirectly, that the reductive 
amination of the ketone 51 had proceeded as expected. 
The formation of the desired peptide drug construct was confirmed through the 
observation of a CIGAR correlation from H6' to the amide carbonyl C21. 
Observation of the coupling constants ofH5' in the proton spectrum allowed 
determination of the stereochemistry ofH6'. The measured coupling constants for H5' 
were 4.4 and 10.7 Hz, with the larger of the two constants being due to coupling to H4'. 
Thus, the coupling between H5' and H6' is 4.4 Hz, which, although slightly larger than 
the reported value for the free amine of 3 Hz, is consistent with a gauche relationship as 
discussed in Section 3.4.4. 
The molecular formula of72, CSOH63Ns09' was confIrmed by HRESIMS which allowed 
identification of the protonated parent ion at 878.47 Daltons (0.57 ppm). 
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The side products, which were also isolated, were obtained in insufficient quantities to 
allow their structural characterisation. 
5.7.2 H2N-Gly-Phe-Leu-Gly-R-Fumagillol (74) 
Compound 72 was dissolved in a solution consisting of20% piperidinelMeOH and 
allowed to stand for 20 minutes before removing the solvents under a stream of nitrogen. 
The deprotected product 74 was isolated in an 81 % yield by passing the crude reaction 
material through a C18 cartridge. 
A proton NMR spectrum of74 which was obtained showed the expected peaks and an 
absence of peaks corresponding to an Fmoc group; however, a full characterisation was 
not carried out as the material was carried through to form the polymer conjugate 
immediately to avoid any potential for degradation. 
ConfIrmation ofthe molecular formula of74, C3sHs2Ns07' was provided by HRESIMS 
which showed a peak corresponding to the protonated adduct ion at 656.40 Daltons 
(2.89 ppm). 
H2N-Gly-Phe-Leu-Gly-R-Fumagillol (74) 
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5.7.3 Synthesis and purification of targeted polymer drug conjugate 
The polymer precursor 61 (50 equiv.) was reacted overnight in dry DMSO with 74 and 
42 (1 equiv.) in the presence of triethylamine (3 equiv.). The remaining active ester 
groups of the polymer were then reacted with l-amino-2-propanol (150 equiv.) after 
which the polymer was purified by chromatography by gel filtration on LH20. After two 
columns the low molecular weight contaminants were removed and the polymer was 
isolated in a 53% yield. 
Proton NMR spectroscopy and LRESIMS of all of the fractions collected from the size 
exclusion chromatography showed that the polymer conjugate had been satisfactorily 
purified away from low molecular weight contaminants. Furthermore, they showed that 
neither the biolinker-drug or targeting components were present as unconjugated 
contaminants, thus indicating that the coupling of these to the polymer backbone had 
proceeded successfully. 
There are no proton NMR shifts in 74 that are suitable for providing positive 
confirmation of drug conjugation to the polymer as all resonances fall in the same region 
as protons of the polymer backbone itself. The olefinic proton at 5.15 ppm is the most 
likely candidate, but in the proton spectrum of the polymer that was obtained this region 
is obscured by the HOD solvent peale As described in Section 5.6.3, a shoulder on the 
amide peak at 7.2 ppm which can be ascribed to the aromatic protons of the 
phenylalanine residue could be clearly seen. This could not be used for quantification, 
but did provide positive evidence of successful conjugate, which, when taken in concert 
with the lack of evidence of a failed reaction, suggests that the desired polymer has been 
formed. 
Chapter 5: Polymer Drug Conjugates 158 
5.8 S-Fumagillol 
5.8.1 Fmoc-Gly-Phe-Leu-Gly-S-Fumagillol (75) 
Compound 75 was produced by acylating 58 with 40 (1.1 equiv.) using DCC (1.9 equiv.) 
and NHS (2 equiv.) in THF overnight. After removing the reaction solvent, the 
biolinker-drug co~ugate 75 was isolated by preparative HPLC (C18, isocratic 69% 
ACN/H20) in a 56% yield. 
The proton and carbon NMR chemical shifts of 75 were fully assigned through reference 
to COSY, HSQC-DEPT and CIGAR spectra. The assignment of the peptide and drug 
elements of the compound were made in a similar manner to that used for the 
characterisation of the separate components (Sections 2.2.4 and 3.4). 
CIGAR correlations from both the amide proton and H6' of the fumagillol moiety to the 
C-terminal carbonyl ofthe peptide confirmed that 75 had formed as expected. The 
chemical shift of position 6' was also consistent with the formation of the amide bond 
with the proton shifting downfield by 1.16 ppm and the carbon moving upfield by 4.0 
ppm relative to the amine 58. 
The spectra were taken in d6- DMSO so a useful comparison of the data for the peptide 
portion of75 with the parent peptide 40 could be made. Almost all of the chemical shifts 
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were in close agreement, falling within 0.6 ppm (13C) and 0.03 ppm eH) of each other. 
The only shifts of 75 which fell outside these ranges were the a-proton of leucine, which 
was 0.09 ppm downfield, the a-carbon of the C-terminal glycine, which was 1.5 ppm 
downfield and the carbonyl of the carboxy terminal glycine, which was 3.3 ppm upfield. 
The a-protons of the C-terminal glycine had not only shifted notably up field (by 0.1 and 
0.05 ppm), but the two protons had become coincident where they were observed as two 
separate diastereotopic protons in the parent peptide. 
The coupling patterns ofH5' could not be determined due to an overlap with the two a-
protons of the C-terminal glycine residue so the stereochemistry at position 6' could not 
be confirmed as S. The chemical shifts of75 could, however, be compared with those of 
the enantiomeric structure 73. Despite having their spectra taken in different solvents, 
the chemical shifts of these two structures were similar, with the most significant 
differences being observed near 6'. In particular, the chemical shifts of C6' and H6' were 
shifted 5.3 ppm and 0.78 ppm up field respectively compared to 73. This difference is 
too great to be purely due to a solvent change, so it can be fairly concluded that the 
stereochemistry of6' was different in 75 and 73, and thus 75 must have had S 
stereochemistry as proposed. 
The molecular formula for 75 of C50H63N509 was confirmed by HRESIMS which 
showed a peak for the protonated parent ion at 878.47 Daltons (0.57 ppm). 
5.8.2 H2N-Gly-Phe-Leu-Gly-S-Fumagillol (76) 
Compound 75 was deprotected using 20% piperidine/MeOH, and after removing the 
solvents, the reaction material was purified by passage through a C18 column to afford 
76 in a 25% yield. 
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A proton NMR spectrum was taken of 76 and showed the absence of all the Fmoc 
resonances of the parent compound and the presence of all of the expected peaks. Due 
to the degradation observed during the attempted preparation of a low molecular weight 
analogue as described in Section 4.7.1, 76 was reacted to form a polymer drug conjugate 
as soon as possible and so no further NMR spectroscopy experiments were carried out. 
The molecular formula ofC3sHs2Ns07 for 76 was confirmed by HRESIMS which 
provided a peak corresponding to the sodiated parent ion at 656.40 (1.98 ppm). 
H2N -Gly-Phe-Leu-Gly-S-Fumagillol (76) 
5.8.3 Synthesis and purification of targeted polymer drug conjugate 
Compounds 76 and 42 (1 equiv.) were reacted with the polymer precursor 61 (50 equiv.) 
in the presence of triethylamine (3 equiv.). After overnight reaction, 1-amino-2-propanol 
(150 equiv.) was added to the reaction to aminolyse the remaining active ester sites of 
the polymer precursor. Following a further 12 hours of reaction, the reaction solution 
was applied directly to an LH20 column and eluted with MeOH. After a second passage 
through LH20, the pure polymer conjugate was isolated in a 70% yield. 
Proton NMR spectroscopy and LRESIMS of all of the fractions collected from the size 
exclusion chromatography showed that the polymer had been satisfactorily purified away 
from low molecular weight contaminants. Furthermore, it showed a lack of any signs of 
either the biolinker-drug or targeting components being free, thus indicating that the 
conjugation of these to the polymer backbone had proceeded successfully. 
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As outlined in Section 5.7.3 for the enantiomeric fumagillol derivative, no protons could 
be clearly discerned that were due to the drug itself. Again the aromatic protons of the 
phenylalanine residue could be identified on the edge of the polymer backbone amide 
resonance. This was a non-quantitative indicator of successful conjugation of 76 to the 
polymer backbone. 
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5.9 Biological activity 
The purified polymer drug conjugates were submitted for bioactivity testing against the 
P388 murine leukemia cell line. The toxicities determined, relative to the drug 
component, are shown below in Table 5.3. 
All of the polymer drug conjugates were not cytotoxic to P388 murine leukemia cells at 
the concentrations tested. No attempt was made to retest the compounds at a higher 
concentration in order to determine an actual toxicity level as it was felt that this would 
be a waste of compound. The results below do establish that, in the case of the 
mycalamides, the polymer bound drugs are significantly less cytotoxic than the free 
drugs, which is expected. With the-L-tyrosinamide and fumagillol derivative polymer 
drug conjugates, the low molecular weight compounds showed negligible cytotoxicity 
and these results simply show that their polymeric derivatives have not gained notable 
cytotoxicity. 
Due to the nature of polymer drug conjugates, and even more so targeted polymer drug 
conjugates, in vitro testing is oflimited utility as they are only able to show their full 
potential, through the EPR effect, reduced immunogenicity and enhanced circulation 
times, in in vivo studies. 
Table 5.3 Results of cytotoxicity testing of polymer drug conjugates expressed relative 
to the drug component 
Compound 
L-tyrosinamide polymer drug conjugate (67) 
Mycalamide A polymer drug conjugate 
Mycalamide B polymer drug conjugate 
R-Fumagillol polymer drug conjugate 
s-Fumagillol polymer drug conjugate 
rC"fl (g/mL) 
> 280 X 10-9 
> 700 X 10-9 
> 760 X 10-9 
> 430 X 10-9 
> 430 X 10-9 
rem (mo1JL) 
> 1.5 X 10-6 
> 1.5 X 10-6 
> 1.5 X 10-6 
> 1.5 X 10-6 
> 1.5 X 10-6 
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5.9 Conclusions from Polymer Drug Conjugate Preparation 
With the exception of doxorubicin, all ofthe desired polymer drug conjugates are 
believed to have been successfully prepared. In the case of doxorubicin, the base-
catalysed deprotection of the amino terminus of the tetrapeptide led to total 
decomposition of the doxorubicin moiety. While this could be possibly circumvented 
through the use of alternative protecting group chemistry, it was not considered to be 
important enough to warrant the time and effort of resynthesis. 
Quantitation ofthe levels of drug and targeting motifwas difficult in some cases and 
impossible in most. The targeting peptide has no proton NMR resonances that fall 
outside the range dominated by the-polymer backbone and no UV absorbance at all. 
Detection ofthe level of attachment ofthis structure to the polymer is thus not possible. 
Use oflR to detect the targeting peptide would also not be possible as the peptide 
contains no functionalities with strong and distinctive absorbtion bands. The biolinker-
drug components could be detected in some cases through olefInic resonances ofthe 
drug component and in all cases peal(s could be seen that corresponded to aromatic 
protons. In the case of both L-tyrosinamide (39) and mycalamide A derivative 45, it was 
possible to use integration of a peak in the proton NMR spectrum to obtain an estimate 
of the amount of drug present. In all other cases quantifIcation using proton NrVlR 
spectroscopy was not possible. The problem of quantifIcation and characterisation ofthe 
polymer drug conjugates is concerning, although the use of poorly characterised drugs in 
research is not without precedent. 
The strategy of acylating the crude amines produced by derivatisation ofthe natural 
products prior to purifIcation was found to be far superior to purifIcation ofthe free 
amine. The free amines had poor chromatographic properties and could not be usefully 
analysed by HPLC; however, acylation with the Fmoc-protected biolinker greatly 
improved their chromatographic behaviour as well as providing the characteristic Fmoc 
chromophore which was useful in analytical examinations. 
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The observed ring opening reaction of the succinllnide of the polymer precursor is a 
cause for concern for the long term development ofthe NHS-activated ester precursor. 
It appears that this side-reaction is driven by the high steric hindrance of the carbonyl of 
the polymerised methacrylic acid causing reaction to occur at the slightly less hindered 
succinllnide carbonyl. Although no adducts of peptide-drug with the succinllnide moiety 
were detected by ESIMS or proton NMR spectroscopy, it would be advantageous to 
subsititute the NHS with a different activating group which is unable to undergo side-
reactions such as p-nitrophenol. 
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Chapter 6 
Conclusion 
6.1 Summary and Conclusions 
The aim of this project was to produce a family of targeted polymer drug constructs 
incorporating both a peptidic targeting motif to direct the drug to angiogenic endothelial 
cells and a natural product drug attached via a biodegradable linker. A secondary target 
of this work was the production ofa series of low molecular weight analogues of the 
polymeric constructs that could be used to assess the benefit of using a polymer 
backbone. 
The biolinker and targeting motif and the targeted biolinker construct were all 
successfully prepared by stepwise solid phase peptide synthesis. The yields obtained 
were, with the exception of the biolinker, lower than desired but no optimisation of the 
synthesis was carried out. If the targeting motif or the targeted biolinker construct are to 
be prepared on a larger scale, it will be necessary to carry out studies varying the 
protecting groups and strategies used in order to maximise the yield and minimise the 
amount purification required. Due to the limited amounts required for initial biological 
testing, it would not have been worthwhile to carry out such an investigation for this 
project. 
The natural products used, mycalamides A (31) and B (32) and fumagillol (35), required 
modification to provide amine functionalities suitable for conjugation to the biolinker. 
This was successfully carried out, although the yields obtained were often disappointing 
and purification of the amine derivatives was found to be problematic. In all cases the 
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amines could be purified and characterised fo llowing acylation. The difficulties 
experienced throughout this work with degradation indicate that it would be wise to 
focus future work on drugs that are chemically stable. This would not only simplify any 
synthetic or hemi-synthetic procedures, but would also remove the possibility of drug 
degradation following administration, for example in lysosomes. 
The preparation of low molecular weight drug conjugates was plagued with failure of the 
acylation reaction. In the case of L-tyrosinamide and doxorubicin the reaction was 
successful; however, in all other instances the desired product could not be prepared. 
The cause of the failed reaction remains unknown but is 1ilcely to be due to the presence 
of the targeting peptide, as the analagous reactions in the polymer drug syntheses were 
all successful. An alternative preparation of the low molecular weight conjugates could 
be carried out in which the targeting motif is coupled to the biolinker after the drug, 
although this has the disadvantage of exposing the valuable drug to more reactions and 
thus risking degradation. 
With the exception of doxorubicin, all of the desired polymer drug conjugates were 
successfully prepared. The level of characterisation of the conjugates was not ideal, and 
this is an area that will require much work if polymer drug conjugates are to come into 
clinical use. The use of very low polydispersity polymers is a useful starting point, but 
techniques are required that will enable the accurate quantification of all components of 
the conjugate. To this end, it may be worthwhile to incorporate specific labels such as 
2H or 13e for NMR analysis or use highly UV active components so their level of 
incorporation can be accurately determined. 
The compounds produced have been tested in vitro against the P388 murine leukemia 
cell line, with results being largely unsurprising. The free mycalamide derivatives tested 
all showed strong cytotoxicity, while the fumagillol derivatives all displayed low toxicity 
to the P388 cells. The conjugates were all non-toxic at the concentrations tested. The 
conjugates have not yet been tested in vivo, but a proposed dosing regime can be 
outlined. For the doxorubicin conjugate, a dose of 5 j.Lg/week/mouse is planned. This is 
a relatively small dose, but is in line with the putative anti-angiogenic action of the drugs. 
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At this dose level there is sufficient drug conjugate for 136 doses, thus allowing for the 
possibility of alternative dosing schemes or extended duration trials. The L-tyrosinamide 
conjugates will be radio labelled with 1231 or 1251 prior to administration to allow a 
determination ofbiodistribution and pharmacokinetics to be made. This will highlight 
the difference between the low and high molecular weight conjugates. The remaining 
conjugates, all polymeric, have been prepared in quantities that are more than adequate 
for in vivo testing, even if a dose as high as 10 Ilg/week/mouse was used, which is 
unlikely given the cytotoxicity of the mycalamides and the anti-angiogenic activity of 
fumagillo 1. 
In the absence of in vivo testing it is difficult to comment on the likely future of the 
compounds produced in this work; however, the independent promise of both polymeric 
and anti-angiogenic drugs suggests that a combination of these two approaches may well 
lead to a useful treatment for cancer. 
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Chapter 7 
Experinlental 
7.1 General Methods 
Nuclear Magnetic Resonance Spectroscopy 
All proton detected NMR spectra were obtained on a Varian Inova 500 spectrometer at 
23°C, operating at 500 MHz. Carbon detected NMR spectra were recorded on a Varian 
Unity 300 spectrometer at 23°C, operating at 75 MHz. Other NMR experiments 
described in this thesis viz COSY, ROESY, NOESY, and the reverse detected HSQC, 
CIGAR and IMPRESS experiments were obtained on the Inova 500 spectrometer at 500 
MHz. Chemical shifts in this thesis are described in parts per million (ppm), on the 0 
scale, and were referenced to the appropriate solvent peaks: CDC13 referenced to CHC13 
at 0H 7.26 ppm eH) and CHC13 at Oc 77.0 ppm (l3C); CD30D referenced to CHD20D at 
0H 3.30 ppm (lH) and CD30D at Oc 49.3 ppm (l3C); D20 referenced to HOD at OH 4.7 
ppm (lH) and (C2H40)2 (added dioxan) at Oc 67.4 ppm; d6-DMSO referenced to 
CDlCHD2)SO at OH 2.6ppm and (CD3)2S0 at Oc 39.6 ppm; d3-acetonitrile referenced to 
CHD2CN at OH 2.0 ppm and CD3CN at Oc 1.3 ppm or CD3CN at Oc 117.7 ppm. lH 
NMR spectra were recorded using an acquisition time (AT) of2.0 s; l3C NMR spectra 
were recorded using an AT of 0.878 s and a delay (Dl) of 1 s. COSY experiments were 
typically recorded using an AT of 0.137 s and a relaxation delay (D!) of 1.0 s. ROESY 
experiments were carried out with an AT of 1.89 s, a relaxation delay (Dl) of 1.0 s and a 
mixing time of 0.3 s. NOESY experiments were recorded with an AT of 1.0 s, a delay 
(Dl) of 1.0 s and a mixing time of 0.5 s. HSQC-DEPT experiments with the Pulsed 
Field Gradient system were generally run with an AT of 0.133 s, a relaxation delay (Dl) 
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of 1.0 sand Jc_Hof 130-165 Hz. CIGAR experiments with the Pulsed Field Gradient 
system were run with an AT of 0.303 s, a delay (Dl) of 1.0 s, J= 140 Hz and a nJCH of 
8.0 Hz. IMPRESS experiments were acquired using the Pulsed Field Gradient system 
with an AT of 0.128 s, a Dl of LOs, J= 140 Hz and a nJCH of 8.0 Hz. 
Mass Spectrometry 
Mass spectrometry of some samples (stated) was performed on a Kratos MS80 RFA 
Mass Spectrometer operated at 4 000 V in electron impact (EI) ionisation mode. 
Ionisation was performed at 70 eV. 
The majority of the samples were analysed on a Micromass LCT mass spectrometer 
equipped with an electro spray ionisation (ESI) probe. Samples were analysed at a probe 
voltage of 3 200 V at 150°C with a nebuliser gas flow of 160 Llhr and desolvation gas 
flow of 520 Llhr with the source temperature at 80°C. The cone voltage was typically 
20 V. The solvent flow from a syringe pump in direct injection ESIMS mode was 20 
IlLimin. 
High Pressure Liquid Chromatography 
The High Pressure Liquid Chromatography (HPLC) work described in this thesis was 
performed on one of two machines. A Shimadzu LC-4A instrument equipped with a 
Shimadzu UV Spectrotometric Detector SPD-2AS and Hewlett Packard 3390A 
integrator was used for preparative reverse phase work with the stated column, solvent 
mixture and flow rate. Solvents were degassed using a flow of helium. 
Analytical and small scale preparative work was performed on a Shimadzu VP system. 
The complete setup involved a Shimadzu LC-I0AC VP liquid chromatograph coupled to 
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a SIL-10A VP autoinjector, aCTO-lOA VP column oven set to 40°C, and a SPD-M10A 
VP diode array detector. This system was controlled by Shimadzu CLASS-VP (Version 
5.023) software. A Shimadzu degasser (DGU-14A) was utilised for the degassing of all 
solvents used in this machine. 
Columns and flow rates used were a Phenomenex ODS(3) column (250 x 4.6 mm, 60 A, 
5 Ilm APD, 1 mL/min) for analytical work, a Phenomenex Luna C18(2) (250 x 10mm, 
60 A, 5 Ilm APD, 5 mL/min) for semi-preparative work and a Dynamax C18 (270 x 20 
nun, 60 A, 12 mL/min) for preparative work. 
The solvents used were either mixtures of acetonitrile (BDH HiperSolvTM 'Far UV' 
grade) or methanol (BDH HiperSolvTM grade) with water (purified using a MilliQ 
. deionising system). The aqueous phase was acidified with 0.05% trifluoroacetic acid 
(Scharlau, synthesis grade) where possible, as indicated by H20(A). 
Standard gradients used are presented below: 
Gradient I Gradient II Gradient III 
Time B conc Time B conc Time B conc 
0 10% 0 10% 0 37% 
2 10% 2 10% 12 40% 
14 75% 14 75% 32 80% 
24 75% 19 75% 34 100% 
26 100% 20 100% 36 100% 
30 100% 22 100% 37 37% 
32 10% 23 10% 40 37% 
40 10% 26 10% 
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Medium Pressure Liquid Chromatography 
Medium Pressure Liquid Chromatography (MPLC) was performed using a Merck Lobar 
size B (310 x 25 mm) RP-18 Li Chroprep (40-63 Ilm) column connected to a Mill-Royal 
D pump with a flow rate of 10 mL/min. The system was equipped with a LKB Broma 
2238 UVICORD SII detector and a LKB Broma 2210 recorder with detection at 254 
nm. 
Column Chromatography 
All column chromatography was performed using glass columns of stated dimensions 
(height x diameter). Solvents were all of commercial grade, distilled once in glass 
distillation apparatus, except MeOH, which was distilled twice. 'Flash' columns were 
run under oxygen-free N2 gas pressure (0.5 kPa). 
Silica flash chromatography was performed on Merck silica gel 60 (230-400 mesh). 
Reverse phase C18 chromatography used Bakerbond spe™ Octadecyl (CIS) disposable 
solid phase extraction columns (40 mm APD, 60 A) of a 500 mg I 3 mL size or iflarger 
columns were required, they were prepared using Bakerbond CIS (40 Ilm preparative LC 
packing). Size-exclusion chromatography was carried out using Sephadex LH-20 
(Pharmacia Biotech AB). Small scale ion-exchange chromatography was performed on 
either Bond Elut SCX solid phase extraction columns (40 Ilm APD, 60 A, 500 mg, 3 
mL) Analytichem International) or Bakerbond spe™ CBX (Carboxylic acid) disposable 
solid phase extraction columns (40 Ilm APD, 60 A, 500 mg, 3 mL). Larger scale ion-
exchange chromatography was performed on Trisacryl® M CM (carboxymethyl) 
preparative LC packing (40-80 Ilm swollen bead size, LKB). 
Where UV detection is indicated, the system was equipped with a LKB Broma 2238 
UVICORD SII detector and a LKB Broma 2210 recorder with detection at the stated 
wavelength. 
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Thin Layer Chromatography 
All analytical thin layer chromatography (TLC) was performed on Merck silica gel 60 
F2S4 aluminium backed sheets (0.2 rum thickness). The solvent(s) used for development 
are indicated in each case. Visualisation was performed frrst visually under normal light 
followed by short wavelength UV (254 run). Staining was carried out using either iodine 
(12), potassium permanganate dip (3 g KMn04, 20 g K2C03 and 5 mL 5% aqueous 
NaOH in 300 mL H20), phosphomolybdic acid spray (PMA, 10 % w/v phosphomolybdic 
acid in ethanol), vanillin dip (60 g vanillin and 10 mL c.H2S04 in 1 L 95% EtOH) or 
ninhydrin spray (1.5 g ninhydrin and 5 mL glacial acetic acid in 500 mL 95% EtOH). 
UV -Vis Spectroscopy 
UV -Vis measurements were taken on a Hewlett Packard HP 8452A Diode Array 
Spectrometer. Samples were placed in 10 rum quartz glass cuvettes (Starna) with a 
solvent blank carried out prior to sample measurement. 
Biological Assays 
Compounds were assayed for cytotoxicity where applicable using the P388 MTT 
antitumour assay. The antitumour assay is the most sensitive assay for cytotoxicity. It 
consists of a 2-fold dilution series of the sample of interest followed by incubation for 72 
hours with P388 (murine leukaemia) cells. The concentration of sample required to 
reduce the P388 cell growth by 50% (compared to control cells) is determined using the 
absorbance values obtained when the yellow MTT tetrazolium is reduced by healthy cells 
to produce the purple colour MTT formazan. The result is expressed as the lCso 
(ng/mL). 
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IR Spectroscopy 
IR measurements were taken on a Shllnadzu FTIR-8201PC Spectrometer. Samples 
were measured using an ATR cell with a background measured first. 
Kaiser Test 
173 
For SPPS of peptides the Kaiser test was used to determine the presence or absence of 
free amines. Several beads from the resin synthesis were removed and washed with 
EtOH (3 x 1 mL) in a small glass vial. The following three stock solutions were made 
and three drops from each were added to cover the beads. 
2.5 g ninhydrin in 50 mL ofEtOH 
40 g phenol in 10 mL ofEtOH 
2 mL 0.001 M KCN (6.5 gin 100 mL water) and 98 mL of pyridine 
The vial was capped and placed in an oven (l20DC) for three minutes. A positive result 
was indicated by the beads turning blue while a negative result was shown by no change 
in colour (beads remained yellow). 
Solvents 
All technical grade solvents were distilled prior to use. MeOH was distilled twice. Dry 
solvents were obtained using the following standard methods. MeOH, toluene and 
pyridine were all refluxed over calcium hydride and distilled immediately before use. 
THF was refluxed over sodium metal and benzophenone before distillation directly prior 
to use. Both DMF and DMSO were dried by treating twice overnight with activated 4A 
molecular sieves, followed by storage over 4A sieves. 
Chapter 7: Experimental 174 
7.2 Work described in Chapter 2 
7.2.2.1 Fmoc-Gly-Wang resin 
A typical procedure is as follows: Wang resin (1 g, 0.83 mmol available benzyl alcohol 
positions) was stirred gently with Fmoc-glycine (284 mg, 0.95 mmol) in dry DMF 
(7 mL) for approximately fifteen minutes prior to the addition of pyridine (463 j.1L, 
5.73 mmol) and 2,6-dichlorobenzoyl chloride (410 j.1L, 2.86 mmol). The reaction flask 
was then sealed with gentle stirring continuing overnight after which the resin was 
fIltered under vacuum and washed thrice with DMF (5 mL each) and DCM (5 mL each). 
The resin was then dried thoroughly in vacuo prior to determination of the loading. 
To ascertain the degree of resin loading, a small amount of resin (0.7 and 1.0 mg) was 
accurately weighed into two quartz cuvettes. Freshly made 20% piperidine/DMF (3 mL) 
was then dispensed into the cuvettes along with a third empty cuvette which was used as 
a solvent blank. The UV spectrum of each sample was taken after they had been mixed 
for approximately fIve minutes and allowed to settle and the exact absorbance at 290 nm 
was recorded (0.893 and 1.356 respectively). The loading of the resin was then 
calculated on the basis of a linear relationship between absorbance at 290 nm and the 
quantity of Fmoc-amino acid present, with one mmol of Fmoc-amino acid giving an 
absorbance of 1.650 to give loadings of 0.77 and 0.82 meq/g with an average of 0.8 
meq/g. The remaining benzyl alcohol groups of the resin were capped by stirring the 
resin (1 g, 0.83 mmol total benzyl alcohol groups) with pyridine (404 j.1L, 5 mmol) and 
benzoyl chloride (406 j.1L, 3.5 mmol) inDCE (5 mL) for two hours followed by fIltration 
and washing thrice with DCE (5 mL each) and DCM (5 mL each) before drying 
thoroughly. 
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7.2.2.2 Fmoc-Gly-Phe-Leu-Gly-Wang resin synthesis 
The synthesis ofFmoc-Gly-Phe-Leu-Gly-Wang resin was carried out by standard solid 
phase technique in a glass reaction vessel equipped with a frit (porosity 3) to allow both 
filtration and agitation of the resin by application of vacuum or positive nitrogen 
pressure. The reaction sequence was carried out a number oftimes, with a typical 
synthesis proceeding as follows. Fmoc-glycine-Wang resin (1.2 g, 0.96 mmol) was 
allowed to swell in DMF (6 mL) for fifteen minutes, drained, and the Fmoc protecting 
group removed by reacting the resin with freshly made 20% piperidine/DMF (12 mL) for 
ten minutes. After draining and washing (3 x 15 mL DMF followed by 3 x 15 mL IPA) 
the Kaiser test was carried out (see Section 7.1) with a blue colour change indicating the 
presence of free amines and hence the success of the deprotecting reaction. The resin 
was then washed again (3 x 15 mL DMF) before changing the collection flask to remove 
all traces of piperidine. A DMF solution (6 mL) ofFmoc-leucine (679 mg, 1.92 mmol) 
was activated for two minutes with HBTU (728 mg, 1.92 mmol) and DIPEA (669 ilL, 
3.84 mmol) prior to addition to the resin. The coupling reaction was gently agitated for 
one hour before draining, washing with DMF (3 x 15 mL) and carrying out the Kaiser 
test, resulting in no colour change thereby indicating an absence offree amines and 
thereby the success of the coupling reaction. This process of deprotection and coupling 
was repeated for Fmoc-phenylalanine (744 mg, 1.92 mmol) and Fmoc-glycine (571 mg, 
1.92 mmol) with all other reagents used in the same quantities as described above. 
Following the final coupling reaction, the resin was washed with DMF (3 x 15 mL), 
MeOH (3 x 15 mL) and DCM (3 x 15 mL) before drying thoroughly. 
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7.2.2.3 Fmoc-Gly-Phe-Leu-Gly-OH (40) 
The N-protected biolinker, 40, was cleaved from the resin (3.0 g, 1.75 mmo1) by 
agitation with a cleavage brew consisting of95% TFAl2.5% H20I2.5% TES (15 mL) for 
20 minutes followed by a wash with the cleavage brew (5 mL) then a second cleavage 
(10 mL, 20 minutes) and wash (5 mL). The combined acid solution was diluted with 
water (100 mL) and extracted with DCM (3 x 50 mL). The organic fractions were 
combined and taken to dryness before being dissolved in THF (25 mL) and filtered. 
Hexane (250 mL) was then added to the THF solution to give a white precipitate which 
was filtered off to give pure 40 (384 mg, 36%). HRESIMS 615.2807, C34H39N407 (M + 
H+) requires 615.2819. lH NMR (d6-DMSO) 0 8.22 (d, JHH = 8.3 Hz, 1H, H12), 0 8.19 
(t, JHH = 5.9 Hz, 1H, H19), 0 8.10 (d, JHH = 8.3 Hz, 1H, H4), 0 7.99 (d, JHH = 7.5 Hz, 
2H, H9'), 0 7.80 (d, JHH = 7.6 Hz, 2H, H6'), 0 7.62 (t, JHH = 6.1 Hz, 1H, HI), 07.51 (t, 
JHH = 7.4 Hz, 2H, H8'), 0 7.42 (t, JHH = 7.6 Hz, 2H, H7'), 0 7.31 (0, 2H, H8), 07.31 (0, 
2H, H9), 07.26 (m, 1H, H10), 0 4.65 (m, IH, H5), 04.44 (dt, JHH = 7.3,8.3 Hz, 1H, 
H13), 04.35 (0, 2H, H3'), 0 4.31 (0, IH, H4'), 0 3.86 (dd, JHH = 5.9,17.5 Hz, IH, 
H20a), 0 3.81 (dd, JHH = 5.9, 17.5 Hz, 1H, H20b), 0 3.73 (dd, JHH = 6.1, 16.8 Hz, 1H, 
H2a), 0 3.61 (dd, JHH = 6.1, 16.8 Hz, IH, H2b), 0 3.12 (dd, JHH = 4.1, 13.7 Hz, 1H, 
H6a), 02.88 (d, JHH = 9.3, 13.7 Hz, 1H, H6b), 0 1.70 (m, IH, H15), 0 1.58 (t, JHH = 7.3 
Hz, 2H, H14), 00.97 (d, JHH = 6.8 Hz, 3H, H16), 0 0.93 (d, JHH = 6.5 Hz, 3H, H17), 
13C NMR (d6-DMSO) 0 172.9 (C18), 172.0 (C21), 171.7 (C11), 169.6 (C3), 157.2 
(C1'), 144.0 (C5'), 141.5 (C10'), 138.3 (C7), 129.8 (C8), 128.5 (C9), 128.3 (C8'), 127.7 
(C7'), 126.8 (C10), 125.9 (C6'), 120.7 (C9'), 66.3 (C3'), 54.3 (C5), 51.4 (C13), 47.1 
(C4'), 43.3 (C2), 41.5 (C14), 41.2 (C20), 37.6 (C6), 24.7 (C15), 23.5 (C16), 22.3 (C17). 
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7.2.3.1 Fmoc-Cys(Acm)-Wang resin 
This preparation was carried out in exactly the same manner as described above for the 
synthesis of Fmoc-Gly-Wang resin (Section 7.2.1.1) but using Fmoc-S-
acetamidomethylcysteine (396 mg, 0.95 mmol) in place ofFmoc-glycine. All other 
procedures and reagents were identical. The loading level was determined to be 
approximately 0.74 meq/g from an average of two readings. 
7.2.3.2 Fmoc-Cys(Acm )-Asn-Gly-Arg(Mtr )-Cys(Acm)-Wang resin 
This synthesis proceeds as described above for the SPPS ofFmoc-Gly-Phe-Leu-Gly-
Wang resin (Section 7.2.1.2) but using Fmoc-Cys(Acm)-Wang resin (1.2 g, 0.89 mmol), 
Fmoc-AP-4-methoxy-2,3,6-trimethylbenzenesulfonylarginine (1081 mg, 1.78 mmol), 
Fmoc-glycine (528 mg, 1.78 mmol), Fmoc-asparagine (629 mg, 1.78 mmol) and Fmoc-
S-acetamidomethylcysteine (736 mg, 1.78 mmol). For the final two coupling reactions, 
NHS (205 mg, 1.78 mmol) was included. 
7.2.3.3 Fmoc-Cys(Acm )-Asn-Gly-Arg(Mtr)-Cys(Acm )-OH (41) 
In a typical reaction, the fully protected peptide 41 was liberated from the resin (600 mg) 
by agitation with 87% TFAl8% pheno1l5% H20 (6 mL, 20 minutes) followed by washing 
with the same solution (2 x 3 mL) then repetition of the cleaving/washing process. The 
combined TF A solutions were repetitively diluted with water and dried under vacuum to 
yield a yellow-brown oil (520 mg). 
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Purification was carried out using reverse phase MPLC run using an isocratic 50% 
ACN/HzO(A) eluant. The peak eluting at 18-23 minutes was collected in three cuts-
early, middle and late. The middle cut was pure except for the presence of a single 
contaminating p-substituted aromatic compound which co-eluted, even in analytical 
HPLC chromatography (CI8, A: HzO(A), B: ACN, gradient: 50% B (0 min), 50% B (4 
min), 56% B (7 min), 100% B (8 min)). 
In order to remove this lower molecular weight contaminant, size exclusion 
chromatography was carried out using LH20 (70 g, 420 x 18 mm) with UV detection at 
254 nm and 50% ACN/HzO as the eluant. The frrst peak, eluting at a volume of 
approximately 270 mL consisted of primarily the desired peptide 41 . 
It was found that by an iterative cycle ofMPLC and size exclusion chromatography the 
fully protected peptide 41 could be isolated in a pure state (135 mg, 6.6%). HRESIMS 
1128.3947, C49H66N11014S3 (M + H+) requires 1128.3953. IH NMR (CD3CNlDzO) 0 
7.85 (t, J HH = 7.6 Hz, 2H, H9'), 07.71 (t, JHH = 7.6 Hz, 2H, H6'), 07.46 (d, JHH = 7.6 
Hz, 2H, H8'), 0 7.38 (t, J HH = 7 Hz, 2H, H7'), 0 6.71 (s, IH, H20'), 04.65 (t, JHH = 5.9 
Hz, IH, H6), 0 4.57 (dd, JHH = 4.9, 8.3 Hz, IH, H25), 04.39 (0, IH, H3'a), 04.38 (0, 
IH, H2), 04.34 (0, IH, H3'b), 04.34 (0, IH, Hll'a), 04.32 (0, IH, HI5), 04.27 (0, 
IH, H4'), 04.27 (0, 2H, H26'), 04.20 (0, IH, Hll'b), 0 3.91 (0, IH, HI2a), 03.82 (s, 
3H, H24'), 0 3.82 (m, IH, HI2b), 03.12 (m, 2H, HI8), 03.08 (dd, JHH = 4.8,14.1 Hz, 
IH, H26a), 03.03 (dd, JHH = 4.9, 14.3 Hz, IH, H3a), 02.93 (dd, JHH = 8.3, 14.1 Hz, 
IH, H26b), 0 2.82 (dd, JHH = 8.8, 13.7 Hz, IH, H3b), 0 2.78 (d, JHH = 5.8 Hz, 2H, H7), 
02.63 (s, 3H, H25'), 0 2.55 (s, 3H, H22'), 02.10 (s, 3H, H23'), 0 1.95 (s, 3H, HI4'), 0 
1.94 (s, 3H, H29'), 0 1.79 (m, IH, HI6a), 0 1.68 (m, IH, HI6b), 0 1.52 (m, 2H, HI7), 
13C NMR (CD3CNlDzO) 0 173.3 (C8), 172.3 (C13'), 172.3 (C23), 172.1 (C28'), 172.0 
(C27), 171.8 (CI0), 171.5 (C4), 170.1 (C13), 158.2 (CI9'), 156.7 (Cl'), 143.4 (C5'), 
140.6 (CI0'), 138.1 (CI7'), 132.9 (CI6'), 131.4 (C21'), 127.4 (C8'), 126.9 (C7'), 124.9 
(C6'), 124.3 (CI8'), 119.6 (C9'), 111.7 (C20'), 66.5 (C3'), 55.0 (C24'), 54.2 (C2), 52.6 
(CI5), 52.2 (C25), 50.7 (C6), 46.3 (C4'), 42.9 (CI2), 40.7 (26'), 40.6 (C26'), 40.0 
(Cll'), 40.0 (CI8), 36.4 (C7), 31.8 (C3), 31.3 (C26), 27.9 (CI6), 25.7 (CI7), 22.8 
(C25'), 21.6 (CI4'), 21.6 (C29'), 17.3 (C22'), 10.8 (C23'). 
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7.2.3.5 cyclo-Cys-Asn-Gly-Arg-Cys-OH (42) 
The deprotection and cyclisation of the resin bound peptide 41 (700 mg, 0.45 mmol) was 
achieved by first cleaving the amino terminal Fmoc protecting group with 20% 
piperidine/DMF (7 mL, 10 minutes), washing the resin with DMF (3 x 10 mL), then 
deprotecting and cyclising the cysteine residues by agitation with Tl(CF3COO)3 (268 mg, 
0.49 mmol) in DMF (5 mL) at O°C for 80 minutes. Following this reaction, the resin was 
drained and washed thoroughly with DMF (3 x 10 mL), MeOH (3 x 10 mL) and DCM 
(3 x 10 mL) before being dried under vacuum. The peptide was removed from the resin 
with cleavage solution (10 mL) consisting of95% TFAl5% H20 and finally the resin was 
rinsed with the solution (2 x 5 mL). The progress of the arginine deprotection reaction 
was monitored by analytical HPLC (C18, A: H20(A), B: ACN, gradient I), and once 
determined to be complete,.the reaction mixture was diluted with ACN and dried under 
vacuum repetitively to yield a thick yellow-brown oil (approximately 300 mg). 
The oil was chromatographed on a small C18 column (3 g, 40 x 10 mm), with the 
peptide eluting in the initial aqueous fraction which was dried down to provide the crude 
peptide (49 mg), which was subjected to semi-preparative HPLC (Phenomenex Luna 
C18 column). The solvent system used was 100% H20(A) for eight minutes then a 
switch to 1 % ACN/H20(A) for four minutes followed by a one minute rinse with 100% 
ACN before equilibrating back to 100% H20(A). The peak eluting at twelve minutes 
was collected and determined to be 42. The yield of pure 42 was 19.3 mg (7.8%). 
HRESIMS 550.1862 ClsH32N907S2 (M + H+) requires 550.1866. IH NMR (D20) 0 4.80 
(dd, JHH = 6.8,7.8 Hz, 1H, H6), 04.56 (dd, JHH = 3.4, 10.3 Hz, 1H, H25), 04.18 (t, JHH 
= 7.3 Hz, 1H, H15), 0 4.07 (t, JHH = 6.8 Hz, 1H, H2), 0 4.04 (d, JHH = 15.6 Hz, 1H, 
H12a), 0 3.55 (d, JHH = 15.6 Hz, 1H, Hl2b), 0 3.27 (dd, JHH = 3.5, 14.6 Hz, 1H, H26a), 
03.22 (dd, JHH = 6.8, 14.6 Hz, 1H, H3a), 0 3.14 (dd, JHH = 7.4, 14.6 Hz, 1H, H3b), 0 
3.11 (t, JHH = 6.9 Hz, 2H, H18), 0 3.01 (dd, JHH = 10.3,14.6 Hz, 1H, H26b), 02.73 (dd, 
JHH = 6.7, 15.4 Hz, 1H, H7a), 02.61 (dd, JHH = 7.9, 15.4 Hz, 1H, H7b), 0 1.74 (m, 1H, 
H16a),o 1.67 (m, IH, H16b), 0 1.57 (m, 2H, H17), 13C NMR (D20) 0 174.1 (C8), 
173.9 (C23), 173.2 (C27), 171.7 (C10), 170.8 (Cl3), 167.3 (C4), 156.8 (C20), 53.6 
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(CI5), 52.9 (C2), 52.4 (C25), 50.2 (C6), 42.4 (CI2), 41.2 (C3), 40.6 (CI8), 40.2 (C26), 
36.2 (C7), 27.3 (CI6), 24.2 (CI7). 
7.2.4.1 Fmoc-cyclo-Cys-Asn-Gly-Arg-Cys-Gly-Phe-Leu-Gly-OH (43) 
Fmoc-Gly-Phe-Leu-Gly-Wang resin (250 mg, 0.13 mmol) was deprotected by agitation 
with 20% piperidine/DMF (5 mL, 10 minutes) followed by washing with DMF (3 x 5 
mL) and IPA (3 x 5 mL) at which point a Kaiser test was carried out. The test result 
was positive (blue colour change) so the resin was washed again with DMF (3 x 5 mL). 
The protected peptide 41 (135 mg, -0.12 mmol) was dissolved in dry DMF (5 mL) and 
activated with HBTU (90.7 mg, 0.24 mmol) and DIPEA (83.4 ilL, 0.48 mmol) in the 
presence ofNHS (55.1 mg, 0.48 mmol) for two minutes before addition to the resin. 
The coupling reaction was allowed to proceed for one hour before draining and washing 
with DMF (5 mL). These combined washings were analysed by HPLC CI8, A: H20(A), 
B: ACN, gradient: 50% B (0 min), 50% B (4 min), 56% B (7 min), 100% B (8 min)) 
which indicated the presence ofunreacted 41. The combined washings were dried and 
the fraction stored to allow recovery ofthe unused 41. 
The resin was acetylated with acetic anhydride (12.8 ilL, 0.13 mmol) in DMF (3 mL) for 
20 minutes, drained and washed with DMF (3 x 5 mL). 
Cysteine deprotection and cyclisation was carried out by reacting the resin with 
Tl(CF3COO)3 (78 mg, 0.14 mmol) in DMF (2 mL) at O°C for 80 minutes, after which the 
resin was drained, washed with DMF (3 x 5 mL), MeOH (3 x 5 mL) and DCM (3 x 5 
mL) and dried thoroughly. 
Cleavage of the peptide from the resin was carried out using 87% TFA/8% phenoV5% 
H20 (10 mL, 20 minutes) followed by washing with the same solution (2 x 3 mL). The 
acid solutions were combined and the removal ofthe arginine side-chain protection was 
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monitored by HPLC (C18, A: H20(A), B: ACN, Gradient II). After 60 hours the 
reaction mixture was repetitively diluted with water and dried under vacuum to give the 
crude peptide mixture. 
7.2.4.1.1 Purification of Fmoc-cyclo-CNGRCGFLG-OH (43) 
The crude peptide material was dissolved, with sonication and heating, in 50% 
ACN/H20 (5 mL) but remained cloudy so was filtered. The soluble material was 
sUbjected to size exclusion chromatography on LH20 (70 g, 420 x 18 mm) with UV 
detection at 254 nm using 50% ACN/H20 as the eluant. Eight fractions were collected, 
which did not consist of specific peaks, but rather consisted of cuts across one very 
broad peale, with the desired material being found in fractions three (primarily) and four; 
however, these fractions were still heavily contaminated. The insoluble material was 
analysed by HPLC (C18, A: H20(A), B: ACN, Gradient II) and found to contain a low 
proportion of 43. 
Weak cation-exchange chromatography was attempted on a Trisacryl M CM column (30 
g, 130 x 20 mm) which was equilibrated to 30% ACN/H20 before application of the 
sample and elution with 30% ACN/H20 (2 x 25 mL) followed by 30% ACN/H20 + 
0.1 % TFA (3 x 25 mL) with the desired product eluting in the first two, un-acidified 
fractions which were combined and dried. 
This material was then chromatographed on a silica column (lOg, 180 x 12 mm) running 
50% ACN/H20 + 0.1 % TFA with UV detection at 254 nm; however, no peaks were 
detected so all fractions were combined and taken to dryness. 
Semi-preparative HPLC (Phenomenex Luna C18 column) was then carried out on the 
combined silica fractions as well as the insoluble material isolated prior to size exclusion 
chromatography, running an isocratic solvent system of35% ACNIH20 + 0.1 % TFA for 
12 minutes followed by a one minute wash with 100% ACN before re-equilibration. 
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Peaks eluting at 7:30, 8:00 and 12:00 minutes were collected and examined by NMR 
spectroscopy but were found to contain too little material to allow structural 
determination. 
7.2.4.2 Resynthesis of Fmoc-cyclo-CNGRCGFLG-OH (43) 
182 
Fmoc-Gly-Phe-Leu-Gly-Wang resin (800 mg, 0.42 mmol) was used as the starting point 
for a synthesis that proceeded as described above for the SPPS ofFmoc-Cys(Acm)-Asn-
Gly-Arg(Mtr)-Cys(Acm)-Wang resin (Section 7.2.2.2) but using Fmoc-l'P-4-methoxy-
2,3,6-trimethylbenzenesulfonylarginine (510 mg, 0.84 mmol), Fmoc-glycine (271 mg, 
0.84 mmol), Fmoc-asparagine (297-mg, 0.84 mmol) and Fmoc-S-
acetamidomethylcysteine (347 mg, 0.84 mmol) and including NHS (97 mg, 0.84 mmol) 
in the final two coupling reactions. 
The cysteine residues ofthe peptide were deprotected and cyclised with Tl(CF3COO)3 
(377 mg, 0.69 mmol) at O°C for 80 minutes in DMF (4 mL) before being washed 
thoroughly with DIVLF (3 x 10 mL), MeOH (3 x 10 mL) and DCM (3 x 10 mL) and 
dried. 
7.2.4.2.1 Cleavage of Fmoc-cyclo-CNGRCGFLG-OH (43) 
Two subsamples of resin bound 43 (5 mg each, 2.7 !lmol each) were cleaved using 95% 
TF AlH20 and 87% TF Al8% phenol/5% H20 and the reaction progress monitored by 
analytical HPLC (C18, A: H20(A), B: ACN, Gradient II). 
The remaining resin bound 43 (820 mg, 0.42 mmol) was cleaved with 95% TF AlH20 for 
24 hours then the solvent was removed under vacuum to yield a dark yellow oil (220 
mg). 
Chapter 7: Experimental 183 
7.2.4.2.2 Purification of Fmoc-cyclo-CNGRCGFLG-OH (43) 
The crude peptide mixture was dissolved, with sonication, in 50% ACNIH20 (15 mL) 
and ACN was added (100 mL). The precipitate that formed was fIltered off and washed 
with ACN (20 mL) and MeOH (20 mL). The collected washings were analysed by 
analytical HPLC ((CI8, A: H20(A), B: ACN, Gradient III) and found to contain 
negligible quantities' of 43. The solid was collected, analysed by HPLC and then purified 
collecting the peale eluting at 4.9 min on semi-preparative HPLC (CI8, A: H20(A), B: 
ACN, gradient: 50% B (0 min), 50% B (4 min), 56% B (7 min), 100% B (8 min), 100% 
B (9 min, 50% B (10 min), 50% B (13 min)) to afford pure 43 (32.3 mg, 6.7%). 
HRESIMS 1146.4491, CS2H68Nl30l3S2 (M + H+) requires 1146.4501. IH NMR (d6-
DMSO) 0 8.77 (d, JHH = 7.6 Hz, IH, H5), 0 8.34 (t, JHH = 5.6 Hz, IH, H28), 0 8.25 (d, 
JHH = 8.4 Hz, IH, H39), 08.20 (t, JHH = 5.4 Hz, IH, H46), 0 8.11 (0, IH, H24), 0 8.09 
(0, IH, H31), 0 7.97 (d, JHH = 7.4 Hz, 2H, H9'), 0 7.94 (br s, IH, Hll), 0 7.86 (d, JHH = 
8.0 Hz, IH, HI), 0 7.80 (0, 2H, H6'), 07.79 (0, IH, HI4), 0 7.62 (t, JHH = 5.5 Hz, IH, 
HI9), 0 7.51 (t, JHH = 7.4 Hz, 2H, H8'), 0 7.42 (m, 2H, H7'), 07.33 (0, 2H, H36), 0 
7.31 (0, 2H, H35), 0 7.26 (m, IH, H37), 0 4.63 (0, IH, H32), 04.62 (0, IH, H6), 0 
4.57 (m, IH, H25), 04.46 (0, 2H, H3'), 04.43 (0, IH, HI5), 0 4.41 (0, IH, H40), 0 
4.32 (m, IH, H4'), 0 4.28 (0, IH, HI2a), 0 4.27 (0, IH, H2), 0 3.83 (0, 2H, H47), 0 
3.75 (0, 2H, H29), 0 3.51 (0, IH, HI2b), 0 3.31 (0, IH, H26a), 0 3.27 (0, IH, H3a), 0 
3.17 (0, 2H, HI8), 0 3.13 (0, IH, H33a), 0 3.05 (0, IH, H26b), 03.01 (0, IH, H3b), 0 
2.84 (0, IH, H33b), 02.81 (0, IH, H7a), 0 2.40 (dd, JHH = 15.1,4.4 Hz, IH, H7b), 0 
2.00 (br s, IH, HI6a), 0 1.69 (m, IH, H42), 0 1.63 (0, 2H, HI6b), 0 1.58 (0, 2H, H41), 
o 1.55 (0, 2H, HI7), 00.97 (d, JHH = 6.3 Hz, 3H, H43), 0 0.93 (d, JHH = 6.3 Hz, 3H, 
H44), l3C NMR (d6-DMSO) 0 172.6 (C45), 172.0 (C8), 171.9 (C23), 171.3 (C48), 
171.0 (C38), 171.0 (C4), 170.9 (CI0), 170.2 (C27), 169.9 (C13), 168.5 (C30), 156.9 
(C20), 156.4 (Cl), 144.0 (C5'), 141.0 (CI0'), 137.8 (C34), 129.5 (C35), 128.3 (C36), 
128.0 (C8'), 127.4 (C7'), 126.5 (C37), 125.5 (C6'), 120.4 (C9'), 66.0 (C3'), 55.0 (C2), 
54.0 (C32), 52.0 (C25), 52.0 (CI5), 51.2 (C40), 49.8 (C6), 46.9 (C4'), 42.9 (CI2), 42.1 
(C29), 41.4 (C41), 41.3 (C3), 41.1 (C26), 40.9 (C47), 40.6 (CI8), 37.8 (C33), 36.3 
(C7), 28.5 (CI6), 25.3 (CI7), 24.3 (C42), 23.3 (C43), 21.9 (C44) 
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7.3 Work described in Chapter 3 
7.3.2.1 Mycalamide A oxidative cleavage 
To a vigorously stirred suspension of silica (50 mg) in DCM (300 ilL) was added an 
aqueous solution ofNa104 (50 ilL of 0.65 M, 32.5 Ilmol) followed 15 minutes later by 
mycalamide A 31 (10 mg, 19.9 Ilmol) in DCM (200 ilL). After one hour, TLC (Si02, 
EtOAc, 12) indicated the reaction was complete by the movement of the Rr 0.09 spot to 
Rr 0.59 so the reaction nrixture was filtered and the solid washed with DCM. The 
organic fractions were combined and dried under vacuum to give pure 45 (9.3 mg, 19.8 
Ilmo1) in a 99.5% yield. HRES1MS 494.2373, C23H37N09Na (M + Na+) requires 
494.2366. lH NMR (CDCl3) 0 9.54 (t, JHH = 2 Hz, 1H, H17), 0 7.48 (d, JHH = 9.8 Hz, 
1H, H9), 0 5.88 (t, JHH = 9.5 Hz, 1H, H10), 0 5.13 (d, JHH = 6.9 Hz, 1H, H10-0CH2a), 
04.87 (d, JHH = 6.9 Hz, 1H, H10-0CH2b), 04.84 (t, JHH = 2 Hz, 1H, H4=CH2a), 04.75 
(t, JHH = 2 Hz, 1H, H4=CH2b), 04.27 (s, 1H, H7), 0 4.20 (dd, JHH = 6.6, 10.0 Hz, 1H, 
H12), 04.09 (dd, JHH = 4.4,8.0 Hz, 1H, HIS), 04.02 (dq, JHH = 3.0,6.6 Hz, 1H, H2), 0 
3.76 (dd, JHH = 6.6,9.3 Hz, IH, H11), 0 3.56 (s, 3H, H13-0CH3), 0 3.51 (d, JHH = 10.2 
Hz, 1H, H13), 0 3.29 (s, 3H, H6-0CH3), 0 2.37 (0, 2H, H16), 0 2.36 (0, 1H, H5a), 0 
2.23 (dq, JHH = 2.9, 7.0 Hz, 1H, H3), 0 2.08 (dt, JHH = 2.0, 14.0 Hz, 1H, H5b), 0 1.17 
(d, JHH = 6.6 Hz, 3H, H2-CH3), 0 1.02 (s, 3H, H14-CH3a), 0 0.92 (d, JHH = 7 Hz, 3H, 
H3-CH3), 0 0.86 (s, 3H, H14-CH3b) l3C NMR (CDCl3) 0200.7 (C17), 171.9 (C8), 
145.0 (C4), 111.0 (C4=CH2 ), 100.0 (C6), 86.5 (C10-0CH2 ), 79.1 (C13), 74.2 (CIS), 
74.1 (C12), 74.0 (ClO), 71.2 (C7), 70.6 (Cll), 69.5 (C2), 61.8 (C13-0CH3), 48.5 (C6-
OCH3), 43.3 (C16), 41.2 (C14), 40.9 (C3), 33.2 (C5), 23.3 (C14-CH3), 12.1 (C3-CH3). 
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7.3.2.2 Reductive amination of aldehyde 
Ammonium acetate (147 mg, 1.9 mmol) and 44 (9.0 mg, 19 ~mol) were dried together 
under hi-vacuum before being dissolved in (NH4)2C03 saturated dry MeOH (900 ~L) 
and stirred for 30 minutes prior to the addition ofNaCNBH3 (6.0 mg, 95 ~mol) in 
(NH4)2C03 saturated dry MeOH (1 00 ~L). A TLC (Si02, EtOAc, PMA) taken after 
twelve hours of reaction showed the disappearance ofthe aldehyde 45 (Rr 0.59) and the 
appearance of a baseline spot (Rr 0.01) that was positive to both ninhydrin and PMA. 
The reaction mixture was then dried down, redissolved in H20, applied to a CIS cartridge 
which had been equilibrated to H20, washed with H20 (7 mL) and eluted with MeOH (3 
mL) to give crude 45 which was acylated (Sections 4.4.1 and 5.5.1) without further 
purification. HRESIMS 473.2876, C23H4IN20S (M + H+) requires 473.2863. 
7.3.3.3 Mycalamide B azide (49) 
Mycalamide B (32, 3.6 mg, 7.0 ~mol) and PPh3 (4.6 mg, 17.4 ~mol) were dissolved in a 
suspension ofZn(N3)2.2Pyr (2.1 mg, 7.0 ~mol) in dry toluene (200 ~L). DEAD (2.7 ~L, 
17.4 ~mol) was added. After four hours, HPLC (CI8, A: H20, B: ACN, Gradient II) 
showed the reaction was still not complete so a solution of more PPh3 (1.4 mg, 5.3 
~mol) and DEAD (0.8 ~L, 5.3 ~mol) in toluene (30 ~L) was added. A further HPLC 
(CI8, A: H20, B: ACN, Gradient II) analysis after four more hours showed some 
starting material remaining so the reaction was refreshed with additional PPh3 (0.9 mg, 
3.5 ~mol) and DEAD (0.5 ~L, 3.5 ~mol) in toluene (20 ~L). After another two hours 
of reaction the starting material was seen to be completely consumed so the reaction was 
worked up by removal ofthe solvent under vacuum then passage through a CI8 
cartridge, washing with water, and 40% ACN/water before eluting the product with 80% 
ACN/water and 100% ACN. The combined product-containing fractions were dried 
down to provide the desired azide 49 (3.2 mg, 84%). HRESIMS 565.2847, 
C25H42N409Na (M + Na+) requires 565.2849. IH NMR (CDC13) 0 7.53 (d, JHH = 9.8 Hz, 
H, H9), 0 5.78 (t, JHH = 9.7 Hz, lH, HIO), 0 5.12 (d, JHH = 7 Hz, lH, HIO-OCH2a), 0 
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4.88 (t, JHH = 2 Hz, lH, H4=CH2a), 04.87 (d, JHH = 7 Hz, lH, HlO-OCH2b), 04.76 (t, 
JHH = 2 Hz, IH, H4=CH2b), 04.30 (s, lH, H7), 04.21 (dd, JHH = 6.5, 10.4 Hz, IH, 
H12), 04.07 (dq, JHH = 2.9,6.8 Hz, lH, H2), 0 3.78 (dd, JHH = 6.6, 9.6 Hz, lH, Hll), 0 
3.56 (s, 3H, H13-0CH3), 0 3.44 (d, JHH = 10.2 Hz, lH, H13), 0 3.41 (dd, JHH = 2.4, 
13.1 Hz, lH, H18a), 03.32 (s, 3H, H6-0CH3), 03.31 (0, lH, H15), 0 3.30 (0, lH, 
H17), 0 3.25 (s, 3H, H17-0CH3), 0 3.22 (0, lH, H18b), 0 2.41 (d, JHH = 14 Hz, IH, 
H5a), 0 2.28 (dq, JHH = 2.9, 7.1 Hz, lH, H3), 0 2.23 (dt, JHH = 1.9, 13.9 Hz, lH, H5b), 
o 1.60 (m, 2H, H16), 0 1.22 (d, JHH = 6.8 Hz, 3H, H2-CH3), 0 1.03 (d, JHH = 7 Hz, 3H, 
H3-CH3),o 1.00 (s, 3H, H14-CH3a), 00.87 (s, 3H, H14-CH3b), BC NMR (CDC13) 0 
171.7 (C8), 144.8 (C4), 111.4 (C4=CH2 ), 100.0 (C6), 86.5 (CIO-OCH2 ), 79.1 (C13), 
77.6 (C17), 75.5 (C15), 74.3 (C12), 74.0 (ClO), 71.2 (C7), 70.9 (Cll), 69.6 (C2), 61.8 
(C13-0CH3), 56.7 (C17-0CH3), 52.2 (C18), 48.6 (C6-0CH3), 41.6 (C14), 41.2 (C3), 
33.6 (C5), 30.8 (C16), 23.3 (C14-CH3(eq)), 18.0 (C2-CH3), 13.6 (C14'-CHiax)), 12.2 
(C3-CH3) 
7.3.3.4 Mycalamide B amine (50) 
Compound 49 (2.2 mg, 4.1 f,Lmol) and PPh3 (1.6 mg, 6.1 f,Lmol) were dissolved in dry 
THF (160 f,LL) and allowed to react at 40°C. After three hours, TLC (Si02, 
50:50:10:0.1 CHC13:Et20:MeOH:cNH40H) showed the replacement ofthe starting 
material (Rf-=0.83, PMA+) with a more polar compound (Rf-=0.02, UV+ PMA+). Water 
(200f,LL) was added and the reaction was continued for a further three hours at 40°C at 
which point TLC (as above) indicated reaction was complete by the loss of UV response 
of the baseline spot. The reaction was dried down and the product 50 used without 
further purification. 
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7.3.4.1 Fumagillol oxidation 
Chromium trioxide (106.3 mg, 1.06 mmol) was added to a stirred solution of pyridine 
(172 ~L, 2.13 mmol) in DCM (1 mL) followed 15 minutes later by fumagillol 35 (20 mg, 
0.071 mmol) in DCM (200 ~L). TLC (Si02, 20% EtOAcIDCM, PMA) was used to 
follow the disappearance of the alcohol (Rf 0.40) and the appearance of the ketone at Rf 
0.73 with the reaction reaching completion after 90 minutes. The reaction mixture was 
then applied directly to the top of a dry silica column (10 g, 80 x 18 mm) and eluted with 
DCM (20 mL) and EtOAc (15 mL). The organic fractions were combined and taken to 
dryness to yield pure 51 (18.5 mg, 0.066 mmol) in 97% yield. HREIMS 280.1673, 
CIsH2404 (M+) requires 280.1675. IH NMR (CDCI3) 0 5.16 (m, IH, H4'), 0 4.07 (dd, 
JHH = 0.7, 10.7 Hz, IH, H5), 0 3.48 (s, 3H, H8), 0 3.04 (dd, JHH = 4.4 Hz, IH, H7a), 0 
2.71 (dd, JHH = 4.4 Hz, IH, H7b), 0 2.66 (dddd, JHH = 0.7,6.5,6.7, 14.3 Hz, IH, Hla), 
02.58 (dd, JHH = 5.8, 6.8 Hz, IH, H2'), 0 2.48 (ddd, JmI = 4.0,5.3, 14.2 Hz, IH, Hlb), 
02.37 (m, IH, H3'a), 0 2.13 (m, IH, H3'b), 0 2.04 (ddd, JHH = 5.4, 6.8, 13.4 Hz, IH, 
H2a), 0 1.86 (d, JHH = 10.6 Hz, IH, H4), 0 1.72 (s, 3H, H6'), 0 1.69 (ddd, JHH = 4.0, 
6.5, 13.8 Hz, lH, H2b), 0 1.63 (s, 3H, H7'), 0 1.27 (s, 3H, H8'), !3C NMR (CDCI3) 0 
207.1 (C6), 135.0 (C5'), 118.2 (C4'), 83.2 (C5), 60.4 (C2'), 58.6 (Cl'), 58.5 (C8), 58.4 
(C3), 53.6 (C4), 51.8 (C7), 36.8 (Cl), 33.2 (C2), 27.3 (C3'), 25.7 (C6'), 18.0 (C7'), 13.8 
(C8'). 
7.3.4.2 Fumagillone reductive amination 
Compound 51 (7.0 mg, 0.025 mmol) was stirred with NH4CH3COO (192.6 mg, 2.5 
mmol) in (NH4)2C03 saturated dry MeOH (400 ~L) for 15 minutes prior to the addition 
ofNaCNBH3 (7.9 mg, 0.13 mmol). After two hours, TLC (Si02, 20% EtOAcIDCM, 
PMA) indicated the reaction was complete through disappearance of 51 (RfO.73) and 
appearance of a baseline spot (Rf 0.05), so the reaction solution were diluted with H20 
(8 mL) and passed through a CI8 cartridge which was then washed with H20 (10 mL) 
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and eluted with MeOH (2 mL). The methanol fraction was dried down to provide crude 
52 which was acylated without further purification. 
7.3.4.3 Fumagillol S-tosylate (53) 
A solution ofZnCl2 (4 g, 29.3mmol) in H20 was added slowly to a stirred solution ofp-
toluenesulphonic acid hydrate (11.2 g, 58.9 mmol) in H20 (5 mL). The white precipitate 
of Zn(OTos)2 that formed was filtered and dried thoroughly before use. 
Fumagillol (35,20 mg, 71 Ilmol) and PPh3 (186 mg, 0.71 mmol) were dissolved in a 
stirred suspension ofZn(OTos)2 (28.9 mg, 71 Ilmol) in dry toluene (500 ilL). DEAD 
(111.6 ilL, 0.71 mmol) was then added and the reaction was allowed to proceed at room 
temperature for ten hours. The crude reaction nllxture was filtered through a silica 
column (0.6 g, 60 x 5 mm) eluting with Et20. The ether was removed under a stream of 
nitrogen and the material was chromatographed on a silica column (5 g, 90 x 12 mm) 
eluting with 20% PElEtOAc. The product-containing fractions were combined and re-
chromatographed on silica (5 g, 90 x 12 mm) using 10% Et20IDCM as the eluant. The 
only compound isolated was an undesired elimination product 53 (7.1 mg, 38%). 
HREIMS 264.1725, Cl6H2403 (M+) requires 264.1730. IH NMR (CDCI3) 0 5.97 (m, 
1H, H6), 0 5.84 (m, 1H, HI), 0 5.21 (rn, 1H, H4'), 0 4.22 (m, 1H, H5), 0 3.39 (s, 3H, 
H8), 0 2.84 (d, JHH = 4.4 Hz, lH, H7a), 02.72 (t, JHH = 6.5 Hz, 1H, H2'), 0 2.6 (d, JHH 
= 4.4 Hz, lH, H7b), 02.38 (m, 1H, H2a), 0 2.37 (m, lH, H3'a), 0 2.2 (m, lH, H3'b), 0 
2.05 (m, lH, H2b), 0 1.74 (s, 3H, H6'), 0 1.66 (s, 3H, H7'), 0 1.6 (d, JHH = 6.9 Hz, 1H, 
H4),o 1.28 (s, 3H, H8'), BC NMR (CDCI3) 0 134.7 (C5'), 127.8 (C6), 127.3 (Cl), 
118.6 (C4'), 76.0 (C5), 62.0 (C2'), 59.2 (C1'), 57.2 (C3), 55.4 (C8), 52.6 (C7), 50.5 
(C4), 34.1 (C2), 27.4 (C3'), 25.8 (C6'), 18.0 (C7'), 14.4 (C8'). 
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7.3.4.4 Fumagillol phthalimide (55) 
To a stirred solution offumagillol (35,40 mg, 0.14 mmol) and phthalimide (31.3 mg, 
0.21 mmol) in dry THF (1 mL) was added triphenylphosphine (78.1 mg, 0.3 mmol) and 
DEAD (37.7 ilL, 0.28 mmol) in dry THF (200 ilL). The reaction was allowed to stir 
overnight then TLC (Si02, 70% Et20/PE, PMA) showed the appearance of a non-polar 
compound (RfO.58) and disappearance of the starting material 35 (RfO.05) Reaction 
mixture was then dried and chromatographed on a silica column (20 g, 160 x 18 mm), 
eluting isocratically with 70% Et20/PE. Two large fractions (20 mL each) were taken 
followed by 16 smaller fractions (5 mL each), with the pure product 55 eluting in 
fractions nine and ten and co-eluting with 1,2-dicarbethoxyhydrazine in fractions eleven 
to 14. These contaminated fractions were combined and run on silica (10 g, 70 x 14 
mm) eluting with 20% EtOAc/DCM, collecting twelve fractions (5 mL each) of which 
two (fractions 6 and 7) contained pure 55. The pure material from both columns was 
combined to give an overall yield of39.6 mg (68%). HRESIMS 450.1684, C24H29N05K 
(M + K+) requires 450.1683. lHNMR (CDC13) 0 7.83 (dd, JHH = 3.4,5.3 Hz, 2H, H3"), 
07.71 (dd, JHH = 3.4, 5.3 Hz, 2H, H4"), 0 5.2 (t, JHH = 7.5 Hz, 1H, H4'), 04.68 (t, JHH = 
10.6 Hz, 1H, H5), 04.34 (m, 1H, H6), 0 3.3 (s, 3H, H8), 0 2.96 (d, JHH = 4.4 Hz, 1H, 
H7a), 0 2.58 (m, 1H, H2'), 02.58 (m, 1H, H1a), 02.56 (m, IH, H7b), 02.35 (m, 1H, 
H3'a), 0 2.15 (m, 1H, H3'b), 0 1.94 (m, 1H, H2a), 0 1.76 (m, IH, H1b), 0 1.72 (s, 3H, 
H6'),o 1.68 (d, JHH = 11.2 Hz, IH, H4), 0 1.64 (s, 3H, H7'), 0 1.29 (s, 3H, H8'), 0 1.26 
(m, 1H, H2b) BC NMR (CDC13) 0 168.3 (C1"), 135 (C5'), 133.97 (C4"), 131.84 (C2"), 
123.26 (C3"), 118.4 (C4'), 76.16 (C5), 61.36 (C2'), 59.09 (C1'), 58.78 (C3), 55.67 (C8), 
52.9 (C6), 52.02 (C4), 50.12 (C7), 33.45 (C2), 27.38 (C3'), 25.7 (C6'), 25.45 (Cl), 
17.98 (C7'), 14.31 (C8'). 
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7.3.4.6 Fumagillol R-tosylate (56) 
Tosic acid hydrate (1 g, 5.26 mmol) and P20 S (3 g, 21.1 mmol) were stirred overnight in 
dry DCM then more P20 S was added (1 g, 7.05 mmol). After reacting for a total of24 
hours, the crude reaction mixture was passed through a dry silica column (30 g, 45 x 30 
mm) and eluted with dry DCM. The combined organic solvent was removed under 
vacuum to yield tosic anhydride (520 mg, 61 %) as a white crystalline solid (mp 112-
124°C, lit 129.5-131.5°C). 
Fumagillol (35, 10 mg, 35 !lmol) and tosic anhydride (17.4 mg, 53 !lmol) were dissolved 
in dry pyridine (200 !lL) to give a solution which turned yellow immediately. After ten 
minutes the reaction was monitored by HPLC (C18, A: H20, B: ACN, Gradient II) and 
showed complete reaction. TLC (Si02, Et20, UV IPMA) showed a single UV and PMA 
positive spot at Rf=0.86. The reaction was worked up by dilution of the reaction 
solution with distilled water (2 mL) which was then applied to a CI8 cartridge. The 
cartridge was then washed with distilled water (5 mL) and 20% ACNIH20 before being 
eluted with ACN which was removed under nitrogen to yield pure tosylate 56 (14.7 mg, 
95%). HREIMS 436.4925, C23H320 6S (M+) requires 436.1920. IH NMR (CDC13) 0 
7.84 (d, JHH = 8.1 Hz, 2H, H3"), 0 7.30 (d, JHH = 8.1 Hz, 2H, H4"), 0 5.16 (m, 1H, H4'), 
05.04 (m, 1H, H6), 0 3.48 (dd, JHH = 2.5, 10.8 Hz, IH, H5), 0 3.01 (s, 3H, H8), 02.92 
(d, JHH = 4.4 Hz, 1H, H7a), 0 2.53 (t, JHH = 6.3 Hz, IH, H2'), 02.52 (d, JHH = 4.4 Hz, 
1H, H7b), 0 2.41 (s, 3H, H6"), 0 2.30 (m, IH, H3'a), 0 2.23 (m, 1H, H1a), 0 2.13 (m, 
1H, H3'b), 02.12 (m, 1H, H2a), 0 1.92 (d, JHH = 10.8 Hz, IH, H4), 0 1.78 (m, IH, 
H1b),o 1.72 (s, 3H, H6'), 0 1.62 (s, 3H, H7'), 0 1.13 (s, 3H, H8'), 0 1.12 (m, 1H, H2b), 
BC NMR (CDC13) 0 144.5 (C5"), 134.8 (C5'), 133.6 (C2"), 129.6 (C4"), 128.1 (C3"), 
118.4 (C4'), 79.2 (C5), 75.5 (C6), 60.5 (C2'), 59.1 (C1'), 58.2 (C3), 56.4 (C8), 51.1 
(C7), 47.7 (C4), 28.7 (C2), 27.2 (C3'), 26.4 (Cl), 25.7 (C6'), 21.6 (C6"), 17.9 (C7'), 
14.0 (C8') 
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7.3.4.8 Fumagillol azide (57) 
Sodium azide (13 g, 0.2 mol) was added dropwise to a stirred aqueous solution of 
ZnO\J03)2.6H20 (29.75 g, 0.1 mol). The solution was heated to 50°C and pyridine (17 
mL, 0.21 mmol) was added dropwise to form a dense white precipitate. The solution 
was allowed to cool to room temperature while stirring continued then the precipitate 
was filtered off and washed with cold H20. The product ZnO\J3).2Pyr was used without 
further analysis or purification. 
To a vigorously stirred suspension ofZn0\J3).2Pyr (21.8 mg, 71 Ilmol), PPh3 (46.5 mg, 
177 Ilmol) and fumagillol (35,20 mg, 71 Ilmol) in dry toluene (200 ilL) was added 
DEAD (27.9 ilL, 172 Ilmol). After stirring for 12 hours, HPLC (CI8, A: H20, B: ACN, 
Gradient II) indicated that the reaction was approximately 50% complete, so a solution 
ofPPh3 (46.5 mg, 177 Ilmol) and DEAD (27.9 ilL, 172 Ilmol) in dry toluene (50 ilL) 
was added. After another 12 hours the reaction was worked up by passage through 
silica (5 g, 90 x 12 mm) eluting with 20% PE/Et20. The desired product 57 was 
isolated in a relatively low yield (9.3 mg, 43%) HRESIMS 346.1527, C16H25N303K (M + 
K+)requires 346.1533. lHNMR(CDCl3) 0 5.18 (m, IH, H4'), 0 3.67 (s, 3H, H8), 0 
3.58 (dd, JHH = 9.2, 10.7 Hz, lH, H5), 0 3.45 (m, lH, H6), 02.92 (d, JHH = 4.0 Hz, lH, 
H7a), 02.53 (t, JHH = 6.1 Hz, IH, H2'), 0 2.53 (d, JHH = 4.0 Hz, IH, H7b), 0 2.36 (m, 
IH, H3'a), 0 2.14 (m, IH, H3'b), 0 1.96 (m, IH, Hla), 0 1.84 (m, lH, H2a), 0 1.73 (s, 
3H, H6'), 0 1.68 (m, IH, Hlb), 0 1.64 (s, 3H, H7'), 0 1.54 (d, JHH = 10.9 Hz, IH, H4), 0 
1.25 (s, 3H, H8'), 0 1.20 (m, IH, H2b) l3C NMR (CDCl3) 0 135.1 (C5'), 118.3 (C4'), 
82.3 (C5), 64.9 (C6), 61.2 (C2'), 58.9 (C8), 58.8 (C3), 58.3 (CI '), 52.3 (C4), 50.1 (C7), 
32.5 (C2), 27.4 (C3'), 27.0 (CI), 25.7 (C6'), 18.0 (C7'), 14.3 (C8'). 
7.3.4.9 Fumagillol azide reduction 
Fumagillol azide 57 (3.1 mg, 10 Ilmol) and PPh3 (2.9 mg, 11 Ilmol) were dissolved in 
THF (100 ilL). Water (1.5 ilL, 83 Ilmol) was added immediately and the reaction was 
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stirred at room temperature for 18 hours. At this point, TLC (Si02, Et20) indicated the 
complete disappearance ofthe starting material (Rr=0.95, PMA) and appearance ofa 
much more polar compound at Rr=0.08. The reaction mixture was dried down under a 
stream ofnitrogen and chromatographed on a silica column (0.6 g, 60 x 5 mm) eluting 
with a solvent system consisting of 50:10:0.1 CHC13:MeOH:cNH40H to yield the 
desired amine 58 (1.5 mg, 53%). HRESIMS 282.2080, C16H2SN03 (M + H+) requires 
282.2069. lH NMR (CDC13) 0 5.21 (m, IH, H4'), 0 3.55 (s, 3H, H8), 03.47 (dd, JHH = 
9.3, 10.7 Hz, 1H, H5), 02.91 (d, JHH = 4.4 Hz, 1H, H7a), 02.90 (m, 1H, H6), 02.55 (t 
,JHH = 6.3 Hz, IH, H2'), 02.51 (d, JHH = 4.4 Hz, 1H, H7b), 02.36 (m, 1H, H3'a), 0 
2.15 (m, 1H, H3'b), 0 1.88 (d, H, H1a), 0 1.85 (m, H, H2a), 0 1.74 (s, 3H, H6'), 0 1.65 
(s, 3H, H7'), 0 1.57 (d, JHH = 11.2 Hz, 1H, H4), 0 1.57 (m, 1H, HI b), 0 1.27 (s, 3H, 
H8'),o 1.16 (m, IH, H2b), 13C NMR (CDC13) 0 135.3 (C5'), 118.6 (C4'), 84.2 (C5), 
61.7 (C2'), 59.8(C3), 58.9 (C1'), 56.5 (C8), 53.8 (C6), 51.1 (C4), 50.3 (C7), 33.2 (C2), 
29.8 (Cl), 27.6 (C3'), 25.9 (C6'), 18.0 (C7'), 14.7 (C8'). 
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7.4 Work described ill Chapter 4 
7.4.2.1 Fmoc-cyclo-CNGRCGFLG-L-Tyrosinamide (59) 
Fmoc-cyclo-Cys-Asn-Gly-Arg-Cys-Gly-Phe-Leu-Gly-OH (43,3.2 mg, 2.8 !-Lmol), L-
tyrosinamide (39, 1.0 mg, 5.6 !-Lmol), DCC (1.1 mg, 5.3 !-Lmol) and NHS (0.6 mg, 5.6 
!-Lmol) were dissolved in DMF (320 !-LL). The reaction was allowed to proceed overnight 
at which point HPLC (C18, A: H20(A), B: ACN, Gradient III) and ESIMS showed no 
evidence of product formation. The reaction was recharged by the addition of extra 
DCC (3.1 mg, 15.0 !-Lmol) and allowed to continue for a further 24 hours. At this point a 
small amount of product could be seen by HPLC (C18, A: H20(A), B: ACN, Gradient 
III). HBTU (2 mg, 5.3 !-Lillo1) was then added to recharge the reaction instead ofDCC. 
An HPLC carried out one hour after the addition of the HBTU indicated the total 
consumption of the starting material so the reaction was quenched by the addition of 
water (50 !-LL) and refrigerated. Purification was carried out by semi-preparative HPLC 
(Phenomenex Luna C18 column) using an isocratic 40% ACN/H20(A) method on which 
the peak eluting at about 4.5 minutes was collected to provide the desired conjugate 59 
(2.1 mg, 57%). HRESIMS 1308.5285, C61H78N15014S2 (M + H+) requires 1308.5294. 
7.4.2.2 H2N-cyclo-CNGRCGFLG-L-Tyrosinamide (60) 
Compound 59 (2.1 mg, 1.6 !-Lmol) was dissolved in 20% piperidinelMeOH (500 !-LL) and 
allowed to stand at room temperature for 20 minutes before being dried under a stream 
of nitrogen. The residue was passed through a C18 cartridge, eluting with a stepped 
gradient from H20 to MeOH followed by DMSO and fmally 90% MeOH/H20 + 0.1 % 
TF A. The product was found to have eluted in the last fraction which was dried down to 
afford 60 (1.7 mg, 98%). HRESIMS 1086.4616, C46H6SN15012S2 (M + H+) requires 
1086.4613. 
Chapter 7: Experimental 194 
7.4.3.1 Frnoc-cyclo-CNGRCGFLG-Doxorubicin 
Doxorubicin (19,2.6 mg, 4.8 flmol), 43 (5 mg, 4.4 flm01), HBTU (3.1 mg, 9.3 flm01) 
and NHS (1.0 mg, 9.7 flmol) were dissolved in dry DMF (350 flL) and allowed to react 
at room temperature overnight after which HPLC (C18, A: H20(A), B: ACN, Gradient 
III) indicated the reaction was complete. The reaction was quenched with water (50 flL) 
and refrigerated until purification by semi-preparative HPLC (phenomenex Luna C18 
column) eluting with isocratic 45% ACN/H20(A). The peak eluting at 4.8 minutes was 
collected to provide the desired conjugate 60 (2.1 mg, 29%). HRESIMS 1671.6136, 
C79H9SN14023S2 (M + H+) requires l67l.6136. 
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7.5 Work described in Chapter 5 
7.5.2 Optimisation of Polymer Aminolysis 
l-Amino-2-propanol (33.4 ilL, 433 Ilmol) was stirred with polymer precursor 61 (39.6 
mg, 216 Ilmol) in dry DMSO (400 ilL) for four hours at 40°C. The reaction rillxture 
was diluted with 60% MeOHlH20 (12 mL) and placed in a CentriPrep ultrafiltration 
unit, MW cutoff 5 000 Da, and centrifuged at 1300 g for ten hours, removing the filtrate 
every two hours to leave approximately 500 ilL ofretentate. After removal of the 
solvent, the ftltrate was found to contain nearly all of the mass, with the retentate 
containing less than 5% ofthe mass. The two fractions were combined and applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. The column 
had been previously calibrated by chromatography ofa mixture of blue dextran (MW ~ 
2000000, Ve ~ 20-30 mL), vitaminB12 (MW 1355, Ve ~ 50-SO mL) and fluorescein 
sodium (MW 370, Ve ~ 120-130 mL). Following passage through LH20 twice the 
polymer was isolated from low molecular weight contaminants (37.1 mg, 120%). 
The polymer prepared above was reacted again with l-amino-2-propanol (33.4 ilL, 433 
f.1mol) in stirred dry DMSO (200 ilL) at 40°C for 16 hours before puriftcation by LH20 
chromatography (40 g, 400 x 16 mm). The low molecular weight, late eluting material 
was combined and chromatographed on silica (0.6 g, 60 x 5 mm) eluting with 20% 
MeOHICHCI3. The fractions containing ring-opened succinirnide were combined and 
subjected to semi-preparative HPLC (CIS, isocratic 2% ACNIH20(A)) to furnish the 
pure isomeric compounds 63 and 64. 
63: HRESIMS 175.10S3, C7HlSN203 (M + H+ - 0) requires 175.10S2. 'HNMR(D20) 
o 3.S0 (m, IH, H9), 03.14 (dd, JHH = 13.9,4.5 Hz, IH, HSa),o 3.05 (dd, JHH = 13.9, 7.0 
Hz, IH, HSb), 02.47 (t, JHH = 7.1 Hz, 2H, H5), 02.35 (t, JHH = 7.1 Hz, 2H, H4), 0 1.04 
(d, JHH = 6.4 Hz, 3H, HIO), l3C NMR (D20) 0 173.5 (C6), 172.3 (C3), 67.0 (C9), 46.9 
(CS), 31.6 (C5), 2S.S (C4), 20.2 (CIO). IH NMR (d6-DMSO) 0 10.39 (s, IH, H2), 0 
S.70 (br s, IH, HI), 0 7.S2 (t, JHH = 5.5 Hz, IH, H7), 04.65 (d, JHH = 4.4 Hz, IH, H11), 
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03.62 (m, 1H, H9), 02.98 (m, 2H, H8), 02.33 (t, JHH = 7.S Hz, 2H, HS), 0 2.18 (t, JHH 
= 7.S Hz, 2H, H4), 0 1.01 (d, JHH = 6.2 Hz, 3H, H10), l3C NMR (d6-DMSO) 0 171.3 
(C6), 168.6 (C3), 6S.3 (C9), 46.S (C8), 30.7 (CS), 28.0 (C4), 21.2 (C10). 
64: HREIMS 191.1031, C7H1SN204 (M + H+) requires 191.1032. lH NMR (D20) 0 3.81 
(m, 1H, H9), 0 3.16 (dd, JHH = 13.9,4.6 Hz, 1H, H8a),o 3.07 (dd, JHH = 13.9, 6.9 Hz, 
1H, H8b), 02.46 (m, 4H, H4IHS), 0 1.06 (d, JHH = 6.4 Hz, 3H, H10), 13C NMR (D20) 0 
178.6 (C3), 17S.8 (C6), 67.0 (C9), 46.9 (C8), 31.7 (C4 or CS), 31.2 (C4 or CS), 20.1 
(CIO). lH NMR (d6-DMSO) 0 7.86 (t, JHH = S.6 Hz, IH, H7), 07.37 (br s, IH, HI), 0 
6.82 (br s,lH, H2), 04.73 (br s, lH, H11), 03.70 (m, IH, H9), 03.06 (td, JHH = S.9, 
2.0 Hz, 2H, H8), 02.38 (m, 4H, H4IHS), 0 1.09 (d, JHH = 6.1 Hz, 3H, HIO), l3C NMR 
(d6-DMSO) 0 173.7 (C3), 171.7 (C6), 6S.3 (C9), 46.S (C8), 30.7 (CS, C4), 21.2 (ClO). 
I-Amino-2-propanol (38 IlL, 492 !lmol) was reacted with polymer precursor 61 (30 mg, 
164 !lmol) in stirred DMSO (300 IlL) at 60°C with SO IlL samples being removed at 30 
minute intervals. Each sample was passed once through LH20 (40 g, 400 x 16 mm) 
prior to examination by proton NMR spectroscopy. 
I-Amino-2-propanol (38 IlL, 492 !lmol) was reacted with polymer precursor 61 (30 mg, 
164 !lmol) in stirred DMSO (300 IlL) at 40°C. SO!lL samples were removed after 6, 8, 
14,24 and 48 hours of reaction. Each sample was passed once through LH20 (40 g, 400 
x 16 mm) prior to examination by proton NMR spectroscopy. 
7.5.3.1 Fmoc-Gly-Phe-Leu-Gly-L-Tyrosinamide (65) 
L-Tyrosinamide (7 mg, 39 !lmol), 40 (23.9 mg, 39 !lmol), NHS (8.9 mg, 78 !lmol) and 
DCC (1S.2 mg, 74 !lmol) were dissolved in dry THF (1 mL) and allowed to react 
overnight at 4°C after which HPLC (CI8, A: H20(A), B: ACN, Gradient II) indicated 
the reaction was complete. The reaction solvent was removed under a stream of 
nitrogen and the crude reaction product was purified by preparative HPLC (Dynamax 
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C18 column) eluting isocratically with 90% MeOH/H20. The peak eluting at about 8.5 
minutes was collected and dried down to furnish the desired conjugate 65 (13.6 mg, 
45%). HRESIMS 777.3615, C43H49N60S (M + H+) requires 777.3612. lH NMR 
(CD30D) 0 7.80 (d, JHH = 7.5 Hz, 2H, H9"), 0 7.63 (t, JHH = 8.3 Hz, 2H, H6"), 0 7.37 (t, 
JHH = 7.5 Hz, 2H, H8"), 07.29 (m, 2H, H7"), 07.19 (0, 2H, H8), 0 7.19 (0, 2H, H9), 0 
7.12 (0, 1H, HlO), 07.05 (d, JHH = 8.3 Hz, 2H, H5'), 0 6.68 (d, JHH = 8.3 Hz, 2H, H6'), 
04.59 (dd, JHH = 5.9, 8.3 Hz, 1H, H5), 0 4.50 (dd, JHH = 4.9,9.0 Hz, 1H, H2'), 04.31 
(dd, JHH = 7.0, 10.3 Hz, 1H, H3"a), 0 4.25 (dd, JHH = 7.0, 10.7 Hz, 1H, H3"b), 04.20 (0, 
1H, H13), 04.19 (0, IH, H4"), 0 3.81 (d, JHH = 17.1 Hz, 1H, H20a), 0 3.74 (d, JHH = 
16.7 Hz, 1H, H2a), 0 3.69 (d, JHH = 16.7 Hz, 1H, H2b), 03.62 (d, JHH = 17.1 Hz, 1H, 
H20b), 0 3.14 (dd, JHH = 5.5, 14.0 Hz, IH, H6a), 03.07 (dd, JHH = 5.1, 14.0 Hz, 1H, 
H3'a), 0 2.95 (dd, JHH = 8.6, 14.0 Hz, 1H, H6b), 02.85 (dd, JHH = 9.3, 14.0 Hz, 1H, 
H3'b),o 1.60 (m, 2H, H14), 0 1.51· (m, 1H, H15), 0 0.86 (d, JHH = 6.3 Hz, 3H, H16), 0 
0.84 (d, JHH = 6.3 Hz, 3H, H17), l3C NMR (CD30D) 0 176.8 (C8'), 175.9 (C18), 174.4 
(Cll), 173.0 (C3), 171.9 (C21), 159.7 (C1 "), 157.8 (C4'), 145.5 (C5"), 143.1 (C10"), 
138.4 (C7), 131.3 (C5'), 130.3 (C8), 129.6 (C9), 129.6 (C7'), 128.9 (C8"), 128.1 (C7"), 
127.9 (C10), 126.3 (C6"), 120.9 (C9"), 116.3 (C6'), 68.5 (C3"), 56.3 (C5), 56.2 (C2'), 
54.1 (C13), 48.4 (C4"), 45.1 (C2), 43.7 (C20), 41.1 (C14), 38.2 (C6), 38.0 (C3'), 25.7 
(C15), 23.7 (C16), 21.8 (C17). 
7.5.3.2 H2N -Gly-Phe-Leu-Gly-L-Tyrosinamide (66) 
Piperidine (80 ilL) was added to a solution of65 (4.8 mg, 6.2 Ilmol) in MeOH (320 ilL). 
The reaction was allowed to proceed for 20 minutes at room temperature after which it 
was dried down under a stream of nitrogen. The product was isolated by passage 
through a C1S cartridge, eluting with a stepped MeOHIH20 gradient to afford 66 (1.9 
mg,55%). HRESIMS 555.2938, C2sH39N606 (M + H+) requires 555.2931. 
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7.5.3.3 Synthesis and purification of targeted polymer drug conjugate (67) 
Compound 66 (1.9 mg, 3.5 f.Lmol), 42 (1.9 mg, 3.5 f.Lmol) and polymer precursor 61 
(31.6 mg, 173 f.Lmol of reactive sites) were dissolved together in dry DMSO (300f.LL) 
prior to addition of triethylamine (1.4 f.LL, 10.4 f.Lmol). The reaction was stirred at 40°C 
for 16 hours. 1-amino-2-propanol (40 f.LL, 519 f.Lmol) was added to the reaction and 
stirring was continued for a further 12 hours. The reaction solution was then applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. A second 
passage through LH20 afforded the polymer conjugate (67,16.1 mg, 57%). 
7.5.4.1 Fmoc-Gly-Phe-Leu-Gly-Doxorubicin (68) 
A solution of 1 % c]\JH40H/H20 (900 f.LL) was added to an aqueous solution of 
doxorubicin hydrochloride (3.5 mg, 5.8 f.Lmol, 100 f.LL), causing an immediate colour 
change from deep red-orange to violet. The resulting solution was immediately passed 
down a C18 cartridge which was then rinsed with 1 % cNH40H/H20 (2 mL) and H20 (2 
mL) before eluting with acetone (10 mL). The organic fraction was dried down to afford 
desalted doxorubicin (19,2.9 mg, 92%) 
Doxorubicin (19, 2.9 mg, 5.2 f.Lmol), 40 (3.5 mg, 5.7 f.Lmol), NHS (1.2 mg, 10.4 f.Lmol) 
and DCC (2.0 mg, 9.9 f.Lmo1) were dissolved in dry THF (1 mL) and allowed to react 
overnight at 4°C after which HPLC (C18, A: H20(A), B: ACN, Gradient II) indicated 
the reaction was complete. The reaction solvent was removed under a stream of 
nitrogen and the crude reaction product was purified by preparative HPLC (Dynamax 
C18 column) eluting isocratically with 90% MeOHlH20(A). The peak eluting at about 
12.2 minutes was collected and dried down to furnish the desired conjugate 68 (3.1 mg, 
52%). HRESIMS 1162.4281, C61H6SNs017Na (M + Na+) requires 1162.4273. lH NMR 
(CDCl/CD30D) 0 7.94 (d, J HH = 7.8 Hz, 1H, HI'), 07.83 (m, lH, HI), 0 7.69 (0, 1H, 
H12), 0 7.66 (0, 1H, H2'), 0 7.66 (0, 2H, H9"'), 0 7.52 (m, 2H, H6"'), 0 7.37 (0, 1H, 
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H4), 0 7.35 (0, 1H, H19), 0 7.32 (0, 1H, H3'), 07.30 (0, 2H, H8"'), 0 7.22 (t, JHH = 7.3 
Hz, 2H, H7"'), 0 7.15 (m, 2H, H9), 0 7.10 (0, 2H, H8), 0 7.09 (0, IH, H10), 0 7.05 (0, 
1H, 3"-NH), 0 5.42 (m, 1H, HI"), 0 5.16 (m, 1H, H7'), 04.69 (s, 2H, H14'), 04.47 (m, 
1H, H5), 04.25 (m, 1H, H3"'a), 0 4.19 (m, 1H, H3"'b), 0 4.10 (0, 1H, H4"'), 0 4.08 (0, 
1H, H5"), 0 4.05 (0, 1H, H13), 04.02 (0, 1H, H3"), 0 3.96 (s, 3H, H4'-OCH3), 03.74 
(0, 1H, H2), 0 3.72 (0, 1H, H20a), 03.64 (0, 1H, H2), 03.63 (0, 1H, H20b), 0 3.55 (m, 
1H, H4"), 0 3.14 (m, 1H, H10'a), 02.99 (m, 2H, H6), 0 2.94 (m, 1H, H10'b), 02.26 (m, 
1H, H8'a), 02.04 (m, 1H, H8'b), 0 1.82 (m, 1H, H2"a), 0 1.60 (m, 1H, H2"b), 0 1.49 
(m, 2H, H14), 0 1.35 (m, 1H, H15), 0 1.22 (d, JHH = 6.4 Hz, 3H, H5"-CH3), 0 0.78 (0, 
3H, H16), 0 0.77 (0, 3H, H17) l3C NMR (CDC1iCD30D) 0213.8 (C13'), 186.8 (C12'), 
178.7 (C5'), 173.2 (C18), 172.7 (Cll), 171.2 (C3), 169.2 (C21), 161.1 (C4'), 157.4 
(C1"'), 143.5 (C5"'), 141.0 (C10"'), 135.8 (C7), 135.5 (C12a'), 134.5 (C6a'), 133.9 
(ClOa') 129.2 (C8), 128.9 (C9), 127.9 (C8"'), 127.3 (C10), 127.1 (C7"'), 125.1 (C6"'), 
121.1 (C4a'), 121.0 (C2'), 120.1 (C9"'), 120.0 (C1'), 118.6 (C3'), 100.8 (C1"), 76.3 (C9'), 
69.2 (C7'), 68.5 (C4"), 67.6 (C5"), 67.4 (C3"'), 65.3 (C14'), 56.7 (C4'-OCH3), 54.7 (C5), 
53.3 (C13), 47.0 (C4"'), 46.1 (C3"), 44.2 (C2), 43.0 (C20), 39.2 (C14), 37.1 (C6), 35.9 
(C8'), 33.8 (C10'), 29.2 (C2"), 24.5 (C15), 22.7 (C16), 21.4 (C17), 16.8 (C5"-CH3)' 
7.5.5.1 Fmoc-Gly-Phe-Leu-Gly-Mycalamide A (69) 
Crude 45 (8.2 mg, 17 Ilmo1) , 40 (11.7 mg, 19 Ilmo1) , NHS (4.0 mg, 35 Ilmol) and DCC 
(6.8 mg, 33 Ilmol) were dissolved in dry THF (1 mL) and allowed to react overnight at 
4°C after which HPLC (C18, A: H20, B: ACN, Gradient II) indicated the reaction was 
complete. The reaction solvent was removed under a stream of nitrogen and the crude 
reaction product was purified by preparative HPLC (Dynamax C18 column) eluting 
isocratically with 90% MeOHIH20 at a flow rate of 10 mL/min. The peak eluting at 
about 10 minutes was collected and dried down to furnish the desired conjugate 69 (4.2 
mg, 23% over two steps). HRESIMS 1091.5299, CS7H76N6014Na (M + Na+) requires 
1091.5317. IH NMR (CDC13) 0 7.76 (d, JHH = 7.4 Hz, 2H, H9"), 0 7.58 (d, JHH = 6.6 
Hz, 2H, H6"), 0 7.48 (0, 1H, NH9'), 07.47 (0, 1H, H12), 07.41 (t, JHH = 7.4 Hz, 2H, 
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H8"), 0 7.32 (m, 2H, H7"), 0 7.24 (0, 2H, H8), 07.24 (0, 2H, H9), 0 7.22 (0, 1H, H10), 
07.04 (t, JHH = 5.5 Hz, 1H, 17'-NH), 0 6.87 (d, JHH = 7.2 Hz, 1H, H4), 0 6.10 (m, 1H, 
H19),o 5.77 (t, JHH = 9.7 Hz, 1H, H10'), 0 5.65 (t, JHH = 5.3 Hz, 1H, HI), 0 5.14 (d, 
JHH = 6.9 Hz, 1H, H10'-OCH2a), 04.87 (m, 1H, H4'=CH2a), 04.83 (d, JHH = 6.9 Hz, 
1H, H10'-OCH2b), 04.80 (0, IH, H5), 04.77 (0, 1H, H4'=CH2b), 0 4.54 (m, IH, H13), 
04.37 (0, 1H, H7'), 04.34 (0, 2H, H3"), 0 4.20 (0, 1H, H12'), 0 4.18 (0, 1H, H4"), 0 
4.02 (m, IH, H2'), 0 3.96 (m, 1H, H20a), 0 3.82 (0, 2H, H2), 0 3.80 (0, IH, H11'), 0 
3.55 (s, 3H, H13'-OCH3), 0 3.48 (0, 1H, H20b), 0 3.47 (0, 1H, H13'), 0 3.38 (0, 1H, 
H17'a), 0 3.34 (0, IH, H15'), 0 3.30 (s, 3H, H6'-OCH3)' 0 3.09 (d, JHH = 7.1 Hz, 2H, 
H6), 02.79 (m, 1H, Hl7'b), 0 2.43 (d, JHH = 14.2 Hz, 1H, H5'a), 0 2.26 (0, IH, H3'), 0 
2.23 (d, JHH = 14.2 Hz, 1H, H5'b), 0 1.84 (0, 1H, H14a), 0 1.82 (0, 1H, H16'a), 0 1.43 
(0, 1H, H15), 0 1.39 (0, IH, H14b), 0 1.23 (0, IH, H16'b), 0 1.21 (d, JHH = 6.3 Hz, 3H, 
H2'-CH3),o 1.01 (d, JHH = 6.8 Hz, 3H, H3'-CH3), 0 0.93 (s, 3H, H14'-CH3(eq)), 0 0.87 
(d, JHH = 6.4 Hz, 3H, H16), 00.84 (d, JHH = 6.4 Hz, 3H, H17), 0 0.80 (s, 3H, H14'-
CH3(ax)) l3C NMR (CDCl3) 0 172.3 (C18), 172.1 (C8'), 170.9 (Cll), 170.3 (C3), 169.1 
(C21), 157.1 (C1"), 145.2 (C4'), 143.7 (C5"), 141.6 (C10"), 136.1 (C7), 129.7 (C9), 
129.4 (C8), 128.0 (C8"), 127.7 (C10), 127.3 (C7"), 125.1 (C6"), 120.3 (C9"), 111.2 
(C4'=CH2), 100.1 (C6'), 86.4 (C10'-OCH2), 79.2 (C13'), 75.9 (C15'), 74.8 (C12'), 73.8 
(C10'), 71.8 (C7'), 71.5 (C11'), 70.2 (C2'), 67.9 (C3"), 62.0 (C13'-OCH3), 55.0 (C5), 
51.4 (C13), 48.5 (C6'-OCH3), 46.9 (C4"), 44.9 (C2), 43.4 (C20), 41.5 (C3), 41.2 (C14'), 
40.2 (C14), 37.7 (C6), 36.2 (Cl7'), 33.3 (C5'), 27.8 (C16'), 24.7 (C15), 23.3 (C16), 23.0 
(C14'-CH3(eq)), 21.5 (C17), 18.0 (C2'-CH3), 13.3 (C14'-CH3(ax)), 12.1 (C3'-CH3)' 
7.5.5.2 H2N-Gly-Phe-Leu-Gly-Mycalamide A (70) 
Piperidine (160 ilL) was added to a solution of69 (4.2 mg, 3.9 Ilmol) in MeOH (640 
ilL). The reaction was allowed to proceed for 20 minutes at room temperature after 
which it was dried down under a stream of nitrogen. The product was isolated by 
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passage through a CI8 cartridge, eluting with a stepped MeOH!H20 gradient to afford 70 
(3.3 mg, 100%). HRESIMS 847.4825, C42H66N6012 (M + H+) requires 847.4817. 
7.5.5.3 Synthesis and purification of targeted polymer drug conjugate 
Compounds 70 (3.3 mg, 3.9 !lmol) and 42 (2.1 mg, 3.9 !lmol) and polymer precursor 61 
(35.7 mg, 195 !lmol of reactive sites) were dissolved together in dry DMSO (300!lL) 
prior to addition of triethylamine (1.6 IlL, 11.7 !lmol). The reaction was stirred at 40°C 
for 16 hours. l-amino-2-propanol (45.2 IlL, 585 !lmol) was added to the reaction and 
stirring was continued for a further 12 hours. The reaction solution was then applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. A second 
passage through LH20 afforded the pure polymer conjugate (17.6 mg, 53%). 
7.5.6.1 Fmoc-Gly-Phe-Leu-Gly-Mycalamide B (71) 
Crude 50 (1.4 mg, 2.6 !lmol), 40 (1.8 mg, 2.9 !lmol), NHS (0.6 mg, 5.2 !lmol) and DCC 
(1.0 mg, 4.9 !lmol) were dissolved in dry THF (300 IlL) and allowed to react overnight 
at 4°C. The reaction solvent was removed under a stream of nitrogen and the crude 
reaction product was purified by preparative HPLC (Dynamax C 18 column) eluting 
isocratically with 80% ACN!H20 at a flow rate of 10 mL/min. The peak eluting at about 
6 minutes was collected and dried down to furnish the desired conjugate 71 (2.3 mg, 
79% over two steps). HRESIMS 1135.5576, C59H80N6015Na (M + Na+) requires 
1135.5579. IH NMR (CDCl3) 0 7.78 (d, JHH = 7.6 Hz, 2H, H9"), 0 7.63 (d, JHH = 9.3 
Hz, IH, NH9'), 0 7.58 (m, 2H, H6"), 0 7.42 (t, J HH = 7.6 Hz, 2H, H8"), 0 7.32 (m, 2H, 
H7"), 0 7.23 (0, 2H, H9), 0 7.20 (0, 2H, H8) , 0 7.19 (0, IH, HI0), 06.99 (br d, IH, 
HI2), 0 6.85 (0, IH, H4), 0 6.85 (0, IH, HI9), 06.73 (br t, IH, HI8'-NH), 05.93 (br t, 
IH, HI), 0 5.79 (t, JHH = 9.6 Hz, IH, HI0'), 0 5.15 (d, JHH = 6.8 Hz, IH, HI0'-OCH2a), 
04.85 (s, IH, H4'=CH2a), 04.80 (d, JHH = 6.8 Hz, lH, HI0'-OCH2b), 04.71 (s, IH, 
H4'=CH2b), 04.59 (q, JHH = 6.7 Hz, IH, H5), 0 4.40 (br m, IH, H13), 04.37 (dd, JHH = 
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7.0,10.2 Hz, 1H, H3"a), 0 4.28 (0, 1H, H7'), 04.27 (0, 1H, H3"b), 0 4.18 (0, 1H, 
H12'), 04.18 (0, 1H, H4"), 0 4.01 (dq, JHH = 6.6,2.5 Hz, 1H, H2'), 0 3.93 (dd, JHH = 
6.0, 16.0 Hz, 1H, H20a), 03.87 (dd, JHH = 9.7, 7.0 Hz, 1H, H11'), 0 3.79 (d, JHH = 5.2 
Hz, 2H, H2), 0 3.74 (dd, JHH = 5.4, 17.2 Hz, 1H, H20b), 0 3.53 (s, 3H, H13'-OCH3), 0 
3.50 (m, 1H, H13'), 03.42 (d, JHH = 9.7 Hz, 1H, H15'), 0 3.31 (m, 2H, H18'), 0 3.28 (s, 
3H, H6'-OCH3), 0 3.22 (m, 1H, Hl7'), 0 3.17 (s, 3H, Hl7'-OCH3), 0 3.12 (t, JHH = 6.6 
Hz, 2H, H6), 0 2.37 (d, JHH = 14.3 Hz, 1H, H5'a), 02.25 (0, 1H, H3'), 0 2.25 (0, 1H, 
H5'b),o 1.74 (0, 1H, H14a), 01.54 (m, 1H, H16'a), 0 1.48 (m, 1H, H16'b), 0 1.44 (m, 
1H, H14b), 0 1.40 (m, 1H, H15), 0 1.20 (d, JHH = 6.4 Hz, 3H, H2'-CH3), 0 1.01 (d, JHH 
= 6.8 Hz, 3H, H3'-CH3), 00.92 (s, 3H, H14'-CHieq)), 0 0.87 (d, JHH = 6.6 Hz, 3H, 
H16), 00.84 (d, JHH = 6.6 Hz, 3H, H17), 0 0.82 (s, 3H, H14'-CH3(ax)) 13C NMR 
(CDCl3) 0 172.3 (C8'), 171.3 (Cll), 170.6 (C3), 157.4 (C1"), 145.4 (C4'), 143.7 (C5"), 
141.4 (C10"), 136.0 (C7), 129.4 (C8), 129.1 (C9), 128.2 (C8"), 127.6 (C10), 127.3 
(C7"), 125.3 (C6"), 120.3 (C9"), 111.2 (C4'=CH2 ), 100.2 (C6'), 86.5 (C10'-OCH2 ), 
79.1 (C13'), 76.7 (Cl7'), 75.3 (C15'), 74.5 (C12'), 74.1 (C10'), 71.8 (C7'), 71.1 (Cll'), 
69.8 (C2'), 67.7 (C3"), 62.0 (C13'-OCH3), 56.5 (Cl7'-OCH3), 55.6 (C5), 52.1 (C13), 
48.6 (C6'-OCH3), 47.0 (C4"), 45.0 (C2), 43.5 (C20), 41.7 (C18'), 41.5 (C14'), 41.4 
(C3'), 39.8 (C14), 37.3 (C6), 33.6 (C5'), 30.9 (C16'), 24.7 (C15), 23.3 (C17), 23.0 
(C14'-CH3(eq)), 21.4 (C16), 18.0 (C2'-CH3), 13.3 (C14'-CH3(ax)), 12.3 (C3'-CH3). 
7.5.6.2 H2N-Gly-Phe-Leu-Gly-Mycalarnide B (72) 
Piperidine (160 /-LL) was added to a solution of71 (2.3 mg, 2.0 /-Lmol) in MeOH (640 
/-LL). The reaction was allowed to proceed for 20 minutes at room temperature after 
which it was dried down under a stream ofnitrogen. The product was isolated by 
passage through a CI8 cartridge, eluting with a stepped MeOH/H20 gradient to afford 72 
(1.6 mg, 96%). HRESIMS 891.5119, C44H70N6013 (M + H+) requires 891.5079. 
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7.5.6.3 Synthesis and purification of targeted polymer drug conjugate 
Compounds 72 (1.6 mg, 1.8 Ilmol) and 42 (1.0 mg, 1.8 Ilmol) and polymer precursor 61 
(16.4 mg, 89.8 Ilmol of reactive sites) were dissolved together in dry DMSO (300IlL) 
prior to addition oftriethylamine (0.75 ilL, 5.4 Ilmol). The reaction was stirred at 40°C 
for 16 hours. l-amino-2-propanol (21.4 ilL, 270 Ilmol) was added to the reaction and 
stirring was continued for a further 12 hours. The reaction solution was then applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. A second 
passage through LH20 afforded the pure polymer conjugate (10.1 mg, 66%). 
7.5.7.1 Fmoc-Gly-Phe-Leu-Gly-R-Fumagillol (73) 
Crude 52 (7.0 mg, 25 Ilmol), 40 (16.9 mg, 27.5 Ilmol), NHS (5.8 mg, 50 Ilmol) and 
DCC (9.8 mg, 48 Ilmol) were dissolved in dry THF (1 mL) and allowed to react 
overnight at 4°C. The reaction solvent was removed under a stream of nitrogen and the 
crude reaction product was purified by repeated analytical HPLC injections (C 18, A: 
H20, B: ACN, gradient: 68% B (0 min), 68% B (2 min), 71 % B (14 min)). The peak 
eluting at 11.8 minutes was collected and dried down to furnish the desired conjugate 73 
(2.8 mg, 13% over two steps). HRESIMS 878.4709, CSOH64N509 (M + H+) requires 
878.4704. lH NMR (CDC13) 0 7.77 (d, JHH = 7.3 Hz, 2H, H9"'), 0 7.56 (d, JHH = 7.1 
Hz, 2H, H6"'), 0 7.40 (t, JHH = 7.4 Hz, 2H, H8"'), 0 7.39 (m, IH, H4), 0 7.30 (t, JHH = 
7.4 Hz, 2H, H7"'), 0 7.25 (0, IH, HI9), 0 7.25 (0, 2H, H8), 0 7.18 (0, IH, HI0), 0 7.17 
(0, 2H, H9), 0 6.66 (0, IH, HI2), 06.65 (0, IH, H6'-NH), 0 6.05 (br s, IH, HI), 0 5.15 
(t, JHH = 7.4 Hz, IH, H4"), 0 4.84 (m, IH, H6'), 04.39 (0, IH, H5), 04.36 (0, IH, 
H3"'a), 0 4.25 (0, IH, H20a), 04.21 (0, IH, H3"'b), 0 4.17 (0, IH, H13), 04.13 (0, IH, 
H4"'),o 3.88 (dd, JHH = 4.9, 17.0 Hz, IH, H2a), 03.68 (dd, JHH = 4.4, 10.7 Hz, IH, 
H5'), 0 3.65 (0, IH, H2b), 0 3.51 (dd, JHH = 4.4, 17.1 Hz, IH, H20b), 0 3.29 (s, 3H, 
H8'), 0 3.25 (0, IH, H6a), 0 3.14 (dd, JHH = 6.8,14.0 Hz, IH, H6b), 02.92 (d, JHH = 3.9 
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Hz, 1H, H7'a), 0 2.78 (t, JHH = 6.1 Hz, 1H, H2"), 0 2.55 (d, JHH = 3.9 Hz, 1H, H7'b), 0 
2.36 (d, JHH = 11.2 Hz, 1H, H4'), 0 2.25 (0, IH, H3"a), 0 2.20 (0, 1H, H3"b), 0 2.01 (m, 
1H, H2'a), 0 1.88 (m, 1H, H1'a), 0 1.80 (m, 1H, H1'b), 0 1.65 (s, 3H, H6"), 0 1.61 (0, 
1H, H14a), 0 1.58 (s, 3H, H7"), 0 1.49 (m, 1H, H14b), 0 1.31 (m, IH, H15), 0 1.17 (s, 
3H, H8"), 0 1.08 (m, 1H, H2'b), 0 0.83 (d, JHH = 6.2 Hz, 3H, H16), 00.82 (d, JHH = 6.0 
Hz, 3H, H17), l3C NMR (CDC13) 0 172.5 (C18), 172.2 (Cll), 171.9 (C3), 169.7 (C21), 
157.2 (C1"'), 143.9 (C5"'), 141.6 (C10"'), 135.9 (C7), 135.6 (C5"), 129.2 (C8), 129.1 
(C9), 128.0 (C8"'), 127.6 (C10), 127.3 (C7"'), 125.1 (C6"'), 120.3 (C9"'), 118.6 (C4"), 
79.0 (C5'), 67.3 (C3"'), 61.7 (C2"), 60.3 (C1 "),60.2 (C3'), 56.4 (C8'), 55.8 (C5), 53.9 
(C13), 51.7 (C7'), 47.1 (C4"'), 45.0 (C2), 44.5 (C6'), 43.3 (C20), 39.8 (C14), 36.2 
(C6), 29.4 (C2'), 27.4 (C3"), 26.4 (C1'), 25.8 (C6"), 24.7 (C15), 23.3 (C16), 21.2 (C17), 
18.0 (C7"), 13.9 (C8"). 
7.5.7.2 H2N-Gly-Phe-Leu-Gly-R-Fumagillol (74) 
Piperidine (160 flL) was added to a solution of73 (2.8 mg, 3.2 flmol) in MeOH (640 
flL). The reaction was allowed to proceed for 20 minutes at room temperature after 
which it was dried down under a stream of nitrogen. The product was isolated by 
passage through a CI8 cartridge, eluting with a stepped MeOHIH20 gradient to afford 74 
(1.7 mg, 81%). HRESIMS 656.4004, C35H53N507 (M + H+) requires 656.4023. 
7.5.7.3 Synthesis and purification of targeted polymer drug conjugate 
Compounds 74 (1.7 mg, 2.6 flmol) and 42 (1.4 mg, 2.6 flmol) and polymer precursor 61 
(23.7 mg, 130 flmol of reactive sites) were dissolved together in dry DMSO (300flL) 
prior to addition of triethylamine (1.1 flL, 7.3 flmol). The reaction was stirred at 40°C 
for 16 hours. 1-amino-2-propanol (31.2 flL, 390 flmol) was added to the reaction and 
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stirring was continued for a further 12 hours. The reaction solution was then applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. A second 
passage through LH20 afforded the pure polymer conjugate (11.5 mg, 53%). 
7.5.8.1 Fmoc-Gly-Phe-Leu-Gly-S-Fumagillol (75) 
Compounds 58 (2.9 mg, 10 Ilmol) and 40 (7.0 mg, 11 Ilmol), NHS (2.4 mg, 21 Ilmol) 
and DCC (4.0 mg, 20 Ilmol) were dissolved in dry THF (500 ilL) and allowed to react 
overnight at 4°C. The reaction solvent was removed under a stream of nitrogen and the 
crude reaction product was purified by preparative HPLC (Dynamax C 18 column) 
eluting isocratically with 69% ACNIH20 at a flow rate of 10 mL/min. The peak eluting 
at about 10 minutes was collected and dried down to furnish the desired conjugate 75 
(4.9 mg, 56%). HRESIMS 878.4709, C50H64N509 (M + H+) requires 878.4704. IHNMR 
(d6-DMSO) 0 8.25 (d, JHH == 7.4 Hz, IH, HI2), 0 8.19 (t, JHH == 5.9 Hz, IH, HI9), 0 
8.09 (d, JHH == 7.9 Hz, IH, H4), 07.99 (d, JHH == 7.6 Hz, 2H, H9"'), 0 7.92 (d, JHH == 9.2 
Hz, IH, H6'-NH), 07.80 (d, JHH == 7.6 Hz, 2H, H6"'), 0 7.63 (t, JHH == 5.9 Hz, IH, HI), 
07.51 (t, JHH == 7.6 Hz, 2H, H8"'), 0 7.42 (t, JHH == 7.6 Hz, 2H, H7"'), 0 7.32 (0, 2H, 
H8),o 7.32 (0, 2H, H9), 07.26 (m, IH, HI0), 0 5.29 (t, JHH == 7.4 Hz, IH, H4"), 04.65 
(m, IH, H5), 04.35 (0, IH, H13), 04.34 (0, 2H, H3"'), 0 4.30 (0, IH, H4"'), 0 4.06 (dt, 
JHH == 4.1, 10.4 Hz, IH, H6'), 0 3.79 (0, IH, H5'), 0 3.76 (0, 2H, H20), 03.71 (0, IH, 
H2a), 0 3.61 (dd, JHH == 5.5, 16.5 Hz, IH, H2b), 03.31 (s, 3H, H8'), 0 3.15 (dd, JHH == 
4.4,14.1 Hz, IH, H6a), 0 2.92 (d, JHH == 4.4 Hz, IH, H7'a), 02.89 (dd, JHH == 9.3,13.9 
Hz, IH, H6b), 0 2.68 (d, JHH == 4.4 Hz, IH, H7'b), 02.63 (t, JHH == 6.4 Hz, IH, H2"), 0 
2.27 (t, JHH == 6.8 Hz, 2H, H3"), 0 1.99 (dt, JHH == 4.5, 13.7 Hz, IH, H2'a), 0 1.88 (d, JHH 
== 11.5 Hz, IH, H4'), 0 1.80 (s, 3H, H6"), 0 1.79 (0, IH, Hl'a), 0 1.70 (s, 3H, H7"), 0 
1.69 (m, IH, HI5), 0 1.59 (t, JHH == 7.3 Hz, 2H, HI4), 0 1.54 (m, IH, HI 'b), 0 1.20 (s, 
3H, H8"), 0 1.09 (m, IH, H2'b), 00.97 (d, JHH == 6.5 Hz, 3H, HI7), 00.93 (d, JHH == 6.5 
Hz, 3H, HI6), 13C NMR (d6-DMSO) 0 172.8 (CI8), 171.7 (Cll), 169.8 (C3), 168.7 
(C21), 157.1 (Cl"'), 144.4 (C5"'), 141.4 (CI0'"), 138.3 (C7), 134.4 (C5"), 129.8 (C8), 
128.8 (C9), 128.3 (C8"'), 127.7 (C7"'), 126.8 (CI0), 125.9 (C6"'), 120.7 (C9"'), 120.0 
Chapter 7: Experimental 206 
(C4"), 78.8 (C5'), 66.4 (C3"'), 60.6 (C2"), 60.5 (C3'), 58.8 (Cl "), 54.2 (C5), 53.6 (C8'), 
52.0 (Cl3), 51.1 (C7'), 49.8 (C6'), 49.5 (C4'), 47.1 (C4"'), 43.9 (C2), 42.7 (C20), 41.1 
(C14), 37.9 (C6), 32.6 (C2'), 28.8 (Cl'), 27.4 (C3"), 26.1 (C6"), 24.7 (C15), 23.5 (C16), 
22.3 (C17), 18.3 (C7"), 14.4 (C8"). 
7.5.8.2 H2N-Gly-Phe-Leu-Gly-S-Fumagillol (76) 
Piperidine (160 IJ.L) was added to a solutionof75 (4.9 mg, 5.6IJ.mol) in MeOH (640 
f.LL). The reaction was allowed to proceed for 20 minutes at room temperature after 
which it was dried down under a stream of nitrogen. The product was isolated by 
passage through a CI8 cartridge, eluting with a stepped MeOHIH20 gradient to afford 76 
(0.9 mg, 25%). HRESIMS 656.4036, C35H53N507 (M + H+) requires 656.4023. 
7.5.8.3 Synthesis and purification of targeted polymer drug conjugate 
Compounds 76 (0.9 mg, 1.4 IJ.mol) and 42 (0.75 mg, 1.4 IJ.mol) and polymer precursor 
61 (12.6 mg, 68.7 IJ.mol of reactive sites) were dissolved together in dry DMSO (300IJ.L) 
prior to addition of triethylamine (0.6 IJ.L, 4.1 IJ.mol). The reaction was stirred at 40°C 
for 16 hours. l-amino-2-propanol (14.2 IJ.L, 210 IJ.mol) was added to the reaction and 
stirring was continued for a further 12 hours. The reaction solution was then applied to 
the top of an LH20 column (40 g, 400 x 16 mm) and eluted with MeOH. A second 
passage through LH20 afforded the pure polymer conjugate (8.0 mg, 70%). 
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